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 i 
Abstract 
Kinetoplastid parasites pose a huge global health burden on both humans and livestock. 
Current treatments are toxic and difficult to administer. With the emergence of drug-
resistant organisms, it is essential to identify new therapeutic targets. African 
trypanosomiasis, or sleeping sickness, is caused by Trypanosoma brucei. This thesis focuses 
on the characterisation and validation of a potential new drug target in this kinetoplastid 
parasite. Flap endonucleases are essential enzymes involved in DNA replication and repair. 
Synthetic constructs, encoding wild type and mutated FEN genes, were produced and 
expressed in Escherichia coli.  Purification procedures and quantitative enzyme activity 
assays were developed. The catalytic and binding activity of the D183K variant were 
determined and compared to the wild type enzyme. The former was shown to be 
catalytically inert, yet able to bind a DNA substrate with similar affinity to the wild type 
enzyme (Kd = 2.22 and 1.37 μM respectively). The D183K variant was crystallised 
collaboratively and its structure determined by colleagues in the Department of Molecular 
Biology & Biotechnology. The wild type and D183K variant genes were over-expressed in T. 
brucei bloodstream form cells, using a tetracycline-inducible system. Expression of the 
catalytically inert protein had a severely detrimental effect on cell growth, and 
morphological changes were observed 72 hours post-induction. Knock-down assays were 
attempted using siRNA techniques, but results were inconclusive. The recombinant wild 
type enzyme was targeted with known FEN inhibitors. Myricetin, a commercially available 
flavonoid, inhibited T. brucei flap endonuclease (IC50 = 14.81 μM).  T. brucei bloodstream 
form cells were killed upon exposure to myricetin (LD50 = 23.63 μM). A high-throughput 
thermal shift assay was developed to aid fragment-based drug design.  This assay can be 
used to detect binding by myricetin, a known TbFEN inhibitor. Use of this assay will open up 
further avenues of exploration for targeting the T. brucei flap endonuclease. 
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1 Introduction  
1.1 African Trypanosomiasis 
1.1.1 A Brief History 
African trypanosomiasis is caused by kinetoplastid parasites of the Trypanosoma genera. 
This ancient disease was first accurately reported in 1734, although there is evidence 
indicating its prevalence in Ancient Egypt (Steverding, 2008). The causative agent of the 
cattle version of the disease (Nagana) was discovered by David Bruce in 1895, and called 
Trypanosoma brucei brucei (Bruce, 1895). It was in the 1920-1940 human African 
Trypanosomiasis (HAT) epidemic where significant advances in the prevention, control and 
treatment of the disease occurred. The development of two therapeutics (tryparsamide 
and suramin) helped in the early stages of the epidemic (Pearce, 1921; Steverding, 2008). 
The deployment of mobile teams that detected and treated the disease had a significant 
contribution in controlling both the epidemic and the parasite reservoir (Steverding, 2008). 
These factors, in combination with the development and use of Pentamidine and 
Melarsoprol, helped to nearly eliminate HAT in the 1960s (Figure 1-1) (Bray et al., 2003; de 
Raadt, 2005).  The onset of independence from colonial powers resulted in the collapse of 
many screening and control programmes within African countries. This lead to a re-
emergence of the disease that peaked in the 1990s (Figure 1-1) (Brun et al., 2010). 
Concerted efforts by the World Health Organisation (WHO) and a number of non-
governmental organisations has helped to reduce the number of cases by 73% between 
2000-2012 (WHO, 2015b). The WHO Neglected Tropical Diseases initiative aims to eliminate 
HAT by 2020 (WHO, 2015b). 
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Figure 1-1 Comparison between the number of reported HAT cases and the level of 
surveillance 
Grey columns indicate the number of HAT cases reported between 1939 and 2004. Black circles 
indicate the level of surveillance against HAT between 1939 and 2004. The graph was 
reproduced under the creative commons license from Steverding (2008). 
1.1.2 Human African Trypanosomiasis 
There are two sub-species of T. brucei that cause disease in humans: T. brucei rhodesiense 
and T. brucei gambiense. T. brucei gambiense infections are localised to the western and 
central regions of sub-Saharan Africa, whilst T. brucei rhodesiense infections are localised  
to the eastern and southern regions (WHO, 2015b). The localisation of the parasites is 
dependent on the availability of their vector; the tsetse fly (Glossina spp). The life cycle of 
these parasites is complex, as they require two separate hosts in order to develop (Figure 
1-2). Briefly, the mammalian host becomes infected by metacyclic trypomastigotes 
following a bite from an infected tsetse fly (CDC, 2015; Langousis & Hill, 2014). Once in the 
mammalian blood stream, the parasites transform into bloodstream trypomastigotes, 
which divide in the blood. These infect the tsetse fly during feeding. Once in the fly midgut, 
the parasites transform into procyclic trypomastigotes (CDC, 2015; Langousis & Hill, 2014). 
These transform into epimastigotes and migrate to the salivary glands, where they are 
ready to infect another mammalian host (CDC, 2015; Langousis & Hill, 2014).  
  
 3 
 
Figure 1-2 Life cycle of the T. brucei parasite 
The mammalian host becomes infected by metacyclic trypomastigotes following a bite from an 
infected tsetse fly (CDC, 2015; Langousis & Hill, 2014). Once in the mammalian blood stream, 
the parasites differentiate into long slender bloodstream trypomastigotes, which divide in the 
blood (CDC, 2015; Langousis & Hill, 2014). The long slender form differentiates into the short 
stumpy form, which is adapted for survival in the insect vector (Langousis & Hill, 2014). These 
infect the tsetse fly during feeding. Once in the fly midgut, the parasites transform into procyclic 
trypomastigotes (CDC, 2015; Langousis & Hill, 2014). These transform into epimastigotes and 
migrate to the salivary glands via the proventriculus. It is in the proventriculus where the 
parasite divides asymmetrically, producing two epimastigotes: one that is long and one that is 
short (Langousis & Hill, 2014). The short epimastigote attaches to the salivary gland epithelial 
cells where it replicates to produce metacyclic trypomastigotes (Langousis & Hill, 2014). These 
are now ready to infect another mammalian host (CDC, 2015; Langousis & Hill, 2014). Image 
adapted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology, copyright 
2014 (Langousis & Hill, 2014). 
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The two sub-species of Trypanosoma brucei that cause human disease display different 
disease progressions, but are both characterised by two distinct stages. The first, 
haemolymphatic stage occurs shortly after infection, and symptoms tend to be non-
specific. The second, meningoencephalitic stage occurs when the parasite crosses the blood 
brain barrier (Brun et al., 2010). Infection by either parasite will ultimately lead to death if 
left untreated. The T. b. gambiense infection is chronic, with an average survival rate of 
three years. It accounts for 98% of HAT cases (Brun et al., 2010). Neurological symptoms 
occur after 1-2 years (CDC, 2015). Kieft et al showed that the ability of T. b. gambiense 
parasites to infect humans is due to expression of reduced levels of a haptoglobin-related 
protein receptor. This decreases the uptake of the high density lipoprotein sub-fraction 
called trypanosome lytic factor (Kieft et al., 2010). The T. b. rhodesiense infection is acute, 
and death usually occurs within months (Brun et al., 2010) (CDC, 2015). The difference in 
infectivity is because T. b. rhodesiense is ill-adapted to human infection. The ability of T. b. 
rhodesiense to infect humans is thought to be due to a deletion mutation within a variable 
surface glycoprotein (VSG) gene. This produced a serum resistance associated (SRA) gene 
(Campillo & Carrington, 2003; Gibson, 2005). This SRA gene enables the parasite to avoid 
killing by trypanosome lytic factor (Oli et al., 2006). 
A concerted effort by WHO to eradicate HAT by 2020 has led to a decrease in the number 
of new reported cases from 37, 991 in 1998 to 3, 796 in 2014 (WHO, 2015a). Whilst this is 
encouraging, decreases of a similar level have been seen previously, and have been 
followed by resurgence in the number of cases (Figure 1-1).  
1.1.3 Animal African Trypanosomiasis 
Whilst HAT cases are on the decline, African Trypanosomiasis is still a major problem in 
domestic and farm animals.  Animal African trypanosomiasis (AAT) affects many 
domesticated species including dogs, cattle and goats. AAT in cattle is considered to have 
the most economic importance. Bovine trypanosomiasis, or nagana, threatens an estimated 
50 million head of cattle in Africa (FAO, 2015). The economic impact is huge, with an 
estimated loss of US$1.2 billion per year (FAO, 2015). AAT has a detrimental effect on the 
general well-being of infected animals. This in turn affects fertility, growth, and yields of 
milk and meat (Connor, 1992). Diagnosis of the disease requires the identification of 
parasites in bodily fluids, but this can be difficult, as the parasite burden is often low 
(Connor, 1992). This is because many animals reach an equilibrium with the parasites 
(Connor, 1992).  
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There are ten known animal pathogens within the Trypanosoma genus, and these are 
depicted in Figure 1-3. Of these ten, two are also human pathogens (T. b. gambiense and T. 
b. rhodesiense). T. brucei, T. congolense, T. vivax and T. simae are considered the most 
important causative agents of nagana, whilst T. evansi causes surra (trypanosomiasis of 
camels) (Anene et al., 2001). T. vivax is considered the most important parasite of livestock 
in West Africa (Silva et al., 2013). The parasite is specific to ungluates (hooved animals), and 
is found in both wild and domestic animals (Osório et al., 2008). T. vivax is unique in that it 
has moved out of the tsete belt and into South America. This is thought to have occurred in 
the mid-19th Century through cattle importation (Pimentel et al., 2012). Transmission in the 
Americas is thought to occur by mechanical means because the insect vector is not found in 
these locations (Osório et al., 2008). Cases of T. vivax have been reported in French Guiana 
(Desquesnes & Gardiner, 1993), Columbia (Otte et al., 1994), Boliva (Silva et al., 1998) and 
Brazil (Pimentel et al., 2012). Outbreaks of T. vivax disease are characterised by anaemia, 
emaciation, miscarriage and death (Jones & Dávila, 2001; Osório et al., 2008). The financial 
impact of T. vivax in the Brazilian Pantanal and Bolivian lowlands was estimated to exceed 
US$160 million for the 11 million head of cattle thought to be farmed in these regions (Seidl 
et al., 1999). 
1.1.4 Current treatments for HAT 
The current treatments for HAT come with a number of issues, which are discussed in detail 
in the following sections. The drugs are either stage or strain specific, with complex 
treatment regimens and severe side effects. The chemical structures of the current 
treatments are shown in Figure 1-4. 
Suramin is the oldest drug still in use to treat HAT. It was discovered in 1916, by the Bayer 
Company in Germany (Steverding, 2010). The discovery of Suramin (also called Germanin) 
was instigated through the idea of using synthetic dyestuff as therapeutics, a concept 
pioneered by Paul Ehrlich (Greenwood et al., 2007). Suramin is still the first line treatment 
for early stage T. b. rhodesiense infections (Kennedy, 2013). The drug is delivered by 
intravenous injection, with five injections required every seven days for one month (Brun et 
al., 2010). The exact mode of action of Suramin is still not known, but it is taken up by the 
parasites by receptor mediated endocytosis (Vansterkenburg et al., 1993; WHO, 2013).  
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Figure 1-3 Taxonomy of the human pathogenic genera (blue) within the kinetoplastida 
order, and the animal pathogens within the Trypanosome genera 
The taxonomy of the human pathogenic genera is shown alongside the animal pathogenic 
trypanosomes. The human pathogenic genera are shown in blue, with the human pathogenic 
Trypanosoma species highlighted in red. Animal pathogenic Trypanosomes are in bold, whilst 
both human and animal pathogens are in bold and underlined (Federhen, 2012; Uilenberg, 
1998). 
Pentamidine was developed in 1937, and is used to treat first stage T. b. gambiense 
infections (Steverding, 2010). The mode of action is still unknown, but Pentamidine is 
known to bind to AT-rich DNA (Fox et al., 1990). The drug is actively transported into T. 
brucei blood-stream forms using a number of transporters (Damper & Patton, 1976; WHO, 
2013). Pentamidine is delivered intramuscularly for up to ten days. However, clinical trials 
have begun to determine the effectiveness of a three day regimen (WHO, 2013). 
Pentamidine treatment is a highly effective therapy, with a cure rate of between 93 and 
98% (WHO, 2013). 
The organoarsenic Melarsoprol was developed in 1949, and is used to treat the second 
stage disease caused by both T. b. rhodesiense and T. b. gambiense (Brun et al., 2010; 
Steverding, 2010). Melarsoprol is delivered by intravenous injection at 24 hour intervals for 
ten days (Brun et al., 2010). The active compound is melarsen oxide, which is produced 
from metabolised Melarsoprol (Barrett et al., 2011). The main issue with Melarsoprol is the 
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reactive encephalopathy that occurs in 5-10% of cases, with 1-5% of those resulting in 
death (Kuzoe, 1993). The mechanism of action is still unknown, but Melarsoprol is thought 
to inhibit dithiol-containing enzymes in both trypanosomes and mammals (WHO, 2013). 
Eflornithine (also called DFMO) was originally produced as an anti-cancer therapeutic in the 
1970s, but was re-purposed in 1990 for use against T. b. gambiense infections (Meyskens & 
Gerner, 1999; Steverding, 2010). Eflornithine targets ornithine decarboxylase, which is 
involved in polyamine synthesis (Oredsson et al., 1980). Eflornithine is only active against T. 
b. gambiense because the turnover rate of the ornithine decarboxylase enzyme is 
approximately 4 times slower in this species then in T. b. rhodesiense (18/19 hours and 4 
hours respectively) (Iten et al., 1997). Eflornithine is difficult to administer as it requires 
slow intravenous delivery at six-hour intervals for fourteen days (Brun et al., 2010). 
Nifurtimox is used for the treatment of American trypanosomiasis, caused by the related 
trypanosome T. cruzi (WHO, 2013). It is not registered as a treatment for HAT, but is used in 
combination with Eflornithine (referred to as Nifurtimox Eflornithine combination therapy, 
or NECT) (WHO, 2013). This combination therapy involves the intravenous administration 
of Eflornithine every twelve hours for seven days, with Nifurtimox administered orally three 
times daily for ten days (Barrett & Croft, 2012). This combination not only improves the 
administration regimen, but it is hoped it will delay the onset of drug resistance (Barrett & 
Croft, 2012). Nifurtimox is a prodrug, meaning it requires additional processing for it to be 
trypanocidal. This processing is performed by trypanosomal type I nitroreductases, which 
reduce nifurtimox to its trypanocidal nitrile product (Hall et al., 2011). The targets of this 
nitrile product have yet to be identified (Hall et al., 2011). 
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Figure 1-4 Current treatments for HAT 
Chemical structures of the compounds currently used to treat HAT. Structures were rendered 
using Chemdraw 14, and based on the structures depicted in (Steverding, 2010). 
The establishment of the Drugs for Neglected Diseases initiative (DNDi) has triggered a 
massive increase in the amount of research into drugs for diseases such as HAT. The 
ultimate aim of DNDi (with regards to HAT) is to deliver a treatment against both stages of 
the disease that is safe, effective when administered orally, and affordable (DNDi, 2016). 
The side effects, delivery route and length of treatment require drug administration to be 
performed in either a hospital setting, or under close supervision. (Keating et al., 2015). 
This significantly increases the cost of treatment, and has been reviewed recently (Keating 
et al., 2015). Three drugs identified by the DNDi initiative to help address these issues are 
described below. 
Fexinidazole was originally identified in the 1970s, where its trypanocidal properties were 
first observed (Jennings & Urquhart, 1983; Raether & Seidenath, 1983; Torreele et al., 
2010). In the current studies, Fexinidazole is administered orally, and has been shown to be 
effective against both stages of T .b. gambiense and T. b. rhodesiense infections (Torreele et 
al., 2010). Phase I clinical trials began in 2009, with phase II/III clinical trials commencing in 
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late 2012 (Torreele et al., 2010; WHO, 2013). Whilst the mechanism of action has yet to be 
elucidated, it is thought that it may be a prodrug that needs to be reduced in order to be 
activated, like nifurtimox (Torreele et al., 2010).  
SCYX-7158 is a member of the benzoxaborole class of compounds (Jacobs et al., 2011). It 
has been shown to be active against both T. b. rhodesiense and T. b. gambiense in vitro, and 
is able to cure both stages of the disease in a murine model (Jacobs et al., 2011). The 
compound is orally active, and progressed to phase I clinical evaluation in 2012 (Jacobs et 
al., 2011; WHO, 2013). Safety profiling was successfully completed in 2015, and patient 
recruitment for trials are due to begin this year (2016) (DNDi, 2015). 
DB829 is an orally active aza-analogue of furamidine (Wenzler et al., 2009). Furamidine was 
under development as a therapeutic against HAT, but it was shown to cause severe liver 
toxicity (Wenzler et al., 2009). DB829 is more effective against T. b. gambiense in vivo, with 
an intraperitoneal injection curing all infected animals (Wenzler et al., 2013). The same 
dose cured only 50% of T. b. rhodesiense infected mice (Wenzler et al., 2013). DB829 is also 
curative in a murine model of second stage T. b. gambiense infection, curing all infected 
mice when administered for 10 days (Wenzler et al., 2009). DB829 is under preclinical 
investigation (WHO, 2013). 
1.1.5 Current treatments for AAT 
The therapeutic arsenal against AAT is rapidly dwindling due to the emergence of drug 
resistance (Delespaux et al., 2008). Despite this, the production of new trypanocides is not 
considered commercially viable, and the last drug was developed in 1961 (Connor, 1992). 
The current drugs against AAT are described below. As with the drugs against HAT, delivery 
method tends to be injection by intramuscular, intravenous or subcutaneous routes. Some 
of these therapeutics are used as prophylactics in animals, although the majority are used 
as curative agents. Certain HAT therapies are also used against AAT. One example is 
Suramin, which is used in camels to combat T. evansi infections (Connor, 1992). The 
chemical structures are shown in Figure 1-5. 
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Figure 1-5 Current treatments for AAT 
Chemical structures of the compounds currently used to treat AAT. Structures were rendered 
using Chemdraw 14, and based on the structures depicted in (Melaku & Birasa, 2013). 
Diminazene aceturate is an aromatic diamidine that is effective against T. congolense, T. 
vivax and T. brucei (Leach & Roberts, 1981). It was introduced in the 1950s as a curative 
therapeutic that can be delivered either intramuscularly or subcutaneously (Connor, 1992; 
Leach & Roberts, 1981). Diminazene aceturate is thought to bind to AT rich regions of the 
kinetoplastid DNA (kDNA), where it can cause the complete loss of this nucleic acid 
(González et al., 1997; Riou & Benard, 1980). Diminazene aceturate is rapidly excreted and 
it was thought that this would help prevent the occurrence of drug resistant strains (Leach 
& Roberts, 1981). However, a naturally occurring resistant T. vivax strain was identified in 
1967 (Leach & Roberts, 1981). 
Homidium is a phenanthridinium compound, and is available in two forms: chloride and 
bromide (Connor, 1992). Homidium bromide (also called ethidium bromide) was developed 
in 1952 (Watkins & Woolfe, 1952). Both forms are active against T. congolense and T. vivax 
infections, and are used as curative therapies (Connor, 1992; Kinabo, 1993). The drug is 
delivered via intramuscular injection (Kinabo, 1993). The mechanism of action for both 
forms of homidium is to intercalate with DNA and RNA and block the actions of DNA 
polymerases (Kinabo, 1993; Youssif et al., 2010). Because of the non-specific nature of the 
drug, it is not surprising that it is highly toxic. In goats, the drug is neurotoxic and can cause 
demyelination, as well as bloody diarrhoea, colic and alopecia (Youssif et al., 2010). The 
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drug needs to be fully eliminated from the animal before the meat is safe for human 
consumption (Youssif et al., 2010).  
Isometamidium is a phenanthridinium compound like homidium, and is active against T. 
congolense, T. vivax, T. brucei and T. evansi (Kinabo, 1993). It was synthesised in 1958, and 
is delivered intramuscularly (Wragg et al., 1958). It is used as both a therapeutic and a 
prophylactic treatment (Sahin et al., 2014). Isometamidium is an irritant and can cause 
tissue damage at the injection site (Connor, 1992; Kinabo, 1993). 
Quinapyramine is a bis-quaternary compound that was introduced in the 1950s as both a 
therapeutic and a prophylactic (Kinabo, 1993). It was effective against T. congolense, T. 
vivax, T. brucei, T. evansi, T. equinium and T. equiperdum, but was withdrawn in 1976 due 
to increased resistance against it (Anene et al., 2001; Leach & Roberts, 1981). 
Quinapyramine has since been introduced in two forms: quinapyramine prosalt and 
quinapyramine sulphate. The sulphate form is used against T. brucei, T.congolense and T. 
vivax as a therapeutic, and is delivered by subcutaneous injection (Leach & Roberts, 1981). 
The prosalt form is used as both a therapeutic and prophylactic (Connor, 1992). 
1.1.6 Drug Resistance 
Drug resistance seen in Trypanosoma parasites will be either innate or acquired (Anene et 
al., 2001). One example of innate resistance can be seen with eflornithine. This treatment is 
only effective against T. b. gambiense, not T. b. rhodesiense. This is because the enzyme 
targeted by eflornithine has a faster turnover rate in T. b. rhodesiense (Iten et al., 1997). 
Acquired resistance requires exposure of the parasite to sub-lethal concentrations of the 
drug. Factors that increase the likelihood of resistance include over use, failure to complete 
course of treatment and the use of drugs prophylactically (Barrett et al., 2011). Another 
factor that plays an important role in AAT is the availability of poor quality counterfeit drugs 
(Schad et al., 2008).  
The mechanism of action for many of the trypanocidal drugs (for both HAT and AAT) is not 
fully understood. It is therefore difficult to fully understand how the parasites have evolved 
resistance. However, a decrease in drug uptake or an increase in drug efflux appears to be 
behind many cases of resistance. In eflornithine resistance, the enzyme turnover rate is not 
the only resistance mechanism available to the T. b. rhodesiense parasites. A decrease in 
drug accumulation due to the loss of the AAT6 transporter has been reported (Bellofatto et 
al., 1987; Phillips & Wang, 1987; Vincent et al., 2010). 
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The P2 adenosine transporter AT1 (encoded by the gene TbAT1) has been linked to 
resistance to Melarsoprol and diamidines, including Pentamidine and Diaminazene (Baker 
et al., 2013; Carter et al., 1995; Carter & Fairlamb, 1993; Teka et al., 2011). Loss of this 
transporter is not the only way to decrease drug accumulation within the parasite. Analysis 
of melarsen oxide (the active metabolite of Melarsoprol) sensitivity in AT1 knock-out strains 
indicated that, whilst sensitivity was reduced, the parasites were still susceptible to the 
drug (Matovu et al., 2003). A second transporter, HAPT1, has also been linked to resistance 
against Melarsoprol and diamidines (Bridges et al., 2007; de Koning, 2008; Paine et al., 
2010; Teka et al., 2011). The current theory for Melarsoprol and Pentamidine resistance is 
that the loss of both AT1 and HAPT1 is required for high resistance levels within the 
parasites (Barrett et al., 2011). The loss of either transporter may be due to point mutations 
within the gene, loss of the gene, or the gene not being transcribed (Barrett et al., 2011; 
Carter et al., 1995; Lanteri et al., 2006; Stewart et al., 2010). Another transporter thought 
to contribute to Melarsoprol and Pentamidine accumulation within the parasite is 
aquaglyceroporin 2 (AGP2) (Baker et al., 2012). AGP2 a is a porin that is involved in 
osmoregulation and metabolism, but causes resistance when knocked out in blood stream 
form cells (Baker et al., 2012).  A second, unrelated mechanism for Melarsoprol resistance 
has been identified. This involves the overexpression of an efflux pump, specifically MRPA 
(Lüscher et al., 2006). This causes the log IC50 of melarsen to double (Lüscher et al., 2006).  
Resistance to nifurtimox also confers resistance to fexinidazole, a new therapy currently in 
phase III clinical trials (Sokolova et al., 2010). Exactly how this occurs is not fully 
understood, but may be linked to both compounds requiring activation in vivo to produce 
the trypanocidal species (Sokolova et al., 2010) The idea that resistance to a new 
therapeutic is being primed before it has even entered the market is concerning. 
1.1.7 African Trypanosomiasis – a perspective 
The number of cases of HAT have reduced significantly, but the isolation of drug-resistant 
field strains to all current therapeutics (including those used to treat AAT) is very 
concerning (Melaku & Birasa, 2013). This highlights the need for continued research in this 
area. Work on therapies to combat AAT is also sorely needed, not just from an economic 
point of view, but also with regards to human health. Infected animals (both wild and 
domestic) act as a reservoir for human infections, so controlling these through therapeutics 
(as well as additional strategies such as vector control) is vital. As a consequence, potential 
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new drug targets need to be identified, and work on new therapeutics for HAT and AAT 
must be a priority. 
1.2 Flap Endonucleases 
1.2.1 The Cellular Roles of Flap Endonucleases 
Flap endonucleases are essential enzymes involved in the replication and maintenance of 
the genome. Commonly referred to as FENs, 5ʹ nucleases and 5ʹ-3ʹ exonucleases, these 
structure-specific enzymes are characterised by their unique ability to recognise 5ʹ flaps. 
FENs are classed as metalloenzymes, as they require the presence of divalent metal cations 
to process their substrates.  The essential roles of these enzymes in DNA replication and 
repair are discussed below.  
1.2.1.1 DNA Replication 
Precise replication of DNA is essential for cell viability. This semi-conservative process is 
highly regulated, ensuring a low error rate of an estimated 10-9 mutations per base pair per 
year in higher animals  (Kumar & Subramanian, 2002). DNA replication itself is highly 
complex, and is summarised in Figure 1-6. Within the eukaryotic cell, replication begins by 
the assembly of the origin-replication complex at the replication origin (Henneke et al., 
2003). This complex contains helicases, which unwind the DNA duplex. This causes the 
recruitment of Replication Protein A (RPA), which stabilises the single stranded DNA. DNA 
Polymerase α then synthesises a complementary RNA/DNA primer on the parental DNA 
strands. This is followed by a ‘polymerase switch’ from DNA Pol α to DNA Pol δ on the 
lagging strand (Henneke et al., 2003), and to DNA Pol ε on the leading strand (Zheng & 
Shen, 2011). This process requires the presence of two proteins: replication factor C (RFC) 
and PCNA (proliferating cell nuclear antigen). These two proteins, plus DNA Pol δ/ε, form 
the holoenzyme that extends the RNA/DNA primer. This forms the replication fork, which 
moves along the DNA strand as replication progresses.  
The DNA helix is anti-parallel, so replication can only occur in one direction: 5ʹ to 3ʹ (Lodish 
et al., 2004). On the leading strand this is not an issue, because DNA replication can occur 
continuously from a single RNA/DNA primer (Figure 1-6). The problem arises on the lagging 
strand, where replication has to occur in the opposite direction (3ʹ to 5ʹ) to the moving 
replication fork (Figure 1-6). The solution is a series of short RNA/DNA primers (synthesised 
by primase; a heterotetramer of RNA Pol and DNA Pol α) that are produced every few 
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hundred base pairs (Zheng & Shen, 2011). These are elongated by DNA Pol δ to form 
Okazaki fragments (short, discontinuous sections of DNA) (Zheng & Shen, 2011). The initial 
RNA/DNA primer is displaced by DNA Pol δ, and FEN1 is recruited by PCNA to cleave the 
displaced RNA/DNA primer (Henneke et al., 2003). The final step is the recruitment of DNA 
Ligase 1 by PCNA, to seal the nick between the DNA strands and maintain genomic integrity 
(Henneke et al., 2003).  
Three possible pathways for the removal of the RNA/DNA primer have been postulated: the 
RNase H-FEN1, FEN1-Dna2 and FEN1 only pathways.  The RNase H-FEN1 pathway is not 
thought to be the main route in eukaryotes, because  deletion of the genes encoding RNase 
H1 and H2  in yeast does not cause an obvious phenotype  (Zheng & Shen, 2011). The FEN1-
Dna2 pathway (Figure 1-7) is thought to be important in yeast. Studies in Saccharomyces 
cerevisiae where the Dna2 protein was mutated to prevent its endonuclease activity did not 
allow the cells to grow (Lee et al., 2000). However, it is thought to be less important in 
mammals, where DNA2 is primarily associated with mitochondrion, and any that remains in 
the nucleus is not associated with replication foci (Duxin et al., 2009; Zheng et al., 2008). It 
is therefore the FEN1-only pathway (Figure 1-7) that is thought to be the dominant route in 
mammals. This pathway starts with the strand displacement of the RNA/DNA primer by 
DNA Pol δ. Garg et al showed that DNA Pol δ is only capable of displacing 1-2 nucleotides, 
leaving an ideal substrate for FEN1 cleavage (Garg et al., 2004).  
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Figure 1-6 An overview of semi-conservative DNA replication in eukaryotes 
Leading strand synthesis: 1. RNA/DNA primer synthesis by DNA Pol α. 2. DNA Pol α is displaced, 
and PCNA is recruited by RFC. 3. The DNA strand is elongated to produce nascent DNA, by DNA 
Pol ε.  
Lagging strand synthesis: 1. RNA/DNA primer synthesis by DNA Pol α. 2. DNA Pol α is displaced, 
and PCNA is recruited by RFC. 3. The Okazaki fragment is elongated by DNA Pol δ. 4. The 
downstream Okazaki fragment is displaced (via strand displacement) by DNA Pol δ. 5. FEN1 is 
recruited by PCNA. 6. Cleavage of the 5′ DNA/RNA flap by FEN1. The nick is then ligated by DNA 
Lig 1 to maintain genomic integrity.  
Reproduced by permission from John Wiley and Sons: EMBO Reports (Henneke et al., 2003). 
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Figure 1-7 Removal of the RNA primer using either the FEN1 only, or FEN1-Dna2 
pathways 
DNA Pol δ (blue) displaces the 5′ end of the downstream initiator primer to produce a 5′ flap. 
Production of a small flap (A; 2-12 nucleotides) is cleaved by FEN1 (pink) (Garg et al., 2004). 
Production of a large flap (B; ≥30 nucleotides) results in the recruitment of RPA (yellow) (Bae & 
Seo, 2000). Dna2 (purple) is recruited, which displaces RPA and periodically cleaves the single 
stranded DNA (Bae & Seo, 2000). This produces a 5-6 nucleotide flap that cannot be bound by 
RPA, but can be cleaved by FEN1 (Bae & Seo, 2000; Zheng & Shen, 2011). DNA Lig 1 (cyan) 
ligates the two Okazaki fragments together to form a complete nascent DNA strand.  
1.2.1.2 Rescuing Stalled Replication Forks 
During DNA replication, the replication fork moves along the duplex DNA, unwinding it as 
replication progresses. Replication forks are required for complete genomic replication, so 
anything that prematurely halts its progress is detrimental to the cell. In eukaryotic cells, a 
number of checkpoint kinases are activated when a replication fork stalls (Labib & Hodgson, 
2007). Without these, the replication fork will collapse, producing double-stranded DNA 
breaks which are fatal for the cell (Hodgson et al., 2007; Lopes et al., 2001; Tercero & 
Diffley, 2001). Replication forks stall for a number of reasons. Some are part of the cell’s 
normal replicative process, and are referred to as replication fork barriers. These include 
GC-rich regions of DNA, other protein-DNA complexes, polar barriers that form at transfer 
RNA genes, and bidirectional barriers at centromeres (Hodgson et al., 2007). Other, less 
favourable, reasons for replication fork stalling include dNTP depletion, and DNA lesions 
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that form following assault by exogenous factors, for example ultraviolet radiation (Mirkin 
& Mirkin, 2007). 
FEN1 interacts with WRN (Werner Syndrome Protein), a helicase from the RecQ subfamily. 
These two proteins co-localise to the site of the stalled replication fork, where WRN is 
thought to produce a single-stranded 5ʹ substrate. RPA associates with the single-stranded 
DNA, where it is phosphorylated. FEN1 cleaves the single-stranded DNA via its gap 
endonuclease activity (see section 1.2.3.1), which is stimulated two-fold by the presence of 
phosphorylated RPA. This allows the initiation of break induced replication, which rescues 
the replication fork (Sharma et al., 2004a; Zheng et al., 2005). 
1.2.1.3 DNA Repair 
DNA lesions block DNA replication and transcription. If these are left untreated, or they are 
repaired incorrectly, they will lead to mutations that could impact cell viability. DNA lesions 
arise from both exogenous and endogenous agents. Endogenous agents include by-
products from oxidative respiration and redox cycling events involving environmental toxins 
(Jackson & Bartek, 2009). The most common exogenous agent is ultraviolet light, but other 
examples include ionizing radiation and tobacco products (Jackson & Bartek, 2009). 
Consequently, the cell has a large number of DNA repair pathways, including mismatch 
repair, base excision repair and nucleotide excision repair. The repair of DNA is relatively 
straightforward, because DNA is a duplex comprised of two complementary strands. Any 
damage in one strand can be repaired by using the second strand as a template. The 
complexity in this process arises from the number of proteins involved.  
Defects in the cellular DNA repair pathways can predispose the organism to a number of 
diseases. The most commonly associated disease is cancer. Mutations in XPG (a FEN1 family 
protein involved in nucleotide excision repair) can cause xeroderma pigmentosum. This 
predisposes the individual to skin cancer (Jackson & Bartek, 2009). Another example 
involves the BRACA 1+2 genes. These are involved in homologous recombination, and 
mutations in these predisposes the individual to breast cancer (Jackson & Bartek, 2009). 
Overexpression of FEN1 has been seen in a number of cancers. The expression of FEN1 in 
colon, stomach and lung tumours increased 1-2 fold, whilst a 2.5 fold increase in FEN1 
expression was seen in breast and uterine samples (Singh et al., 2008). An increase in FEN1 
expression can be correlated with increasing severity of breast cancer tumours (Singh et al., 
2008). Mutations within the FEN1 protein itself have been observed in a number of human 
cancer types including non-small cell lung carcinoma, melanoma and breast 
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adenocarcinoma (Zheng et al., 2007). Another group of diseases associated with defective 
DNA repair are the neurodegenerative disorders. For example Cockayne syndrome is 
caused by mutations in genes involved in nucleotide excision repair (including XPG); 
similarly with cerebro-oculo-facio-skeletal (COFS) syndrome (Jackson & Bartek, 2009).  
FEN1 is directly involved in base excision repair. Two FEN1 family members, EXO1 and XPG, 
are involved in mismatch repair and nucleotide excision repair respectively. The base 
excision repair (or BER) pathway corrects single base DNA damage caused by alkylation, 
deamination and oxidative damage (Robertson et al., 2009). There are two BER pathways, 
short-patch BER and long-patch BER. Short-patch BER is initiated by DNA glycosylase. This 
enzyme recognises and removes a damaged base by cleaving the N-glycosidic bond 
(Robertson et al., 2009). This leaves a gap called the apurinic/apyrmidinic (AP) site. DNA AP 
endonuclease (APE1) then cleaves the DNA backbone to produce a single stranded DNA 
nick. APE1 processes this to create a single nucleotide gap in the DNA (Robertson et al., 
2009). This is filled  by DNA Pol β, and the process is completed by DNA Lig III (Robertson et 
al., 2009). The long-patch BER pathway was initially described by Frosina et al (1996), and is 
summarised in Figure 1-8 (Frosina et al., 1996). This pathway begins in much the same way 
as the short-patch pathway up until the polymerase recruitment stage. At this step either 
DNA Pol β or DNA Pol δ is recruited, along with PCNA, FEN1 and DNA Ligase 1. DNA Pol β/δ 
then displaces the DNA strand adjacent to the AP site, creating a flap substrate. FEN1 
cleaves this flap, leaving an end that can be ligated by DNA Lig I (Pascucci et al., 2011). 
Nucleotide excision repair (NER) deals with a wide range of structurally unrelated lesions. 
These include cyclobutane pyrimidine dimers and 6,4 photoproducts, which are caused by 
exposure to UV light (Costa et al., 2003). These lesions distort the DNA helix, interfere with 
DNA base pairing and block DNA transcription (Costa et al., 2003). The human NER pathway 
is complex because it requires the coordinated action of a large number of proteins. The 
FEN1 family member involved in NER is XPG. The role of XPG in this process is to cut at the 
3ʹ end of the DNA damage to facilitate its removal (de Boer & Hoeijmakers, 2000). 
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Figure 1-8 The role of FEN1 in long patch base excision repair 
The single stranded nick is processed by APE1to create a single nucleotide gap in the DNA 
(Robertson et al., 2009). DNA Pol β/δ fills the nucleotide gap (red) whilst displacing the adjacent 
DNA strand. This forms a flap that is cleaved by FEN1 (Pascucci et al., 2011). DNA Lig I then 
ligates the nascent DNA to the original backbone to complete the repair process (Pascucci et al., 
2011). 
Mismatch repair (MMR) deals with two types of DNA errors. The first is base-base 
mismatches, caused by DNA polymerase errors (Jiricny, 2006). The second is 
insertion/deletion loops that are produced as a result of microsatellite instability (Jiricny, 
2006). Microsatellite instability occurs when the number of microsatellite repeats (short, 
repeated DNA sequences) changes from the original DNA template (NCI, 2015). Without the 
mismatch repair pathway, these errors are left uncorrected, and ultimately leads to cancer 
(Jiricny, 2006). The FEN1 family member involved in MMR is EXO1. The role of EXO1 in this 
process is to degrade the DNA in a 5ʹ to 3ʹ direction to remove the mismatched DNA 
(Jiricny, 2006). 
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1.2.1.4 Telomere Maintenance 
At the end of each chromosome is a protective cap, known as a telomere. This cap protects 
chromosomes from recombination and end-to-end fusion (Cong et al., 2002). Telomeres 
also prevent the ends of chromosomes from being recognised as DNA damage, and they 
allow complete replication of the chromosomes, specifically in lagging strand synthesis 
(Cong et al., 2002). Telomeres are comprised of tandem repeats of a hexanucleotide 
sequence (Blackburn et al., 2006). In mammals, that sequence is comprised of TTAGGG, 
with a single 3ʹ overhang (Cong et al., 2002). This 3ʹ overhang is able to insert into the 
duplex telomeric DNA, where it forms a T-loop structure (Cong et al., 2002; Stewart et al., 
2012). In addition to the tandem repeats, telomeres are characterised by the presence of 
specialised multi-protein complexes (Stewart et al., 2012).  In mammals, this is known as 
shelterin (Stewart et al., 2012). 
Because of the repetitive nature of the telomeres, their replication is a difficult, but 
essential, process. Without the telomere, the chromosomes shorten with every round of 
DNA replication. This leads to either cellular senescence or apoptosis (Gilson & Géli, 2007). 
Telomeric replication is often hampered by the formation of G quadruplexes (G4), triple 
helices, four-way junctions, D-loops and T-loops (Gilson & Géli, 2007). The process is 
reviewed in Gilson and Géli (2007), but the mammalian cell model is described briefly here. 
The RecQ helicases WRN and BLM are thought to unwind unusual DNA structures formed 
by the repetitive nature of telomeric DNA (Gilson & Géli, 2007). This activity is stimulated 
by two proteins: TTAGGG-repeat factor 2 (TRF2) and protection of telomeres protein 1 
(POT1). TRF2 also stimulates FEN1 activity on Okazaki fragment maturation (Gilson & Géli, 
2007). Mammalian homologues of the RRM3/PIF1 related helicase allows the replication 
fork to continue on through the nucleoprotein complex (Gilson & Géli, 2007). 
More recent work on the role of FEN1 and related enzymes at telomeres has shown that 
FEN1 can form a complex with telomerase. Telomerase is a reverse transcriptase that 
counteracts telomere shortening by extending the 3ʹ end of chromosomes (Gilson & Géli, 
2007; Sampathi et al., 2009). Whilst this interaction may be indirect, knocking down FEN1 in 
telomerase-positive cancer cell lines does cause gradual telomere shortening and retarded 
cell growth (Sampathi et al., 2009). This indicates a role for FEN1 in telomerase regulation 
(Sampathi 2009). Human FEN1 has also been shown to cleave 5ʹ flaps that contain G4 DNA, 
indicating its importance in lagging-strand replication at the telomeres (Vallur & Maizels, 
2010). FEN1 and its family member EXO1 exhibit exonuclease activity on both DNA strands 
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of a substrate with a G-rich, 3ʹ telomeric tail (Vallur & Maizels, 2010). In addition, EXO1, but 
not FEN1, was able to excise G loops that are formed at transcribed telomeric regions 
(Vallur & Maizels, 2010). Whilst the exact roles of FEN1 and its family members in telomere 
maintenance have yet to be fully elucidated, it is clear that both FEN1 and EXO1 play 
separate but essential roles. 
1.2.2 The Essential Nature of Flap Endonucleases 
Flap endonucleases are members of the XPG/Rad2 endonuclease family, which is 
characterised by the presence of two conserved domains; the N-terminal domain and 
intermediate domain (Figure 1-9) (Harrington & Lieber, 1994a; Moritoh et al., 2005). The 
prokaryotic versions are composed of these two domains only, whilst the eukaryotic 
versions also contain a C-terminal domain (Figure 1-9). Flap endonucleases were originally 
divided into four distinct groups based on those three domains: distinct FEN1 type enzymes 
(Group 1), bacteriophage 5ʹ-3ʹ exonucleases (Group 2), prokaryotic DNA Polymerase 
exonuclease domains (Group 3; Figure 1-10) and nucleotide excision repair proteins (Group 
4) (Figure 1-9) (Lieber, 1997). Arguably, a fifth group could now be added to this schematic 
based on the identification of ExoIX, an Escherichia coli flap endonuclease paralogue 
encoded by the xni gene. This gene is common in a number of eubacteria, including 
Staphylococcus aureus and Yersinia spp (Anstey-Gilbert et al., 2013). ExoIX lacks the second 
metal ion binding site, but still retains 3ʹ-5ʹ exonuclease activity, and 5ʹ flap endonuclease 
activity (Anstey-Gilbert et al., 2013; Hodskinson et al., 2007). In eukaryotes, archaea and 
bacteriophages, a separate and distinct flap endonuclease is encoded. This enzyme 
associates with DNA polymerases via a protein platform. Within eukaryotes, there are flap 
endonuclease paralogues, specifically XPG and EXO.  
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Figure 1-9 Domain homology within the flap endonuclease family 
Schematic of FENs from a variety of different organisms, showing the homology domains: the N-
terminal domain (yellow), intermediate domain (blue striped) and C-terminal domain (red 
striped). Only the N and I domains are found in prokaryotic FEN homologues, whilst the N, I and 
C domains are found in eukaryotic FEN homologues (Harrington & Lieber, 1994a). FEN-like 
proteins can therefore be split into four groups: distinct FEN1 type enzymes (Group 1), 
bacteriophage 5′-3′ exonucleases (Group 2), prokaryotic DNA Polymerase exonuclease domains 
(Group 3) and nucleotide excision repair proteins (Group 4) (Lieber, 1997). The N-terminal 
domain typically consists of the initial 100 amino acids. Approximately 18 amino acids 
separates the N-terminal and intermediate domains, except in Group 4 proteins, where this gap 
can consist of over 640 amino acids (Lieber, 1997). The C-terminal domain is typically 
composed of basic amino acids (R, K and H), and is located at the C-terminus of the protein 
(Lieber, 1997). M. tb: Mycobacterium tuberculosis, Therm fla; Thermus flavus, Therm aq; 
Thermus aquaticus.  
Reproduced by permission from John Wiley and Sons: BioEssays (Lieber, 1997). 
  
 23 
 
Figure 1-10 Comparison of the Thermus aquaticus PolI FEN domain, and the T5 
Bacteriophage FEN 
(A) The crystal structure of the full length Thermus aquaticus PolI protein (PDB 1TAQ), 
displaying its two main domains. The FEN domain is coloured according to secondary structure, 
where alpha helices are shown in cyan, and beta sheets in purple and connecting residues in 
pink. The Klenow fragment is coloured grey.  (B) The T. aquaticus PolI FEN domain (residues 1-
296) is located at the N-terminus of the full length protein, and is shown separately. (C) 
Alignment of the T. aquaticus PolI FEN domain with the T5 bacteriophage FEN (PDB 1UT5) 
using PyMol (R = 7.746). The T5 bacteriophage is coloured according to secondary structure, 
where alpha helices are shown in red, beta sheets in yellow and connecting residues in green. 
All images and alignments were rendered using The PyMOL Molecular Graphics System, Version 
1.8 Schrödinger, LLC. 
Flap endonucleases are found in all organisms, and a high level of conservation can be seen 
between them (see Figure 1-11). This high level of conservation provides an indicator to the 
essential nature of the enzyme. This has been studied further in both prokaryotes and 
eukaryotes. Initial studies in E. coli showed that knocking out the DNA PolI gene caused cell 
death when grown on rich media, but cell viability could be restored by adding back the 
FEN domain (Joyce & Grindley, 1984). Interestingly, knocking out the DNA PolI gene in cells 
grown on minimal media had no effect on cell viability, which indicates the presence of a 
‘back-up’ protein (Joyce & Grindley, 1984). This has recently been identified as ExoIX, the 
product of the xni gene (Anstey-Gilbert et al., 2013; Fukushima et al., 2007). Double 
mutants of both the DNA PolI FEN domain and ExoIX are not viable in Bacillus subtilis 
(Fukushima et al., 2007).  
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HsFEN   1 MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQFLIAVRQ-GGDV---LQNE 
ScFEN   1 MGIKGLNAIISEHVPSAIRKSDIKSFFGRKVAIDASMSLYQFLIAVRQQDGGQ---LTNE 
TbFEN   1 MGVLGLSKLLYDRTPGAIKEQELKVYFGRRIAIDASMAVYQFVIAMKGFQEGQSVELTNE 
MjFEN   1 -----MGVQFGDFIPKNI--ISFEDLKGKKVAIDGMNALYQFLTSIRLRDGSP---LRNR 
TaFEN   1 ----------------MRGMLPLFEPKGRVLLVDGHHLAYRTFHALKG--------LTTS 
cons    1 ... ..  .. .  . ...  ... ..*.....*... .*.......   .     *... 
 
HsFEN  57 EGETTSHLMGMFYRTIRMM-ENGIKPVYVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQ 
ScFEN  58 AGETTSHLMGMFYRTLRMI-DNGIKPCYVFDGKPPDLKSHELTKRSSRRVETEKKLAEAT 
TbFEN  61 AGDVTSHLSGIFFRTLRMI-DEGLRPIYVFDGKPPTLKASELESRRQRAEDAKHEFEKAK 
MjFEN  51 KGEITSAYNGVFYKTIHLL-ENDITPIWVFDGEPPKLKEKTRKVRREMKEKAELKMKEAI 
TaFEN  37 RGEPVQAVYGFAKSLLKALKEDGDAVIVVFDAKAPSFRHEAYGGYKAGRAPTPEDF---- 
cons   61  *. .... *......... ........***...* ..  ..  .. .. .... .  .  
 
HsFEN 116 AAGAEQEVEKFTKRLVKVTKQHNDECKHLLSLMGIPYLDAPS-EAEASCAALVKAGKVYA 
ScFEN 117 T---ELEKMKQERRLVKVSKEHNEEAQKLLGLMGIPYIIAPT-EAEAQCAELAKKGKVYA 
TbFEN 120 EEGDDEAMEKMSKRMVRVGRDQMEEVKTLLRLMGIPVVQAPS-EAEAQCAELVKKNKAWA 
MjFEN 110 KKEDFEEAAKYAKRVSYLTPKMVENCKYLLSLMGIPYVEAPS-EGEAQASYMAKKGDVWA 
TaFEN  93 -------------------PRQLALIKELVDLLGLARLEVPGYEADDVLASLAKKAEKEG 
cons  121     . .  .  ........  ... . *. *.*......*. *...... ..*...... 
 
HsFEN 175 AATEDMDCLTFGSPVLMRHLTASEAKKLPIQEFHLSRILQELGLNQEQFVDLCILLGSDY 
ScFEN 173 AASEDMDTLCYRTPFLLRHLTFSEAKKEPIHEIDTELVLRGLDLTIEQFVDLCIMLGCDY 
TbFEN 179 VGTEDMDALAFGSRVMLRHLTYGEAKKRPIAEYHLDEILEASGFSMQQFIDLCILLGCDY 
MjFEN 169 VVSQDYDALLYGAPRVVRNLTTTKEMPELI---ELNEVLEDLRISLDDLIDIAIFMGTDY 
TaFEN 134 YEVRILTADKDLYQLLSDRIHVLHPEGYLI---TPAWLWEKYGLRPDQWADYRALTGDES 
cons  181  ........ ........... ..... .* .  .  ... .........*.....* .. 
 
HsFEN 235 -CES-IRGIGPKRAVDLIQKHKSIEEIVRRLDPN-----KYPVPENWLHKEAHQLFLEPE 
ScFEN 233 -CES-IRGVGPVTALKLIKTHGSIEKIVEFIESGESNNTKWKIPEDWPYKQARMLFLDPE 
TbFEN 239 -VPR-ISGIGPHKAWEGIKKYGSLEAFIESLDG-----TRYVVPEEFNYKDARNFFLEPE 
MjFEN 226 -NPGGVKGIGFKRAYELVRSGVAKDVLKKEVE---------------YYDEIKRIFKEPK 
TaFEN 191 DNLPGVKGIGEKTARKLLEEWGSLEALLKNLD------------------RLKPAIREKI 
cons  241      ..*.*...* ....  .... ... ..       .. ... . ..... ...... 
 
HsFEN 288 VLDPESVELKWSEPNEEELIKFMCGEKQFSEERIRSGVKRLSKSRQGST-QGRLDDFFKV 
ScFEN 291 VIDGNEINLKWSPPKEKELIEYLCDDKKFSEERVKSGISRLKKGLKSGI-QGRLDGFFQV 
TbFEN 292 VTPGEEIDIQFREPDEEGLIKFLVDEKLFSKERVLKGIQRLRDALTKKT-QGRLDQFFTI 
MjFEN 270 VTDNYSLSLKL--PDKEGIIKFLVDENDFNYDRVKKHVDKLYNLIANKTKQKTLDAWFK- 
TaFEN 233 LAHMDDLKLSW---DLAKVRTDLPLEVDFAKRR-EPDRERLRAFLERLEFGSLLHEFGLL 
cons  301 . . ... ...  .... ..... ... *. .*.. .. .*.  .   . ...*. .. . 
 
HsFEN 347 TGSLSSAKRKEPEPKGSTKKKAKTGAAGKFKRGK---------- 
ScFEN 350 VPKTKEQLAAAAKRAQENKKLNKN--KNKVTKGRR--------- 
TbFEN 351 T-KPQKQVNSEASTAGTKRNRGAVALPGVLQRKSSSGHKKAVKK 
MjFEN     -------------------------------------------- 
TaFEN 289 ESPKALEE------------------------------------ 
cons  361                   .            .            
Figure 1-11  Multiple sequence alignment of FEN enzymes from archaea and eukaryotes 
The sequences obtained from the NCBI database were aligned using the Multalin alignment tool, 
and are depicted using BoxShade (Corpet, 1988). Amino acid residues shaded black are 
identical, whilst residues shaded grey display similar properties. A high level of conservation 
can be seen. 
HsFEN = Homo sapiens (NP_004102.1), ScFEN = Saccharomyces cerevisiae (P26793.1), TbFEN = 
Trypanosoma brucei (XP_843679.1), MjFEN = Methanocaldococcus jannaschii (Q58839.1), 
TaFEN = Thermus aquaticus (AAA27507.1). 
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Initial studies in eukaryotes focused on the budding yeast Saccharomyces cerevisiae. The S. 
cerevisiae FEN homologue, Rad27, is a separate protein from the yeast DNA polymerase. 
RAD27 null mutants are viable, but show a phenotype characterised by temperature-
sensitivity and spontaneous mutations (Tishkoff et al., 1997). Over-expression of ExoI, the 
flap endonuclease paralogue, in the RAD27 null mutants can suppress this phenotype 
(Tishkoff et al., 1997). EXOI null mutants do not display the same phenotype as the RAD27 
mutants in that they do not display any growth defects or methylmethanesulphonate 
sensitivity (Tishkoff et al., 1997). However, the double EXOI/RAD27 mutations are lethal 
(Tishkoff et al., 1997). This implies that ExoI is capable of compensating for the loss of 
Rad27, but only when over-expressed in a laboratory environment is the phenotype fully 
recovered (Tishkoff et al., 1997).  
Five years later, similar studies were carried out in higher eukaryotes by two separate 
groups. Matsuzaki et al analysed flap endonuclease knockouts in chicken DT40 cells. The 
cells were viable, but displayed slow growth and sensitivity to both methylating agents and 
hydrogen peroxide when compared to the wild type cells (Matsuzaki et al., 2002). 
Kucherlapati et al used an in vivo model to study the effect of a null mutation within the 
FEN1 gene in mice. Heterozygotes for the null mutation were viable, but they do display a 
predisposition towards tumour development, with 17% of mice developing non-Hodgkins 
lymphoma (Kucherlapati et al., 2002). Homozygotes for the null mutation led to embryonic 
death.  
1.2.3 Properties of Flap Endonucleases 
1.2.3.1 Substrate Specificity 
Flap endonucleases display two types of structure specific endonuclease activity (gap and 
flap), and exonuclease activity. These properties are used to process DNA/RNA 
intermediates formed within the cell. 
Exonucleases remove nucleotides from the end of a polynucleotide chain. Eukaryotic flap 
endonucleases display 5ʹ-3ʹ exonuclease activity. This means they cleave nucleotides from 
the 5ʹ end, releasing mono, di- or tri-nucleotides. The exonuclease activity of FEN1 allows it 
to process single-stranded DNA, and double-stranded DNA with branched structures, 
including a 5ʹ flap, nick, gap or recessed end (Figure 1-12) (Harrington & Lieber, 1994b; 
Murante et al., 1994). The human FEN can process 5ʹ-recessed ends, but cannot process 
blunt, or 3ʹ-recessed ends (Harrington & Lieber, 1994b). Harrington and Lieber (1994b) 
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showed that FEN1 was unable to cleave single-stranded DNA. However, earlier work by 
Goulian et al (1990) showed a different result. This work looked at the cleavage capability 
of cca/exo (later thought to be FEN1) to cleave the single-stranded homopolymers dA, dT 
and dC (Goulian et al., 1990). The dT homopolymer was a better substrate than the other 
two tested. However, cleavage of the paired homopolymer to its unlabelled 
complementary strand was 98% more efficient than the single stranded version (Goulian et 
al., 1990). This difference between the two groups may be because Harrington and Lieber 
(1994b) did not use a homopolymer, or may be due to differences in the reaction 
conditions. 
Endonucleases cleave the phosphodiester bond within a polynucleotide chain. This 
cleavage is often sequence specific. However, flap endonucleases are a unique family of 
enzymes because they are structure specific (Harrington & Lieber, 1994b).  Eukaryotic FENs 
display optimal cleavage when a 5ʹ flap and a 1 nucleotide 3ʹ flap are present. The 3ʹ flap 
sits in a pocket in the human FEN (Figure 1-13), where the 3ʹ hydroxyl group of the 
nucleotide interacts with the backbone carbonyl of Lys314, and the Thr61 hydroxyl 
(Tsutakawa et al., 2011).  The 5ʹ flap is thought to fit through a characteristic helical arch, 
comprised of two alpha helices: α2 and α4. These helices are between 13-15 Å apart, which 
allows single-stranded DNA to pass through, but is too small for double-stranded DNA, 
which requires a gap of ~20 Å (Tsutakawa et al., 2011). The pseudo-Y structure (Figure 1-12) 
can be cleaved by eukaryotic FENs, but the efficiency of the reaction is reduced up to 100-
fold when compared to the 5ʹ flap structure  (Harrington & Lieber, 1994b). Additional work 
shows that all studied eukaryotic FENs are unable to process the following substrates: 
mismatched bubble, heterologous loops, 3ʹ flaps, D-loops, Holiday junctions, 3ʹ overhangs 
and 5ʹ overhangs (Alleva & Doetsch, 1998; Bornarth et al., 1999; Lieber, 1997). However, a 
recent study by Kazak et al showed that a mitochondrial HsFEN1 isoform, truncated at the 
N-terminus, is capable of binding to 5ʹ RNA flaps, R-loops and, to a lesser extent, D-loops in 
vitro (Kazak et al., 2013).  
Gap endonuclease activity is the ability to cleave single-stranded closed-circular DNA. This 
was initially described for the T5 D15 exonuclease (a bacteriophage T5 FEN family member), 
and later observed in the human enzyme (Sayers & Eckstein, 1991; Zheng et al., 2005). 
Zheng et al found that HsFEN1 can cleave a DNA bubble structure, which can arise in vivo by 
the stalling of the replication fork following exposure to UV radiation (Zheng et al., 2005). 
This gap endonuclease activity is often utilised in conjunction with the WRN protein (Zheng 
et al., 2005). 
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Figure 1-12 Branched DNA structures 
A variety of DNA structures available within the cell are depicted, including substrates 
processed by flap endonucleases. The red arrows indicate the cleavage site for flap 
endonuclease (FEN) activity. The green arrow indicates the cleavage site for gap endonuclease 
(GEN) and exonuclease (EXO) activity. Partial arrow heads represent the 3ʹ end of the DNA 
strand. Reproduced by permission from John Wiley and Sons: BioEssays (Lieber, 1997). 
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Figure 1-13 The HsFEN 3ʹ nucleotide binding pocket 
(A) The human FEN (blue) with the 3′ nucleotide pocket highlighted in yellow. Residues L53, 
Q54, T61, K314, F316, S317 and R320 are shown as sticks (Friedrich-Heineken & Hubscher, 
2004). (B) An alternative view of the human FEN 3′ nucleotide pocket is shown, with DNA 
product present (red). The images were produced using RCSB PDB 3Q8L, and rendered using 
The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. 
1.2.3.2 The Role of Divalent Metal Ions 
Flap endonucleases are members of the metal ion dependent phosphoryl transferase 
family. This means they catalyse the transfer of a phosphoryl group from a donor molecule 
onto an acceptor molecule. FENs do this by targeting the phosphodiester bond present 
between the 3ʹ oxygen and the phosphorous atom. This bond is then broken by hydrolysis 
and forms two products: one that terminates in a 5ʹ phosphate, and a second that 
commences in a 3ʹ hydroxyl group. 
Until recently, it was thought that the FENs used a two-metal-ion system to facilitate 
cleavage. In this mechanism, the two metal ions sit either side of the scissile phosphate 
(Yang, 2008). The first metal ion is situated on the nucleophile side, whilst the second is 
positioned on the side where the phosphoryl group leaves. The process is summarised in 
Figure 1-14. Briefly, the first metal ion polarises a water molecule, resulting in 
deprotonation (Yang, 2008). The nucleophilic water then attacks the phosphorous atom to 
form a pentacoordinate intermediate (Yang, 2008). In this intermediate species, the 
phosphorous atom is at the centre, with five atoms at the corners (Berg et al., 2002b; Yang, 
2008). It is thought that the second metal ion may destabilise the substrate and enhance 
catalysis (Yang, 2008; Yang et al., 2006). The nucleophile and scissile phosphate then form a 
phosphoryl bond, and the 3ʹ leaving group is re-protonated (Yang et al., 2006).  
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Figure 1-14 Two metal ion system of DNA 
cleavage 
The first metal ion polarises a water molecule 
or sugar hydroxyl group (blue), producing a 
nucleophile (A). The pentacovalent 
intermediate is formed by the nucleophile 
attacking the scissile phosphorous atom (B). 
The nucleophile and scissile phosphate form 
a phosphoryl bond, and the 3ʹ leaving group 
is re-protonated (C). Reprinted from 
Molecular Cell (Yang et al., 2006) with 
permission from Elsevier. 
The position of the two metal ions is important, as they are situated very close together. 
The two magnesium ions can neutralise the negative charge on the intermediate phosphate 
species. In the two-ion catalysis system, the preference for magnesium as the metal ion is 
high. This may be because of stringency imposed by the amino acid side chains coordinating 
the two magnesium ions. Magnesium is the metal ion most often associated with nuclease 
because of its high natural abundance in cells, small ionic radius (0.65 Å) and redox 
inertness (Cowan, 1998). However, some enzymes, including FEN family members, are 
capable of using a wide range of cofactors, as shown in Table 1-1. 
Recent work has highlighted the possibility of a three-metal-ion mechanism of action within 
the T5 FEN. This third divalent metal cation is thought to have a lower association constant 
for the enzyme in the absence of DNA, and only binds in the presence of the substrate 
(Syson et al., 2008). The aspartic acid at residue 130 in T5 FEN could be involved in its 
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coordination (Syson et al., 2008). However, in archaeal and mammalian FENs, the N-
terminal region may substitute for one metal ion site (Syson et al., 2008).  
Table 1-1 The wide range of cofactors utilised by nucleases 
Enzyme Cofactors References 
TaqI 
Mg2+, Mn2+, Fe2+, Co2+, Ca2+, 
Ni2+, Zn2+ 
(Cao & Barany, 1998). 
DNase I Mg2+, Mn2+, Co2+, Ca2+, Zn2+ (Price, 1975). 
BamHI Mg2+, Mn2+, Co2+, Zn2+, Cd2+ (Viadiu & Aggarwal, 1998). 
T5FEN 
Mg2+, Mn2+, Fe2+, Co2+, Ni2+, 
Cu2+ 
(Garforth et al., 2001), (Feng 
et al., 2004). 
EcoRV 
Mg2+, Mn2+, Co2+, Ca2+, Ni2+, 
Zn2+, Cd2+ 
(Vipond et al., 1995). 
 
1.2.4 Structural Characteristics of Flap Endonucleases 
The structure of the human FEN1 (HsFEN) enzyme can be simplified by dividing it into seven 
distinct structural elements: the helix-two turn-helix (H2TH), β pin, acid block, hydrophobic 
wedge, helical gateway, active site and cap (Tsutakawa et al., 2011). These elements are 
described further in Table 1-2, and depicted in Figure 1-15. Seven amino acids in the active 
site are required for metal ion coordination, and are essential for catalytic function 
(Tsutakawa et al., 2011). The seven amino acids in HsFEN are D34, D86, E158, E160, D179, 
D181 and D233. These can be split into two distinct sites: metal ion binding site 1 and 2. 
Site 1 is comprised of D86 and E160, whilst site 2 is comprised of D179, D181 and E160. The 
remaining amino acids, D34, D233 and E158, interact with both metal ions via water 
mediated interactions (see Figure 1-15) (Tsutakawa et al., 2011). Mutational analyses that 
replaced these seven amino acids with alanine residues has been performed, and in all 
cases mutations resulted in the loss of HsFEN activity (Shen et al., 1997). However, loss of 
E158, D179 and D233 also resulted in loss of substrate binding (Shen et al., 1997). 
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Table 1-2 The seven main structural elements of the human FEN 
HsFEN Structural 
Element 
Secondary structures/amino acid 
residues involved 
Function 
Helix-two turn-helix 
(H2TH) 
α helices 10 and 11 
Binds double-stranded DNA 
located upstream of the 5′-
flap. 
β pin β 6 and 7 loop 
Involved in the approximate 
100° bend of the DNA 
template strand that allows 
the enzyme to recognise 5′- 
DNA flaps. 
Acid block Residues 56-59 
Inhibits longer 3′-flap 
formation by blocking 
additional DNA movement 
(beyond the one base pair 
pocket) by charge repulsion. 
Hydrophobic wedge α helix 2, and the α2-α3 loop 
Breaks the DNA path, and 
forms the binding site of the 
3′-flap. 
Helical gateway α helix 4 
Ensures only single stranded 
DNA/RNA gains access to the 
active site. 
Active site 
Residues 34, 86, 158, 160, 179, 181, 
233 
Coordinates divalent metal 
ions, binds the 5′-flap and 
cleaves the scissile 
phosphodiester bond. 
Cap α helices 4 and 5 
Imposes a preference for 5′-
termini on the protein. 
Information obtained from Tsutakawa et al (2011). 
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Figure 1-15 The structural elements of the human FEN 
(A) The seven essential amino acids involved in the coordination of the two divalent metal ions. 
The five aspartic acid residues and two glutamic acid residues are depicted surrounding two 
Sm3+ ions (black). (B) Six of the HsFEN structural elements involved in DNA binding and 
coordination are depicted. The hydrophobic wedge (purple), helical gateway (yellow), acid 
block (red), cap (pink), β pin (cyan) and helix-two turn-helix (black) are shown in relation to the 
enzyme as a whole (grey). The remaining protein structure is shown in green. (C) Alternate view 
of the HsFEN. The images were produced using the RCSB PDB file 3Q8L, and rendered using The 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. 
The other six elements within the HsFEN protein are involved in DNA recognition, and 
ensure that only the correct substrate is recognised by the enzyme. The H2TH interacts 
with the double-stranded DNA located upstream from the 5ʹ-flap, whilst the helical cap 
ensures HsFEN only recognises 5ʹ-termini (Tsutakawa et al., 2011). The hydrophobic wedge 
and the acid block are involved in the recognition of 3ʹ-flaps. The former produces the 
binding site for the 3ʹ-flap, whilst the latter ensures that the 3ʹ-flap is no longer than one 
nucleotide in length (Tsutakawa et al., 2011). Fredrich-Heineken and Hübscher (2004) 
showed that the extrahelical 3ʹ flap pocket is conserved in FENs, and is comprised of the 
following amino acids in the human enzyme: L53, Q54, T61, K314, F316, S317 and R320 
(Friedrich-Heineken & Hubscher, 2004). Replacing four of these amino acids with alanines 
(specifically L53, T61, F316 and R320) resulted in severe loss of substrate specificity 
(Friedrich-Heineken et al., 2003). Replacing all seven amino acids with alanines resulted in 
complete loss of the 3ʹ flap specificity (Friedrich-Heineken & Hubscher, 2004). However, 
both mutants retained their general DNA binding ability, but were no longer able to 
distinguish their ‘physiological’ substrate from other ones (Friedrich-Heineken & Hubscher, 
2004). This conserved hydrophobic pocket binds to the 3ʹ flap and anchors the DNA in a 
defined orientation that positions the scissile phosphate near the active site (Friedrich-
 33 
Heineken & Hubscher, 2004). The helical gateway is the entry point of single-stranded DNA 
within the enzyme, and it also forms the active site in which the metal ions are located 
(Tsutakawa et al., 2011). The β pin is involved in bending the template DNA strand 100° 
(Tsutakawa et al., 2011). All of these elements are involved in the recognition and 
endonucleolytic cleavage of the DNA/RNA substrate by HsFEN. 
The C-terminus is involved in protein-protein interactions and DNA binding. Analysis of four 
acetylatable lysines in the C-terminus (K354, K375, K377 and K380) was performed by 
mutating them to alanines (Friedrich-Heineken et al., 2003). This had reduced activity on all 
flap substrates except for the optimal, double-flap substrate, where the cleavage efficiency 
remained the same (Friedrich-Heineken et al., 2003). Mutating Arg47 and Arg70 to alanines 
showed their importance in DNA substrate interactions (Qiu et al., 2002).  One of the first 
proteins shown to interact with HsFEN was PCNA, the processivity factor for the DNA Pol δ 
and ε. The crystal structure of PCNA, with HsFEN bound to it, is shown in Figure 1-16. HsFEN  
binds to PCNA by its C-terminus, and 3 molecules of HsFEN bind to one PCNA trimer (Chen 
et al., 1996). PCNA is therefore thought to sequester HsFEN to its site of cleavage (Li et al., 
1995). Within the HsFEN C-terminus, the amino acids TQGRLDDFFK (residues 336-345) were 
shown to be important for PCNA- HsFEN binding (Warbrick et al., 1997). A report published 
in the same year described amino acids 328-355 as being required by HsFEN to bind PCNA 
(Gary et al., 1997). This report went one step further by identifying R339 as being essential 
for HsFEN -PCNA interaction (Gary et al., 1997). PCNA is not the only protein that interacts 
with HsFEN. A search performed on the BioGRID interaction database in February 2016 
identified sixty one proteins that interact with the human FEN1 (Chatr-Aryamontri et al., 
2015). These proteins include those involved in DNA repair, replication and telomere 
maintenance (Brosh et al., 2002; Dianova et al., 2001; Lee et al., 2011; Sharma et al., 2004a; 
Sharma et al., 2004b). 
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Figure 1-16 Crystal structure of HsFEN bound to PCNA 
(A) The PCNA trimer (red) bound to three separate HsFEN enzymes (blue). (B) A single PCNA 
monomer attached to a single HsFEN enzyme. Magnesium ions are shown in black. . The images 
were produced using the RCSB PDB file 1U1L, and rendered using The PyMOL Molecular 
Graphics System, Version 1.8 Schrödinger, LLC. 
1.2.5 DNA-Protein Binding Models 
Until recently, there were two primary models to describe how flap endonucleases bind to 
5ʹ flaps. The first model, called the threading model, involves the FEN1 enzyme recognising 
the double-stranded DNA junction. The enzyme then threads the 5ʹ flap through its 
positively charged helical arch, similar to threading a needle (Xu et al., 2001).  The second 
model, called the tracking model, involves FEN1 recognising the 5ʹ end of the 5ʹ flap and 
tracking along it. Both these models rely on the presence of a free 5ʹ end. Indeed, blocking 
the 5ʹ end by hairpin formation, annealing primers or the presence of biotin-streptavidin 
complexes on the flap prevented cleavage (Murante et al., 1995; Robins et al., 1994; Xu et 
al., 2001). However, smaller modifications to the 5ʹ flap structure, for example small 
covalent adduct and RNA segments, could be tolerated and did not prevent cleavage 
(Barnes et al., 1996; Murante et al., 1995). This could not be explained by either model. 
Much of the data that corroborates the threading model also corroborates the tracking 
model. Xu et al (2001) do provide an interesting theory as to why the threading model is 
more biologically relevant. This theory was based on the observation that a 30 nucleotide 5ʹ 
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flap is cleaved with considerably less efficiency then a flap that is 10 nucleotides in length. If 
the rate-limiting step in this reaction is the formation of the DNA-substrate complex, 
tracking along three times the amount of nucleotides is not going to take that much longer 
(Xu et al., 2001). However, threading 30 nucleotides through a gap would take considerably 
longer than threading 10 nucleotides. A breakthrough came in 2012, when Patel et al 
proposed a new, threading based model. This model, descriptively named the disorder-
thread-order model, involves the FEN1 enzyme binding the substrate at the double-
stranded DNA junction and threading the 5ʹ flap through the disordered helical arch (Patel 
et al., 2012). Once threading was complete, the arch becomes ordered (Patel et al., 2012).  
Threading through the disordered arch explains why small 5ʹ flap modifications do not 
inhibit cleavage, but larger ones do. Binding of the enzyme at the DNA junction appears to 
orient the 5ʹ flap in such a way that it enters the disordered arch (Patel et al., 2012). Finally, 
ordering of the helical arch positions the catalytic residues correctly, thus linking reaction 
site selection to catalysis (Patel et al., 2012).  
1.2.6 Targeting the Human Flap Endonuclease 
HsFEN is upregulated in a number of cancers, specifically colon, stomach, lung, breast and 
uterine (Singh et al., 2008). The concept of using HsFEN as an anti-cancer target has been 
validated in vitro by McManus et al (2009). They showed that reducing HsFEN activity by 
either siRNA silencing or inhibition decreases cellular proliferation in human colorectal 
cancer cells (McManus et al., 2009). The identification and development of specific low 
molecular weight inhibitors has been of considerable interest (Dorjsuren et al., 2011; 
McWhirter et al., 2013; Panda et al., 2009; Tumey et al., 2005; Tumey et al., 2004; van Pel 
et al., 2013). The use of a HsFEN inhibitor alongside chemotherapeutics such as 
temozolamide (TMZ) would ideally lower the effective dose of TMZ required to kill the 
cancerous cells (Tumey et al., 2004). This would sensitise the cells to the DNA alkylating 
agent. Indeed, Panda et al (2009) showed that a FEN1 specific small molecular weight 
inhibitor (NSC-281680) blocked colon cancer growth when administered with TMZ (Panda 
et al., 2009). This shows the potential of HsFEN inhibitors as anti-cancer therapeutics, either 
alone or in conjunction with current chemotherapeutic agents. However, HsFEN inhibitors 
may not be specific to the enzyme in malignant cells, so measures must be in place to both 
determine and prevent the effects of these inhibitors on healthy cells (Panda et al., 2009). 
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1.3 Research Hypothesis 
There is a wealth of information available regarding flap endonucleases from 
bacteriophages, bacteria, archaea, yeast and mammals. The flap endonucleases of one 
category of organism have thus far been ignored: protozoans. Within this category are 
many medically relevant organisms where additional therapeutic targets are urgently 
required. The focus of my thesis is on the flap endonuclease from the Trypanosoma brucei 
parasite, the causative agent of African trypanosomiasis. The hypothesis that this thesis will 
test is: 
The Trypanosoma brucei flap endonuclease has the potential to be a drug target because 
the functional protein is essential for parasite survival. 
1.4 Project Aims 
In order to test my research hypothesis, five project aims were identified. These aims are as 
follows: 
1. To over-express, purify and begin to characterise the T. brucei FEN (Chapter Two). 
Using a lactose-inducible expression system, the wild type enzyme was over-expressed and 
purified. Characterisation of the enzyme was started, using a number of biochemical 
techniques. 
2. To produce an active site mutant that can bind DNA, but is catalytically inert in the 
presence of magnesium ions (Chapter Two). 
As of yet, no substrate: protein complex has been identified where the scissile 
phosphodiester bond rests in the active site. The most recently published HsFEN structure 
(PDB 3Q8L) is of the enzyme with the substrate, but the scissile phosphate is 5.2 Å away 
from the active site, and the ions occupying the divalent metal cation sites are samarium 
ions (Sm3+) (Tsutakawa et al., 2011). An active site mutant that supports DNA binding, but 
not cleavage, was produced. This was sent for crystallisation trials with collaborators in the 
Department of Molecular Biology and Biotechnology, The University of Sheffield. 
3. To determine if the T. brucei FEN is a potential therapeutic target (Chapter Three). 
In collaboration with Dr Helen Price at Keele University, the Trypanosoma brucei FEN was 
knocked down, and the wild type and D183K variant were over-expressed within the 
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parasite. Analysis of the phenotype produced by these manipulations will determine if the 
enzyme is an appropriate therapeutic target. 
4. To screen previously identified FEN inhibitors against the T. brucei and human FENs 
(Chapter Four). 
Previous work in the Sayers laboratory identified two FEN inhibitors. One inhibited T5FEN 
only, whilst the second inhibited both the T5 and T7 FENs. These were tested against the 
human and Trypanosoma brucei FENs alongside a known human FEN inhibitor: myricetin.  
5. To develop a high through-put thermal shift assay capable of screening large 
fragment libraries for FEN binding (Chapter Five). 
Thermal shift assays are increasing in popularity as initial stages in both fragment and 
compound screens. A commercially available assay was optimised for both the 
Trypanosoma brucei and human FEN, and tested against myricetin.  
  
 38 
2 Mutational Analysis and Characterisation of 
the TbFEN enzyme 
2.1 Introduction 
The aim of this chapter is to extend the previous work performed in the Sayers laboratory 
on the T5 exonuclease to a medically relevant organism. This involved analysing active site 
mutations where the functional amino acids (either aspartic or glutamic acids) were 
replaced with lysine residues. The aim is to produce catalytically inert proteins that can 
bind, but not cleave DNA. This work was primarily performed to produce a crystal structure 
of a FEN protein with its DNA substrate, in the presence of biologically relevant divalent 
cations.  
2.2 Results 
2.2.1 Bioinformatics Analysis of the TbFEN 
The Trypanosoma brucei FEN1 (TbFEN) protein sequence (XP_843679.1) was obtained from 
NCBI Protein database. This was compared to the Homo sapiens FEN1 (HsFEN) protein 
sequence (UniProtKB P39748.1). Protein sequences were aligned using Multalin, a multiple 
sequence alignment software (Corpet, 1988), and shaded in BoxShade (Figure 2-1). The 
proteins display a 51% sequence identity, as determined by BLASTP (Altschul et al., 1990). 
The TbFEN protein sequence was used to produce a predicted structure with Phyre2 (Kelley 
et al., 2015). The structure is shown in Figure 2-2, aligned to the crystal structure of the 
HsFEN (RCSB PDB 3Q8L). Aligning the Phyre2 prediction with PDB 3Q8L in The PyMOL 
Molecular Graphics System gives an RMS of 0.000. The predicted TbFEN structure displays 
the characteristic twisted β-sheet core surrounded by α helices. These provide the base for 
the characteristic helical arch that rises above the enzyme’s central beta core. Amino acid 
substitutions were modelled into the active site in silico in order to allow initial evaluation 
of their likely impact on metal ion binding. DNA constructs capable of expressing the seven 
active-site variants were produced. Two were purified (D34K and D183K), and the D183K 
variant analysed in detail (Figure 2-3).  
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TbFEN  1 MGVLGLSKLLYDRTPGAIKEQELKVYFGRRIAIDASMAVYQFVIAMKGFQEGQSVELTNE 
HsFEN  1 MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQFLIAVR---QGGDV-LQNE 
cons   1 **. ** **. *  * **.*...* ****..****** .***.**..... *  *.* ** 
 
TbFEN  61 AGDVTSHLSGIFFRTLRMIDEGLRPIYVFDGKPPTLKASELESRRQRAEDAKHEFEKAKE 
HsFEN  57 EGETTSHLMGMFYRTIRMMENGIKPVYVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQA 
cons   61  *. **** *.*.**.**.. *..*.******** **  **  *  *  .* .    *   
 
TbFEN 121 EGDDEAMEKMSKRMVRVGRDQMEEVKTLLRLMGIPVVQAPSEAEAQCAELVKKNKAWAVG 
HsFEN 117 AGAEQEVEKFTKRLVKVTKQHNDECKHLLSLMGIPYLDAPSEAEASCAALVKAGKVYAAA 
cons  121  * .  .** .**.*.* .   .* * ** ***** . ******* ** ***  * .* .  
 
TbFEN 181 TEDMDALAFGSRVMLRHLTYGEAKKRPIAEYHLDEILEASGFSMQQFIDLCILLGCDYVP 
HsFEN 177 TEDMDCLTFGSPVLMRHLTASEAKKLPIQEFHLSRILQELGLNQEQFVDLCILLGSDYCE 
cons  181 ***** * *** *..****  **** ** *.**  **   *    **.******* **   
 
TbFEN 241 RISGIGPHKAWEGIKKYGSLEAFIESLDGTRYVVPEEFNYKDARNFFLEPEVTPGEEIDI 
HsFEN 237 SIRGIGPKRAVDLIQKHKSIEEIVRRLDPNKYPVPENWLHKEAHQLFLEPEVLDPESVEL 
cons  241  * ****..* . * *  *.*  .  **  .* *** .  *.*.. ******   * ...  
 
TbFEN 301 QFREPDEEGLIKFLVDEKLFSKERVLKGIQRLRDALTKKTQGRLDQFFTITKPQKQVN-S 
HsFEN 297 KWSEPNEEELIKFMCGEKQFSEERIRSGVKRLSKSRQGSTQGRLDDFFKVTGSLSSAKRK 
cons  301  . ** ** ****.  ** ** **.  *. **       ****** ** .*       .  
 
TbFEN 360 EASTAGTKRNRGAVALPGVLQRKSSSGHKKAVKK 
HsFEN 357 EPEPKGSTKKKAKTGAAGKFKRGK---------- 
cons  361 *    *. . ..  .  *   *  
 
Figure 2-1 Multiple sequence alignment of the TbFEN and HsFEN protein sequences 
Black boxes indicate conserved amino acids. Grey boxes indicate similar amino acids. 
Annotations: TbFEN; Trypanosoma brucei flap endonuclease, HsFEN; human flap endonuclease, 
cons; consensus. 
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Figure 2-2  Structures of the TbFEN Phyre2 model (green) and HsFEN crystal structure 
(RCSB PDB 3Q8L; magenta)  
Three alternate views of the structures of the TbFEN (green) and HsFEN (magenta). Samarium 
ions (Sm3+) are depicted as black spheres. The images were rendered by the author using The 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. 
2.2.2 Construct Production and Protein Purification 
A synthetic TbFEN sequence, codon optimised for expression in Escherichia coli, was 
designed and supplied by Eurofins MWG Operon. The gene construct was inserted into the 
lactose inducible pET21a+ vector (Figure 2-4). The protein sequence was analysed using 
Expasy ProtParam, an online resource that deduces a number of physico-chemical 
properties from the protein sequence (Gasteiger E., 2005). Knowledge of the theoretical pI 
(7.66) was used to assist with protein purification. The success of the purification procedure 
was monitored by SDS-PAGE (Figure 2-7). Zymogram analysis of the wild type enzyme was 
used to assess nuclease activity of the protein, and to monitor the presence of any 
contaminating nucleases (Figure 2-7). 
A sequence encoding the TbFEN D183K variant was originally synthesised by Eurofins in a 
truncated form, missing the last 53 amino acids (TbFEN D183K ΔC). An insert encoding the 
C-terminal 53 amino acids were introduced using an oligonucleotide cassette by standard 
recombinant DNA technology, producing the TbFEN D183K full-length construct (Figure 
2-5). 
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Figure 2-3 The active site of the wild type and D183K TbFEN variant 
(A, B) Two alternate views of the Phyre2-predicted TbFEN structure, depicting the seven 
conserved amino acids located in the enzyme active site. Residues are displayed as sticks, and 
are coloured green (C) A close-up of the wild type active site. (D) A close-up of the D183K 
mutation within the active site. The mutated lysine is coloured magenta. Images were produced 
using the predicted Phyre2 TbFEN structure, and rendered by the author using The PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC. 
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Figure 2-4 Gel electrophoresis of the cloning process to insert the TbFEN construct into a 
lactose inducible expression vector 
(A) The uncut pBSiiSK (+)-TbFEN construct (U) was digested by NdeI and HindIII (DD) to 
remove the E. coli optimised TbFEN gene. (B) Successful sub-cloning into the pET21a+ 
expression vector was monitored by agarose gel electrophoresis of uncut (U) and restriction 
digested (DD) plasmid and confirmed by DNA sequencing (Medical School Core Genomics 
Facility). (C) A schematic showing part of the pET21a+ expression vector and the arrangement 
of promoters and repressor.  LK; 1 Kbp DNA ladder (NEB).  
  
 43 
Figure 2-5 Production of the full length TbFEN D183K construct 
(A) The full length wild type pET-TbFEN construct was digested by NdeI (N) and BamHI (B), and 
the resulting pET-C-terminus product was purified. (B) The pET-TbFEN D183K ΔC construct 
was digested by NdeI and BamHI (NB), and the resulting cassette was purified. (C) The TbFEN 
D183K cassette was ligated to pET-Cterm, producing the pET-TbFEN D183K full length 
construct. The success of the procedure was determined by restriction digest with NdeI and 
HindIII (NH), and confirmed by DNA sequencing (Medical School Core Genomics Facility). Each 
step was monitored by gel electrophoresis. LK; 1 Kbp DNA ladder (NEB), U; undigested plasmid. 
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Figure 2-6 SDS-PAGE analysis of the over-expression and lysis of the recombinant wild 
type TbFEN (A, B) and the TbFEN D183K variant (C, D) 
(A, C) Analysis of the un-induced (Un) and induced cell pellets at two time points post-induction.  
Samples were normalised against A600.  (B, D) Analysis following lysis of the induced cell pellet, 
as described in the materials and methods. M; low range protein marker (Bio-Rad), +; control of 
the empty pET21a+ vector in the same E. coli strain, 3 ¾, 4; time post-induction, ON; overnight 
induction, R; sample following re-suspension of the cell pellet, SC; sample after sonication, SN 
and P; supernatant and pellet respectively, following centrifugation of the lysed, sonicated 
sample, P-SN and P-P; supernatant and the pellet respectively, from polyethylenimine 
precipitation and centrifugation step.  
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Figure 2-7 SDS PAGE analysis of the wild type TbFEN purification process 
Soluble TbFEN was purified using a series of chromatography steps. (A) TbFEN was applied to a 
Bio-Rad High Q chromatography column (pH 8.7) to which it did not bind. (B) The flow through 
from the previous step was injected into a Bio-Rad High S chromatography column (pH 6.7). 
Fractions were eluted over a 0.05-0.75M salt gradient, and are shown in ascending order (white 
 blue).  (C) Pooled fractions F4-9 underwent buffer exchange by dialysis before being applied 
to a GE Healthcare HiTrap Heparin HP column (pH 6.7). Fractions were eluted over a 0.05-
0.75M salt gradient, and are shown in ascending order (white  blue). (D) Fractions 4-10 were 
concentrated and further purified by size exclusion chromatography (GE Healthcare Superdex 
200 10/300 GL, pH 6.7). Purified TbFEN was concentrated and analysed by zymogram and 
stained with both Coomassie blue (G) and ethidium bromide (H). Annotations: M; low range 
protein marker (Bio-Rad), S; sample from the dialysis bag, S2; supernatant from the dialysis bag 
following centrifugation and filtration to remove precipitation, 1-6; flow through samples 
collected during column loading, FT; flow through collected during column loading, W; column 
wash with the loading buffer, T5; T5Δ192CA positive control. 1.25/6.25; indicates the amount 
(in µg) of pure TbFEN loaded per well. 
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Figure 2-8 SDS PAGE analysis of the TbFEN D183K purification process 
Soluble TbFEN D183K was purified using a series of chromatography steps. (A) TbFEN D183K 
was applied to a Bio-Rad High Q chromatography column coupled to a Bio-Rad High S 
chromatography column. Fractions were eluted from the High S column only over a 0.05-0.75 M 
salt gradient, and are shown in ascending order (pH 7.5). (B) Pooled fractions 7-12 underwent 
buffer exchange by dialysis before being applied to a GE Healthcare HiTrap Heparin HP column 
(pH 7.5), and fractions were eluted over a 0.05-0.75 M salt gradient. (C) Fractions were pooled 
based on purity, then concentrated and purified further by size exclusion chromatography (GE 
Healthcare Superdex 200 10/300 GL, pH 6.7). Purified TbFEN D183K was concentrated and 
analysed by zymogram and stained with both Coomassie blue (D) and ethidium bromide (E). 
Annotations: M; low range protein marker (Bio-Rad), S; sample from the dialysis bag, S2; 
supernatant from the dialysis bag following centrifugation and filtration to remove 
precipitation, FT; flow through collected during column loading, W; column wash with the 
loading buffer, 10; indicates the amount (in μg) of pure TbFEN D183K loaded per well. 
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2.2.3 The Effect of the Active Site Mutation on Structure and Stability 
The effect of the D183K mutation on protein structure and stability were compared to the 
wild type enzyme using two methods: circular dichroism and thermal shift. The buffer used 
for circular dichroism was initially tested to ensure its suitability. The presence of sodium 
chloride does affect the spectra, but only at wavelengths below 195 nm (data not shown). 
The spectra were therefore measured between 195-250 nm, and samples were normalised 
before analysis. The wild type TbFEN spectra has negative values at 222 nm and 208 nm (-
4.8 x1012 and -5.5 x1012 deg cm2 dmol-1 respectively) (Figure 2-9). The spectra also displays a 
negative value at 218 nm (-4.8 x1012 deg cm2 dmol-1) and a positive value at 195 nm (3.1 
x1012 deg cm2 dmol-1) (Figure 2-9). The spectra were analysed further using the K2D3 
software (http://cbdm-01.zdv.uni-mainz.de/~andrade/k2d3/) (Louis-Jeune et al., 2012). 
Both constructs yield the same result; specifically the proteins are comprised of 71 % alpha 
helical regions, and 4.6 % beta sheet regions.  
A thermal shift-based assay was used to assess the effect of the active site mutations on 
the stability of the proteins (Lavinder et al., 2009). The assay conditions were optimised, 
and are described in Chapter 5. The D183K mutation had a de-stabilising effect on the 
TbFEN protein (Figure 2-10).  
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Figure 2-9 Comparison of the two 
recombinant TbFEN proteins by circular 
dichroism 
Far UV circular dichroism spectra for the wild 
type TbFEN (A; blue), TbFEN D183K (B; red), 
and combined (C). Lines indicate the mean of 
three biological replicates. Dotted lines indicate 
standard deviation. Spectra are given as molar    
ellipticity (Ө) at different wavelengths (λ). 
2.2.4 The Wild type TbFEN Displays Divalent Cation Specificity 
The effect of three different divalent metal cations (Mg2+, Mn2+, Ca2+) on the ability of the 
wild type TbFEN to cleave a non-specific DNA substrate was assessed. In the presence of 
Mg2+, wild type TbFEN cleaved DNA with a specific activity of 240 ± 20 U/mg (Figure 2-11). 
The presence of Mn2+ nearly doubled the rate of DNA cleavage when compared to Mg2+, 
with a specific activity of 430 ± 70 U/mg. Both Mg2+ and Mn2+ significantly increased the 
specific activity of the wild type TbFEN compared to the protein in the absence of any 
divalent metal cations (p ≤ 0.0001 for both conditions). The presence of Ca2+ appeared to 
inhibit the cleavage ability of the wild type TbFEN. The specific activity in the presence of 
Ca2+ was not significantly different to the TbFEN in the absence of any divalent metal 
cations (p = 0.9988). 
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Figure 2-10 The effect of the D183K 
mutation on structural stability 
The melting temperature (TM) was 
calculated for each protein using the 
Boltzmann equation (GraphPad Prism 
6.0). Error bars show standard deviation 
of three biological replicates. The D183K 
mutation significantly decreases the TM of 
the protein by approximately 5°C 
(calculated by an unpaired T test in 
GraphPad Prism 6.0).
2.2.5 The D183K Variant is Catalytically Inert 
The TbFEN D183K variant was predicted to be catalytically inert. This was initially assessed 
using a spectrophotometric UV assay on a non-specific DNA substrate (Figure 2-11). The 
presence of ten times the amount of the TbFEN D183K variant did not show cleavage of the 
substrate after two hours in the presence of either Mg2+ or Mn2+. This yielded a specific 
activity close to zero for D183K (3.2 ± 1.5 and 1.5 ± 0.4 U/mg in the presence of either Mg2+ 
or Mn2+ respectively). This difference was statistically significant when compared to the 
activity of the wild type enzyme (p ≤ 0.0001). The activity displayed by the TbFEN D183K 
variant in the presence of either Mg2+ or Mn2+ was not significantly different to the wild 
type TbFEN in the absence of any divalent metal cations (p = 0.9978 and 0.9991 
respectively). 
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Figure 2-11 Ability of the wild type TbFEN and D183K variant to release acid soluble 
products from high molecular weight DNA 
(A) The effect of three different divalent metal cations, and the D183K active site mutation, on 
exonuclease activity. Hydrolysis of the high molecular weight DNA substrate was assayed by UV 
spectroscopy as described in the Materials & Methods. Error bars indicate standard error of the 
mean of three biological replicates. (B) Linear regression analysis was fitted in GraphPad Prism 
(6.0), and used to calculate the specific activity per mg of protein (U/mg). Error bars indicate 
standard deviation of the mean. Statistical significance was measured by One Way ANOVA in 
GraphPad Prism (6.0), and significant results (when compared to the WT) are shown. 
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Figure 2-12 Substrate specificity and activity, determined using a Förster resonance 
energy transfer (FRET) based assay. 
(A) Reaction progress was monitored by fluorescence increase over time at the substrate 
concentrations indicated. Curves were normalised against no protein controls. (B) The initial 
rate of reaction (V0: taken in the first thirty seconds) was plotted against substrate 
concentration and analysed by non-linear regression of the Michaelis-Menton equation 
(GraphPad Prism 6.0). (C) Comparison of the fluorescence profile of 340 nM of wild type and 
D183K TbFEN against 250 nM of the 5ʹ flap substrate. (D) The structure of the DNA substrate. 
One oligonucleotide (red) forms a hairpin, whilst the second oligonucleotide (black) is labelled 
with Cy3 at the 5ʹ end and FAM at the 3ʹ end.  The mean of three biological replicates is shown, 
with error bars displaying standard deviation. 
Table 2-1 Catalytic parameters of the wild type TbFEN protein against the 5ʹ flap 
substrate 
Substrate kcat (sec-1) KM (μM) kcat/KM  (μM-1 sec-1) 
Four nucleotide 5ʹ flap 8.142 ± 1.116 1.088 ± 0.2329 7.483 
Results depict the mean of three biological replicates ± standard deviation. 
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A more specific, Förster resonance energy transfer (FRET) based assay was used to assess 
the substrate specificity of the wild type enzyme. A double stranded substrate with a four 
nucleotide 5ʹ flap was tested (Figure 2-12D). Initial rates of reaction were measured at 
different substrate concentrations ranging from 12.25 nM to 1000 nM (Figure 2-12). The 
catalytic parameters were calculated by non-linear regression of the Michaelis-Menton 
equation (Table 2-1). The TbFEN D183K variant was also tested using the FRET-based assay 
(Figure 2-12C). A single concentration of DNA substrate (250 nM) was tested against 340 
nM  of TbFEN protein, either wild type or D183K. As shown in Figure 2-12 C, incubation of 
the substrate with the TbFEN D183K variant does not produce the increase in fluorescence 
that is associated with DNA cleavage. This indicates that the D183K mutation renders the 
protein catalytically inert.  
2.2.6 The Wild type and D183K Variant Bind DNA at a Similar Level 
The ability of both the wild type and D183K enzymes to bind to the 5ʹ overhang DNA 
substrate was measured using a bio-layer interferometry-based binding assay. Biotinylated 
DNA substrate was attached to a streptavidin probe (Figure 2-13). Binding of the enzyme to 
the probe: DNA complex was measured, and catalytic parameters calculated using the in-
built software (BLItz Pro version 1.1.0.31, FortѐBIO) (Figure 2-14). A peak is seen at the start 
of the dissociation stage in the presence of high concentrations of the wild type TbFEN. The 
affinity of the TbFEN D183K variant for the DNA substrate is approximately double that for 
the wild type enzyme (2.22 and 1.37 μM respectively) (Table 2-2). The koff values remain 
fairly similar at 0.050 and 0.048 1/Ms for the wild type and mutant respectively. The wild 
type enzyme associates with the DNA substrate with greater affinity than the D183K 
mutant enzyme (kon = 1.64 x10
7 and 2.20 x104 1/s respectively). Despite this, no statistical 
significance was observed for the Kd, kon or koff between the wild type and D183K variant, 
calculated using an unpaired T Test in GraphPad Prims (p = 0.295, 0.875 and 0.374 
respectively).  
  
 53 
Table 2-2 Binding parameters for the wild type and D183K TbFEN enzymes to a 5ʹ 
overhang DNA substrate. 
Protein Kd (μM) kon (1/s) koff (1/Ms) 
Wild type 1.37 ± 0.84 0.050 ± 0.018 1.64 x107 ± 2.83 x107 
D183K 2.22 ± 0.89 0.048 ± 0.016 2.20 x104 ± 0.36 x104 
Results depict the mean of three biological replicates ± standard deviation. Parameters were 
analysed for statistical significance using an unpaired T test (GraphPad Prism 6.0). There was no 
statistically significant difference between the wild type and D183K variant. 
 
 
 
Figure 2-13 Preparation and Association of the OHP2 substrate to the streptavidin probe 
(A) Gel electrophoresis (2%) of the Bio_OHP2 substrate before (UH) and after (A) heating at 
95oC for five minutes. This creates the double-stranded 5ʹ overhang substrate. (B) Immobilising 
the biotinylated OHP2 substrate to the streptavidin probe. Binding buffer was applied for 30 
seconds, followed by the annealed substrate for 120 seconds. This was then washed for 120 
seconds in binding buffer to remove unbound DNA. The graph depicts the mean association of 
biotinylated OHP2 from 11 runs. Error bars are depicted as dotted lines, and show standard 
deviation from the mean. (C) The sequence and double-stranded structure of the Bio_OHP2 
substrate, which contains a seven nucleotide 5ʹ overhang. The biotin label is located on the 
hairpin bend (Z). 
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Figure 2-14 Binding of the wild type (A) and D183K variant (B) to the OHP2 substrate 
 (A) Association and dissociation of the wild type TbFEN to the immobilised OHP2 substrate. All 
protein concentrations were repeated at least in duplicate. Error bars are depicted as dotted 
lines, and show standard deviation from the mean. (B) Association and dissociation of the 
TbFEN D183K to the immobilised Bio_OHP2 substrate. All protein concentrations were repeated 
at least in duplicate. Error bars are depicted as dotted lines, and show standard deviation from 
the mean. All experiments were performed on three biological replicates. Graphs depicted here 
display average values of one biological replicate. 
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2.3 Discussion 
2.3.1  Bioinformatics Analysis of the TbFEN  
Comparing the protein sequence of both the TbFEN and HsFEN enzymes shows they have a 
sequence identity of 51%. The C-termini display less similarity to each other. This is thought 
to be where protein-protein interactions occur. TbFEN displays an additional 12 amino acids 
at the very end of the protein sequence (Figure 2-1). Interestingly, a similar protein 
sequence (K*$&GH^K#V^K, where * is A/G/S/T, $ is S/T, & is S/A/G, ^ is K/R and # is A/M/V) 
is seen in flap endonucleases in all trypanosomatidae currently sequenced (data not 
shown). This may indicate a specific function within this order that is currently unknown, 
and deserves further investigation. 
The structure prediction tool Phyre2 was used to model the TbFEN protein structure. Whilst 
other tools are available, Phyre2 has a user friendly interface with minimal difference in the 
accuracy of structural prediction when compared to other software (Kelley et al., 2015). 
The prediction software works on two assumptions: firstly that protein structure is more 
conserved than protein sequence, and secondly that there are a finite number of unique 
protein folds (Kelley et al., 2015). This allows the server to predict the protein structure of 
unknown proteins based on known structures. For the purposes of producing the 
hypothetical TbFEN structure, the structure of HsFEN (PDB 3Q8L) was used as a model. It is 
therefore not surprising that the two align perfectly with a RMS value of 0.00 Å in The 
PyMol Molecular Graphics System. One limitation with the Phyre2 server is that is cannot 
accurately determine the effect of point mutations on the structure of the enzyme as a 
whole, and further analysis would need to be performed (Kelley et al., 2015). The 
hypothetical structure of TbFEN examined here could inform drug discovery work by 
predicting binding modes and compound affinities (Breda et al., 2006).  
The active-site mutation produced and studied in this chapter was designed specifically to 
produce a protein that binds to DNA, but is catalytically inert. Seven amino acids within the 
enzyme’s active site are conserved and are required for metal ion coordination and 
catalytic function. Within HsFEN, these are D34, D86, E158, E160, D179, D181 and D233 
(Tsutakawa et al., 2011). These are equivalent to D34, D90, E162, E164, D183, D185 and 
D237 in the TbFEN. Performing single alanine mutations to these seven amino acids within 
the HsFEN enzyme caused loss of enzymatic activity in all cases. Substrate binding ability 
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was also lost in the E158A, D179A and D233A mutations (Shen et al., 1997). The aspartic 
acid and glutamic acid residues are all negatively charged at physiological pH (Berg et al., 
2002a). This allows them to coordinate the divalent metal cations into the active site for 
substrate cleavage, either directly or by water-mediated interactions (Tsutakawa et al., 
2011). Replacing negatively charged amino acids with positively charged lysine residues 
seemed likely to prevent coordination of one (or both) metal ions. However, it should still 
allow the negatively charged phosphodiester DNA backbone to enter the active site. 
Previous work within the Sayers laboratory with the T5 bacteriophage FEN homologue 
shows that the D155K variant (equivalent to the D183K mutation in TbFEN) was able to bind 
but not cleave the DNA substrate, and bound with a higher affinity to the mutated active 
site compared to the wild type (Zhang, 2012). 
2.3.2 Construct Production and Protein Purification 
Originally, the plasmid encoding the TbFEN D183K variant was supplied in a truncated form, 
lacking the last 53 amino acids. This was done to aid crystallography of the mutant protein, 
as the C-terminal amino acid residues encode the flexible PCNA binding domain on the 
HsFEN homologue. The C-terminus is thought to be disordered when not bound to protein 
partners, and disordered regions do not form a fixed structure under physiological 
conditions (Finger et al., 2012; Le Gall et al., 2007). The C-terminus needed to be inserted 
into the gene because it is important for substrate binding, and was inserted back by 
restriction digest (Stucki et al., 2001). 
A DNA zymogram was used to assess both the purity and nuclease activity of the purified 
enzymes. Bands of reduced fluorescence normally indicate DNA cleavage. However, these 
bands are seen for the TbFEN D183K variant, as well as for the wild type enzyme. However, 
as the work in the rest of this chapter shows, the enzymes are catalytically inert. This may 
be due to the removal of SDS from the gel, which allows the proteins to re-fold and bind to 
the DNA. When the DNA is bound to the protein, ethidium bromide can no longer 
intercalate, thus producing false positive areas of reduced fluorescence. Addition of 1% SDS 
back into the gel, followed by re-staining with ethidium bromide, removes the band of 
reduced fluorescence (data not shown). This shows the enzyme is binding to the DNA 
rather than cleaving it in the zymogram. 
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2.3.3 The Effect of the Active Site Mutation on Structure and Stability 
Circular dichroism is a spectrophotometric method commonly used to determine whether 
amino acid substitutions affect protein conformation (Greenfield, 2006b). The buffer (20 
mM phosphate pH 7.0, 50 mM NaCl, 1 mM DTT, 5% glycerol) was initially tested to ensure 
its suitability for use. Phosphate buffers are suitable for far UV studies as they do not 
absorb strongly at these wavelengths (Kelly et al., 2005). Glycerol and NaCl were used for 
their protective properties, to prevent the protein from precipitating (Kelly et al., 2005). 
Whilst no tests had been performed to see if this was the case for the TbFEN proteins, they 
were purified with a minimum of 5% glycerol and 50 mM NaCl. Having these in the buffer 
was considered a sensible precaution. The reducing agent DTT was added to ensure the 
side chains of all cysteine residues remained in their reduced state (Kelly et al., 2005). There 
are three cysteine residues within the TbFEN enzymes, so the presence of DTT was 
essential. Both DTT and NaCl do absorb strongly in far UV (Kelly et al., 2005), so the buffer 
was checked for suitability. DTT at the low concentration of 1 mM did not appear to cause 
interference between 190-250 nm (Figure 2-9). However, NaCl did absorb strongly below 
195 nm. Because of this, the proteins were measured between 195 – 250 nm, and readings 
were normalised against a no protein control. 
The wild type TbFEN spectra has negative values at 222 nm and 208 nm (-4.8 x1012 and -5.5 
x1012 deg cm2 dmol-1 respectively) corresponding to alpha helical regions, and a negative 
value at 218 nm (-4.8 x1012 deg cm2 dmol-1) and a positive value at 195 nm (3.1 x1012 deg 
cm2 dmol-1) corresponding to beta sheet regions. These characteristic features of alpha 
helical and beta sheet regions are also seen the TbFEN D183K protein (Figure 2-9) 
(Greenfield, 2006b). Both proteins display the same characteristics, specifically defined 
alpha helical and beta sheet regions that comprised 71.18% and 4.63% of the protein 
structure respectively. The K2D3 program was used to calculate this because it has been 
shown to produce improved predictions for beta sheet content within the wavelengths 
200-240 nm (Louis-Jeune et al., 2012). The alpha helical, and beta sheet content is to be 
expected when compared to the hypothetical protein structure produced by Phyre2. A 
beta-sheet core is surrounded by two alpha helical bundles, and a helical arch or clamp 
rises above this base (Figure 2-2). The D183K substitution does not appear to have a gross 
effect on protein conformation.  
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The thermal shift based assay was used to observe the effect of the D183K mutation on the 
thermal stability of the enzyme. The assay uses a dye that fluoresces when bound to 
hydrophobic regions of the protein, and is described in detail in Chapter 5 (Pantoliano et al., 
2001). This assay allows a quick and relatively cheap option for analysing the effect of the 
active site substitution on protein stability. The D183K mutation decreases the melting 
temperature of the protein, implying decreased thermal stability. This may be partially due 
to the changes affecting coordination of the divalent metal cations. The presence of Mg2+ 
increases protein stability by over 3% in the WT protein (Chapter 5). It is also likely that the 
change in charge of the D183K variant has had a negative effect on the protein. Studies 
have shown that charge-reversal point mutations can either increase or decrease protein 
stability (Dao-pin et al., 1991; Grimsley et al., 1999; Pace et al., 2000). The effect appears to 
depend on the ability of the side chains to form hydrogen bonds and ion pairs (Pace et al., 
2000). The TbFEN D183K charge reversal point mutation was detrimental in terms of 
temperature stability, but the exact mechanism remains to be elucidated. It may be due to 
steric clashes within the active site, resulting in structure destabilisation. Additional, more 
in-depth experiments should be performed. For example analysis by circular dichroism at 
different temperatures would allow the thermodynamics of protein unfolding to be 
determined (Greenfield, 2006a). Another useful technique is differential scanning 
calorimetry, which has a variety of applications including measuring thermal stability and 
absolute heat capacity (Johnson, 2013). One benefit of these two techniques is that they do 
not rely on fluorescent dyes. They also provide considerably more information than the 
thermal shift assay can. 
2.3.4 The Wild type TbFEN Displays Divalent Cation Specificity  
The divalent metal cation specificity of the wild type enzyme was tested in the absence and 
presence of three divalent metal cations; Mg2+, Mn2+ and Ca2+. Mn2+ has been shown to 
stimulate cleavage capability of the HsFEN enzyme resulting in an increased rate of reaction 
(Harrington & Lieber, 1994b). However, for the T5 exonuclease, Mg2+ and Mn2+ resulted in 
similar levels of product formation (Garforth et al., 2001). This was explored in the TbFEN 
enzyme. This work shows that the presence of MnCl2 resulted in a two fold increase in the 
amount of product formed over a two hour time period, compared to the same 
concentration of MgCl2. The reason why Mn
2+ is stimulatory is not fully understood. In 
EcoRV, it was thought Mn2+ enhanced stability and accelerated reaction rate (Baldwin et al., 
1999). However, in the T5 FEN, the Mn2+ complex was found to be less stable than the Mg2+ 
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complex (Tock et al., 2003). The T5 FEN was also able to catalyse aberrant reactions in the 
presence of Mn2+, specifically cleavage of double-stranded closed circular plasmid DNA 
(Garforth et al., 2001). This may explain why the presence of Mn2+ causes an increase in 
acid soluble nucleotides, as it is able to cleave a greater variety of the DNA substrates 
present within the solution. However, this needs to be analysed further as no investigation 
into the dependence of reaction rate on metal ion concentration was performed in this 
thesis. The presence of CaCl2 appears to be inhibitory, which was expected as this has been 
seen with HsFEN (Harrington & Lieber, 1994b), and T5FEN (Feng et al., 2004). The presence 
of either Mg2+ or Mn2+ was required for product formation, as shown by the inability of the 
enzyme to cleave DNA in the absence of any divalent metal cations. The ionic concentration 
was kept the same by the addition of more sodium chloride to ensure ionic strength was 
not a factor in DNA cleavage. This work appears to show that the TbFEN displays similar 
characteristics to the HsFEN in that Mg2+ and Mn2+ are absolute requirements for catalysis. 
2.3.5 The D183K Variant is Catalytically Inert 
The effect of the D183K mutation was initially assessed using the UV spectrophotometric 
method. The TbFEN D183K variant was tested at a concentration that was ten times that of 
the wild type enzyme in the presence of both Mg2+ and Mn2+. The results show that the 
TbFEN D183K variant displays activity similar to the wild type enzyme in the absence of any 
divalent metal ions (Figure 2-11). This inactivity was expected, and is consistent with results 
previously obtained for the T5FEN (Zhang, 2012). The FRET-based assay allows DNA 
cleavage to be analysed against a specific substrate. No increase in the fluorescent signal at 
520 nm was seen when the TbFEN D183K variant was incubated with 250 nM assay2flap. 
This indicates that the D183K mutation prevents cleavage of the Cy3 quencher dye from the 
DNA substrate. This analysis alone does not provide a reason as to why the TbFEN D183K 
variant cannot cleave DNA. It may be because the enzyme cannot coordinate the divalent 
metal ions. This would prevent the both formation of the nucleophilic water molecule, and 
substrate destabilisation, thus preventing DNA cleavage (Yang, 2008; Yang et al., 2006). 
Another possibility is that the lysine residue is affecting DNA binding by partially or fully 
blocking the active site. If the scissile phosphodiester is not present in the correct 
orientation and distance from the active site, cleavage will not occur (Horton et al., 2006). 
The ability of the enzyme to bind to DNA was explored further in the following section. 
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2.3.6 The Wild type and D183K Variant Bind DNA at a Similar Level 
DNA binding was assessed in the presence of Ca2+. As shown previously, Ca2+ is inhibitory 
towards substrate cleavage, but has been used previously to assess DNA binding 
interactions with restriction enzymes (Vipond et al., 1995) and T5FEN (Feng et al., 2004; 
Zhang, 2012). The ability of Ca2+ to promote binding, but not cleavage, is thought to be 
partially due to Ca2+ shielding negatively-charged residues located within the active site, 
thus preventing repulsion of the phosphodiester backbone (Feng et al., 2004). 
The substrate that was used to assess DNA binding contains a 5ʹ overhang, and is 
biotinylated on the hairpin of the substrate (labelled ‘Z’ in Figure 2-13 C). The hairpin should 
rest against the streptavidin probe, allowing the 5ʹ overhang to be accessible to the 
enzyme. Prior to use, the substrate was heated to produce the correct substrate. Samples 
were run on 2% agarose gels to determine the success of this procedure (Figure 2-13). The 
sample prior to heating does show as two bands on the gel. This was unexpected, as the 
substrate should be single stranded, thus preventing any ethidium bromide from 
intercalating. However, these two bands are likely to be due to the oligonucleotides pairing 
with each other in an uncontrolled manner. The heating and subsequent cooling of the DNA 
substrate produces a single band, consistent with the formation of one type, specifically the 
hairpin with a 5ʹ overhang. In the higher concentrations of wild type TbFEN used in this 
assay (10 µM, and, to a lesser extent, 5 µM), a slight peak is in seen following the beginning 
of the dissociation step. This may be due to an excess of protein present. 
In order to check the interaction of the protein with the streptavidin probe only, 10 μM of 
the TbFEN was incubated with the empty probe (data not shown). No interaction was seen, 
and the results were comparable to the buffer against the probe. A further control was 
carried out to ensure it is a protein specific interaction with the DNA: probe complex. A 
known haem binding protein, Gly1-0579 from Mannheimia haemolytica (kindly donated by 
Dr Hannah McMellon) was tested at a concentration of 10 μM. Again, no interaction was 
seen, similar to that of the TbFEN against the probe only.  
The D183K variant is able to bind to the DNA substrate with a similar affinity to the wild 
type enzyme. The mean Kd value for this interaction is twice as high as that for the wild type 
enzyme (1.22 µM and 2.22 µM respectively). However, this difference is not statistically 
significant. This data is different to what has been observed in the T5 exonuclease. The 
equivalent active site mutation (D155K) binds to DNA tighter than the wild type enzyme (Kd 
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= 7.7 nM and 13.4 nM respectively) (Zhang, 2012). It is possible that the mutation in the 
TbFEN is more detrimental than that seen in the T5 enzyme. This is feasible as an alanine 
mutation of the equivalent amino acid in the human enzyme (D179A) does loose both 
substrate binding and catalytic activity (Shen et al., 1997). Clearly, the D183K mutation is 
not as detrimental with regards to DNA binding abilities, but it could still be affecting the 
enzyme more than in the T5 version.  
2.4 Conclusions and Perspectives 
Currently, there is no satisfactory structure of any flap endonuclease with the DNA 
substrate present in the active site of the enzyme in the presence of divalent metal ions. A 
structure of the HsFEN has been reported, but the cofactors present are Sm3+. The scissile 
phosphodiester is also located 5.2 Å away from the cleaved phosphate in the HsFEN: 
product complex solved in the same paper (Tsutakawa et al., 2011). Similarly, the T4 RNase 
H enzyme was crystallised with the a forked DNA substrate, in the presence of Mg2+, but the 
DNA was not located in the active site and the enzyme was disordered (Devos et al., 2007). 
As a consequence, there is a clear need for a FEN: substrate complex with appropriate 
cofactors and with the scissile phosphodiester located within the enzyme active site. One 
aim of this chapter was to build on previous work on the T5 FEN, and determine if 
producing charge replacement mutations within the enzyme active site would assist in 
obtaining the elusive protein: substrate complex. The TbFEN D183K variant is catalytically 
inert, and can bind to DNA in the presence of Ca2+. In order to take this further, the binding 
ability of TbFEN D183K should be tested in the presence of magnesium, and in the absence 
of any divalent metal cations, to observe these effects. 
Attempts to crystallise the TbFEN D183K ΔC mutant by Mr Jason Wilson (Department of 
Molecular Biology and Biotechnology, The University of Sheffield) have been successful, 
and a total of ten different DNA substrates have been co-crystallised. However in all cases, 
no threaded DNA is present (Jason Wilson, personal communication). We are still lacking 
the elusive FEN: substrate complex.  
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3 Targeting the TbFEN in vivo 
3.1 Introduction 
The production of a catalytically inert variant provides an opportunity to analyse the effect 
of an inactive protein on the parasite in vivo. Over-expression of the wild type enzyme and 
the D183K variant was analysed. These were compared to RNAi FEN knock down clones. 
These recombinant clones were assessed by estimation of growth rate, RT-qPCR, flow 
cytometry and microscopy. This work highlights the potential of the TbFEN as a therapeutic 
target. 
3.2 Results 
3.2.1 Construct Production 
Genomic DNA from the Trypanosoma brucei brucei strain Lister 427 was provided by Dr 
Helen Price (University of Keele, UK). The FEN gene was isolated from the genomic DNA and 
sub-cloned into pUC19 (see Figure 3-1B). An internal HindIII site was mutated (AAG  AAA) 
by full plasmid PCR (Figure 3-1C). A 5ʹ HindIII site was inserted, and used (alongside the 3ʹ 
BamHI site) to sub-clone the gene into the p2McN vector (provided by Dr Helen Price, 
originally a gift from D. Horn and S. Alsford). The D183K mutation was inserted by SOE-PCR 
prior to insertion into the p2McN vector (Figure 3-2). This vector integrates into the genome 
of the blood stream form of the T. brucei brucei parasite (Frearson et al., 2010).  
The oligonucleotides used to isolate a fragment of the TbFEN gene for RNA interference 
(RNAi) were designed using the online software tool TrypanoFAN: RNAit 
(http://trypanofan.path.cam.ac.uk/cgi-bin/rnait.cgi). The fragment was isolated by PCR (see 
Figure 3-3 A) and inserted into the p2T7ti vector (originally from Dr Helen Price). The 
presence of the gene fragment was checked by restriction digest (see Figure 3-3 B) and 
confirmed by DNA sequencing (Core Genomics Facility, University of Sheffield Medical 
School).  
 
 
 63 
Figure 3-1 Isolation and sub-
cloning of the genomic TbFEN 
gene 
(A) Isolation of the TbFEN gene 
from genomic DNA by PCR. (B) The 
isolated FEN gene was sub-cloned 
into the pUC19 vector by restriction 
digest. (C) Site directed 
mutagenesis of the internal HindIII 
site (AAG  AAA) by full plasmid 
PCR. (D) An external 5ʹ HindIII site 
was inserted to allow insertion of 
the gene into the p2McN expression 
vector. Successful sub-cloning was 
monitored by gel electrophoresis, 
and confirmed by in-house DNA 
sequencing (Core Genomics Facility, 
The University of Sheffield). 
Annotations: LK; 1 Kbp ladder 
(NEB), L; 100 bp marker (Norgen 
Biotek), +; PCR with genomic DNA, 
–; PCR without genomic DNA 
(negative control).  
3.2.2 Effect of RNAi Knock-Down and FEN1 Over-Expression on Cell 
Growth 
All constructs were transfected into Trypanosoma brucei brucei strain Lister 427 
bloodstream form cells. Both over-expression and RNAi were induced by the addition of 1 
μg/mL of tetracycline. Three clones were analysed for over-expression of both the native 
FEN (427::FEN1) and D183K mutant (427::fen1D183K). Two clones were analysed for the 
RNAi knockdowns (427‡FEN1). The parental control (427) was grown as a comparison. 
Results of the growth curve after 24, 48 and 72 hours post-induction are shown in Figure 
3-4, and the statistical analysis is summarised in Table 3-1. 
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Figure 3-2 Production of the D183K (GAT  AAG) active site variant construct by SOE-
PCR 
 (A) PCR using the oligonucleotides Forward_Hind and Reverse_D183K. (B) PCR using 
oligonucleotides Forward_D183K and Reverse_Bam. (C) The final D183K construct was 
produced using the oligonucleotides Forward_Hind and Reverse_Bam, and inserted into the 
p2McN vector. Successful sub-cloning was monitored by gel electrophoresis, and confirmed by 
DNA sequencing (Core Genomics Facility, The University of Sheffield). (D) A schematic, showing 
part of the p2McN vector and the arrangement of the promoter. Annotations: L; 100 bp DNA 
ladder (Norgen Biotek). +; PCR reaction containing the DNA template, –; PCR reaction without 
the DNA template (negative control).  
Over-expression of the wild type FEN does not appear to affect logarithmic cell growth 
(Figure 3-4). However, statistical analysis of the untransformed data does indicate a 
statistically significant effect. After 72 hours, the induced cells grew to a cell density that 
was 29, 23 and 15% lower than their un-induced counterparts (427::FEN1#1, #2 and #3 
respectively) (Figure 3-4). This was only statistically significant for 427::FEN1#1 and #2 
(Table 3-1). After 48 hours, the induced cells grew to a cell density that was 29, 29 and 30% 
lower than their un-induced counterparts (427::FEN1#1, #2 and #3 respectively) (Figure 
3-4). This was statistically significant for 427::FEN1#1 and #3 only (Table 3-1).  
Only one RNAi clone displays any difference compared to the un-induced control: 
427‡FEN1#1. Tetracycline induction caused the cells to grow to a cell density that was 45, 
62 and 44% lower than the un-induced control at 24, 48 and 72 hours respectively. These 
differences were significantly different (Table 3-1). No significant difference was seen in the 
second RNAi clone (427‡FEN1#2; Figure 3-4). 
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Figure 3-3 Production and sub-cloning the RNA interference construct into p2T7ti  
(A) A 597 bp fragment from the native TbFEN gene was isolated using the oligonucleotides 
RNAi_Xba and RNAi_Hind. (B) The fragment was sub-cloned into the p2T7ti vector. Successful 
sub-cloning was monitored by agarose gel electrophoresis of the uncut (U) and double digest 
(DD) of the p2T7-RNAi construct by XbaI and HindIII, and confirmed by DNA sequencing (Core 
Genomics Facility, The University of Sheffield). (C) A schematic showing part of the p2T7ti 
vector, and the arrangement of the regulatory elements. Annotations: D; 100 bp DNA ladder 
(Norgen Biotek). +; PCR reaction containing the DNA template, DK; 1 Kbp ladder (NEB). 
The most striking difference was observed following over-expression of the D183K FEN 
variants. All three 427::fen1D183K clones were unable to reach the same (or similar) cell 
densities as their un-induced controls at 48 and 72 hours post induction. 427::fen1D183K#1 
was also significantly lower at 24 hours post induction. 427::fen1D183K#3 appears to be 
growing slower in the absence of tetracycline than the other two 427::fen1D183K clones. 
The cell density of 427::fen1D183K#3 reached 241 ± 70.11 x104 cells/mL after 72 hours post 
induction, which was 34% lower than the 427 strain, and 61% and 46% lower than 
427::fen1D183K#1 and 427::fen1D183K#2 respectively (Figure 3-4). 
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Figure 3-4 Cumulative growth 
analysis of the transgenic T. brucei 
BSF in the presence and absence of 
tetracycline 
Over-expression/knock down of the 
FEN1 constructs (427::FEN1, 
427::fen1D183K and 427‡FEN1) was 
induced by the addition of 1 μg/mL 
tetracycline. Cells were counted in the 
presence (lilac) and absence (yellow) 
of tetracycline 24, 48 and 72 hours 
post induction. Error bars show the 
standard deviation of the mean of 
three biological replicates. 
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Table 3-1 Statistical analysis of the cumulative growth curves  
Transgenic Strain Clone  
Time (hours 
post induction) 
Significance P value 
427::FEN1 
1 
24 NS 0.4294 
48 *** 0.0006 
72 * 0.0252 
2 
24 NS 0.9380 
48 NS 0.0510 
72 * 0.0347 
3 
24 NS 0.0949 
48 ** 0.0061 
72 NS 0.0677 
427::fen1D183K 
1 
24 **** 6.0 x10-5 
48 **** 5.3 x10-5 
72 **** 3.8 x10-5 
2 
24 NS 0.1284 
48 **** 8.7 x10-5 
72 *** 0.0031 
3 
24 NS 0.4902 
48 *** 0.0007 
72 ** 0.0042 
427‡FEN1 
1 
24 * 0.0239 
48 *** 0.0003 
72 * 0.0023 
2 
24 NS 0.3414 
48 NS 0.3001 
72 NS 0.4837 
Counts in the presence of tetracycline are compared to counts in the absence of tetracycline 
using an unpaired T test on data prior to logarithmic transformation. Statistical significance was 
determined using the Holm-Sidak method in GraphPad Prism (6.0).  
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Quantitative PCR was used as an indicator of the efficiency of the RNAi knockdown and 
overexpression of the proteins, with α tubulin used as the constitutively expressed control. 
Oligonucleotides were designed as described by Thornton and Basu (Thornton & Basu, 
2011). Quantitative PCR was performed using 40 ng cDNA as a template, and results were 
normalised against the control. Small, consistent levels of non-specific amplification were 
present in the ‘no template controls’ of the FEN1 primers only. Samples were normalised 
against this to give accurate copy number values. 
In the 427 parental controls, the relative level of FEN1 mRNA decreases after 24 and 48 
hours post induction compared to the un-induced sample. At 72 hours post induction, the 
levels increase by 69% (see Figure 3-5 D). In order to compare the transgenic clones with 
the parental control (427), a repeated-measures mixed ANOVA was performed in IBM SPSS 
2.2. The results are summarised in Table 3-2. Briefly, post hoc tests were performed on the 
over-expressing clones only (427::fen1D183K#1, #2 and #3, and 427::FEN1#1, #2 and #3). 
This is because these displayed a statistically significant interaction, where F (3.367, 8.978) 
= 44.704, p ≤ 0.0001 for the 427::fen1D183K clones, and F (3.234, 8.625) = 6.186, p = 0.015 
for the 427::FEN1 clones. The detailed statistical analysis is described in Appendix B. 
The 427::FEN1 clones display increased levels of FEN1 mRNA relative to the parental 
control (see Figure 3-5 B). Clones 1 and 3 follow the same pattern, specifically the FEN1 
specific mRNA levels peak at 24 hours post induction, and then decrease by 62% and 46% 
respectively at 48 hours. Levels in clone 2 peak at 48 hours post induction, and then 
decreases by 24% by 72 hours post induction. However, these differences were only 
statistically significant for 427::FEN1#2 at 24 hours post induction, and for 427::FEN1#3 at 
48 hours post induction.  
The 427::fen1D183K clones all display an increase in FEN1 specific mRNA levels that follows 
the same pattern, specifically levels peak at 24 hours post induction, then decrease (Figure 
3-5). These difference was statistically significant (when compared to the parental control) 
for all clones at all time points, except 427::fen1D183K#1 at both 0 and 72 hours post 
induction. Interestingly 427::fen1D183K#2 and #3 both display a significant increase in 
FEN1 specific mRNA levels when un-induced.  
The 427‡FEN1#1 clone displays a slight increase of FEN1 specific mRNA levels compared to 
the parental control, peaking at 48 hour post induction (see Figure 3-5 C). After 24 hours 
post induction, the average relative FEN1 mRNA level is half that of the endogenous sample 
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at the same time point (0.001 and 0.002 respectively). The 427‡FEN1#2 clone does display 
higher FEN1 levels initially, when compared to the endogenous control. These peak at 24 
hours post induction, then decrease by 64% to levels similar to the endogenous control 
(0.065 and 0.071 respectively) (see Figure 3-5 C).  
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Figure 3-5 The effect of tetracycline 
on FEN1 specific mRNA levels 
FEN1 specific mRNA was measured by 
RT-qPCR and normalised by RNA 
quantity, and against a constitutively 
expressed control. Mean normalised 
FEN1 specific mRNA levels for 
427::fen1D183K clones (A), 
427::FEN1 clones (B) and 427‡FEN1 
clones (C) are shown. Statistical 
significance of FEN1 specific mRNA 
levels, compared to the 427 parental 
controls (D), is shown as stars. Error 
bars indicate the standard deviation 
from the mean of three technical 
replicates.  
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Table 3-2 Post hoc analysis of the effect of tetracycline on FEN1 specific mRNA levels in 
the over-expression system 
Transgenic 
Strain 
Clone # 
Time (hours post 
induction) 
Significance P value 
427::FEN1 
1 
0 NS 0.246 
24 * 0.022 
48 NS 0.232 
72 NS 0.117 
2 
0 NS 0.478 
24 NS 0.362 
48 NS 0.114 
72 NS 0.514 
3 
0 NS 0.437 
24 NS 0.304 
48 * 0.012 
72 NS 0.091 
427::fen1D183K 
1 
0 NS 0.708 
24 *** 0.0005 
48 ** 0.01 
72 NS 0.988 
2 
0 *** 0.0005 
24 ** 0.002 
48 ** 0.008 
72 *** 0.0005 
3 
0 *** 0.001 
24 *** 0.0005 
48 ** 0.003 
72 *** 0.0005 
FEN1 specific mRNA levels were normalised against a constitutively expressed control and 
compared to the 427 strain. Values were analysed for statistical significance using a repeated 
measures mixed ANOVA (IBM SPSS statistics 22).  
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3.2.3 Transgenic Clones have no effect on Cell Cycle Progression 
Propidium iodide was used to stain the DNA of the transgenic T. brucei cells to determine 
whether over-expression or knock down of FEN1 had any effect on cell cycle progression. 
Figure 3-6 to 3-8 all display the same pattern, specifically two distinct peaks. The first, larger 
peak corresponds to the G1 phase of the cell cycle. This is followed by a second peak which 
corresponds to G2/M phase of the cell cycle. No obvious differences are evident between 
the samples. 
3.2.4 D183K Over-Expressing Clones Display Altered Cell Morphology 
after 72 Hours 
Immunofluorescence microscopy of all clones at 0, 24, 48 and 72 hours post induction was 
performed against FEN1 (green) and TAT1 (red; donated by Dr Helen Price, originally a gift 
from Professor Keith Gull (Sir William Dunn School of Pathology, University of Oxford, UK)), 
as shown in Figure 3-9 to 3-11. The parental control (427) displays a faint FEN1 signal at all 
time points, but it is difficult to distinguish. The 427‡FEN1#1 clone does display FEN1 
expression in the un-induced sample, but it is hard to distinguish any in the other three 
time points. With 427‡FEN1#2, FEN1 expression can be seen, but faintly. No obvious 
morphological changes are apparent in any of the 427‡FEN1 clones. 
The 427::FEN1 clones show increased levels of the FEN1 protein compared to both the un-
induced samples, and the parental control (see Figure 3-10). The FEN1 protein is localised in 
an oval section that appears to correspond to the nucleus. The 427::fen1D183K clones 
again show increased levels of FEN1 protein at 24, 48 and 72 hours post induction when 
compared to both the un-induced samples and the parental control. Cell morphology 
remains relatively similar until 72 hours post induction. Cells still display high levels of FEN1, 
but now appear rounded.
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Figure 3-6 Cell cycle 
progression of the 427::FEN1 
clones, measured using 
propidium iodide staining 
427::FEN1 cells were measured 
by flow cytometry. The first peak 
(indicated at 0 hours, with the 
red arrow), represents G1, whilst 
the second peak (indicated at 0 
hours with the blue arrow) 
represents G2/M phase of the 
cell cycle. 
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Figure 3-7 Cell cycle 
progression of the 
427::fen1D183K clones, 
measured using propidium 
iodide staining 
427::fen1D183K cells were 
measured by flow cytometry. The 
first peak (indicated at 0 hours, 
with the red arrow), represents 
G1, whilst the second peak 
(indicated at 0 hours with the 
blue arrow) represents G2/M 
phase of the cell cycle. 
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Figure 3-8 Cell cycle 
progression of the parental 
control (427) and the 
427‡FEN1 clones, measured 
using propidium iodide 
staining 
427 or 427‡FEN1 cells were 
measured by flow cytometry. The 
first peak (indicated at 0 hours, 
with the red arrow), represents 
G1, whilst the second peak 
(indicated at 0 hours with the 
blue arrow) represents G2/M 
phase of the cell cycle.
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Figure 3-9 Immunofluorescence 
analysis of the parental control 
(427) and the two 427‡FEN1 clones 
Formaldehyde fixed cells were treated 
with rabbit anti-FEN1 and mouse 
anti-TAT1 primary antibodies. Images 
show merged fluorescence, displaying 
the FEN1 (green) and TAT1 (red) 
proteins at 0, 24, 48 and 72 hours 
post induction. Scale bars represent 1 
μm. 
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Figure 3-10 Immunofluorescence 
analysis of the three 427::FEN1 
clones 
Formaldehyde fixed cells were 
treated with rabbit anti-FEN1 and 
mouse anti-TAT1 primary antibodies. 
Images show merged fluorescence, 
displaying the FEN1 (green) and 
TAT1 (red) proteins at 0, 24, 48 and 
72 hours post induction. Scale bars 
represent 1 μm. 
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Figure 3-11  Immunofluorescence 
analysis of the three 
427::fen1D183K clones 
Formaldehyde fixed cells were 
treated with rabbit anti-FEN1 and 
mouse anti-TAT1 primary antibodies. 
Images show merged fluorescence, 
displaying the FEN1 (green) and 
TAT1 (red) proteins at 0, 24, 48 and 
72 hours post induction. Scale bars 
represent 1 μm. 
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3.3 Discussion 
3.3.1 Construct Production 
Flap endonucleases play a number of vital roles within the cell, specifically in DNA repair 
and replication (Balakrishnan & Bambara, 2013; Pascucci et al., 2011; Zheng & Shen, 2011). 
This, alongside the conserved nature of the enzyme, indicates that it is has an essential role 
within the cell. Essential enzymes have the potential to be therapeutic targets, providing 
that interfering with the native protein’s function results in a lethal, or detrimental, 
phenotype.  
In order to assess the suitability of the TbFEN as a potential drug target, three constructs 
were produced from the genomic DNA of the parental strain T. brucei brucei Lister 427. The 
wild type gene, and D183K variant, was inserted into the pM2cN vector. This vector allowed 
the overexpression of constructs either as the native molecules or with an N-terminal Myc 
tag. The latter approach could not be used here because the N-terminus of the FEN protein 
is located within the active site of the enzyme. The presence of a tag would therefore 
disrupt the activity of the enzyme, and could lead to misleading results. Whilst a similar 
vector that inserts a C-terminal tag was also available (p2McC), this was not used because of 
the importance of the C-terminus in FEN1 protein: protein interactions (Section 1.2.4: 
(Chen et al., 1996; Gary et al., 1997; Hasan et al., 2001; Warbrick et al., 1997).  
The second plasmid, p2T7ti, contains two tetracycline inducible promoters at opposite sides 
of the DNA fragment (LaCount et al., 2000). This allows both sense and antisense RNA to be 
generated simultaneously. These anneal to form double-stranded RNA, which activates the 
RNAi pathway (LaCount et al., 2000). This leads to post transcriptional gene silencing, thus 
preventing translation of the gene of interest. 
3.3.2 Effect of RNAi Knock-Down and FEN1 Over-Expression on Cell 
Growth 
Growth analysis was performed for all constructs in the presence and absence of 
tetracycline. Over-expression of the wild type protein has an effect on cell growth in all 
clones at 72 hours post-induction, compared to the un-induced samples (Figure 3-4). In 
order to assess if this is due to an increase in FEN1 levels, specific mRNA levels were 
measured by RT-PCR (see Figure 3-5). Samples were normalised against the constitutively 
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expressed alpha tubulin control. Tubulin has been shown to have relatively stable 
expression within the different life cycle stages (Brenndörfer & Boshart, 2010). It would 
have been preferential to use multiple reference genes, for example PFR (paraflagellar rod) 
or TERT (telomerase reverse transcriptase) alongside the tubulin. This would have 
decreased the probability of biased normalisation (Brenndörfer & Boshart, 2010). Whilst an 
increase in FEN1 mRNA levels was seen, this increase was only statistically significant at 24 
hours (clone 1) and 48 hours (clone 3) when compared to the endogenous control. 
Analysis of the FEN1 specific mRNA levels of the parental strain (427) showed a decrease 
after 24 and 48 hours, followed by a large increase at 72 hours, when compared to the un-
induced control. This could be linked to the morphological change of slender forms 
transforming to stumpy forms, which occurs above a critical cell density (Reuner et al., 
1997). Both the Spliced Leader Trapping (SLT) Database (http://splicer.unibe.ch/cgi-
bin/gbrowse/Tbrucei_chr3/) and TriTrypDB (http://tritrypdb.org/tritrypdb/) were searched 
for TbFEN specific results (Tb927.3.830, chromosome 3, location 195086-193551). The 
databases yielded a number of datasets for expression of TbFEN in the different 
morphological forms. A small increase between low density bloodstream forms (slender) 
and high density bloodstream forms (stumpy) was apparent, with a larger increase between 
bloodstream forms and procyclic forms (Queiroz et al., 2009). Interestingly, Kabani et al saw 
the same increase between bloodstream forms and procyclic forms, but not between 
slender and stumpy bloodstream forms (Kabani et al., 2009). The difference between these 
two papers is the culture method: Queiroz et al used parasites cultured in vitro, whilst 
Kabani et al used parasites grown in mice (Kabani et al., 2009; Queiroz et al., 2009). 
The presence of the D183K mutation has a hugely detrimental effect on the cells, as they 
only grew to a maximum of 18% of the cell density of the un-induced (Figure 3-4). The third 
clone (427::fen1D183K#3) grew at a slower rate than the other two clones (Figure 3-4). 
However, it still appears to be in logarithmic growth phase at 72 hours post-induction. At 
least one additional time point (96 hours) should have been analysed to determine if the 
un-induced cells would ultimately reach stationary phase. The detrimental effect observed 
on cumulative cell growth caused by the addition of tetracycline correlates with an increase 
in FEN1 specific mRNA levels (Figure 3-5). A statistically significant increase in FEN1 specific 
mRNA levels for clones 1 and 2 in the un-induced samples compared to the same time point 
on the endogenous control was apparent. This indicated that there may be ‘leaky’ 
expression of the D183K FEN1 variant, resulting in a slow-growing phenotype (see Figure 
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3-4). In addition, all clones display a statistically significant increase in FEN1 specific mRNA 
levels when compared to the endogenous control at 24 and 48 hours post induction. The 
levels peak at 24 hours post induction. Clone 1 is the only clone that does not display a 
significant increase in FEN1 specific mRNA levels after 72 hours post induction. This may be 
caused by spontaneous mutation that yields non-expressing cells. This phenomenon of 
increased colony expansion following growth inhibition has been documented in RNAi 
clones, and would also be possible for over-expression clones (Motyka & Englund, 2004).  
There was no obviously detrimental effect of the RNAi clones on cell growth (see Figure 
3-4). One potential explanation is that the RNAi pathway was not activated, so the FEN1 
protein was still being transcribed and expressed. The levels of FEN1-specific mRNA was 
analysed using RT-qPCR (see Figure 3-5). There was no statistically significant change in the 
level of FEN1 specific mRNA when compared to the endogenous control. This indicates that 
the RNAi knockdown was unsuccessful. However, the RT-qPCR for these two clones is not 
accurate. This is because, despite three separate attempts to harvest high quality RNA from 
these constructs, the RNA purity level was around 1.7 (A260/A280) compared to the purity of 
approximately 2.0 for the wild type and D183K constructs. Previous studies in yeast cells 
that knocked down Rad27 (the yeast FEN1 homologue) show that the yeast null mutants 
are viable, but are sensitive to temperature changes, and mutate spontaneously (Tishkoff et 
al., 1997). This is due to the presence of a back-up protein, called EXO1. T. brucei does 
contain an EXO1 protein (XP_847153.1). Further analysis to determine if this synthetic 
lethality is present in T. brucei by using either RT-qPCR, or knock outs of both the TbFEN 
and TbEXO1, would further establish this relationship. Further analysis on the TbFEN knock 
out is also needed to see if it, like the yeast version, displays increased temperature 
sensitivity and a mutator phenotype would be interesting. This does pose the question of 
whether increasing the mutation rate in a human pathogen is advisable. Whilst a mutator 
phenotype is likely to adversely affect the parasite, there is the possibility that the 
mutations may be advantageous. The creation of an advantageous phenotype for parasite 
survival within the host could have drastic consequences for both the infected individual 
and for HAT eradication.  
Whilst the use of RT-qPCR is an excellent indicator of FEN1-specific mRNA levels, it provides 
no indication of what occurs at the post-transcriptional level.  Whilst there is an increase in 
mRNA levels for the D183K variant, we have no quantitative data to show that this mRNA 
increase correlates with an increase in protein expression. Western blot analysis would 
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provide a quantitative measure of protein expression, and antibodies are available for the 
TbFEN protein and the TAT1 constitutively expressed control. However, due to time 
constraints, this work could not be carried out. A qualitative indicator of FEN-specific over-
expression can be seen in the confocal microscopy performed on these clones (Figure 3-9 
to 3-11). 
3.3.3 Transgenic Clones have no effect on Cell Cycle Progression 
Due to the role of flap endonucleases in DNA replication and repair, cell cycle analysis was 
performed to observe the effects of these transgenic clones on cell cycle progression. 
Methanol-fixed cells were incubated with propidium iodide, a commonly utilised DNA 
binding dye. This is often used to analyse cell cycle defects, or to determine whether cells 
are apoptotic (Henry et al., 2013). One initial peak indicates G1. Cells undergoing mitosis 
will have double the amount of DNA as cells in G1, resulting in a second peak (Henry et al., 
2013). Figure 3-6 to 3-8 show that there is no change in the profile for any of the clones 
when compared to the parental control. It is possible that the 72 hour time point is not long 
enough to allow full development of a phenotype, but given that affects can be seen on cell 
growth by 48 hours post induction, this is unlikely. Because the 427::fen1D183k clones are 
unable to reach the cell densities seen in the un-induced controls (see Figure 3-4), the idea 
that the cells may be undergoing apoptosis is possible. However, the flow cytometry results 
do not display a peak before G1. This would correspond to the generation of low molecular 
weight DNA fragments in apoptotic cells (Wlodkowic et al., 2009). In order to assess this 
further, the use of specific early apoptotic markers such as annexin V, would yield definitive 
results, and should be explored in the future. Annexin V has been used as an apoptotic 
marker in kinetoplastids, with success (Bustos et al., 2015; Grazú et al., 2012; Mamani-
Matsuda et al., 2004). 
3.3.4 D183K Over-Expressing Clones Display Altered Cell Morphology 
after 72 Hours 
Morphological changes were analysed for each transgenic clone using immunofluorescence 
microscopy. TAT1 was used as a positive control because tubulin is constitutively expressed 
and covers the whole cell (Imboden et al., 1987). This makes any morphological changes 
easier to visualise. The FEN1 protein is localised in an oval section that appears to 
correspond to the nucleus. This is expected because the HsFEN has a recognisable nuclear 
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localisation signal (KRK-X8-KKK) (Qiu et al., 2001). However, the TbFEN does not. This may 
be due to a lack of information available regarding nuclear localisation signals in 
trypanosomes. However, the lack of DNA staining prevents this localisation from being 
definitive.  
On a qualitative level, FEN1 expression still appears high, whilst the FEN1 specific mRNA 
levels have decreased by 72 hours post induction. This may be due to the delay between 
transcription and translation. What is interesting is that it takes 72 hours for this 
morphological change to become apparent, but the over-expression affects cell growth 
after 24-48 hours. The D183K mutant is unable to cleave DNA, but is able to bind to the 
DNA. This may result in the accumulation of DNA damage that affects cell growth, and 
ultimately leads to cell death. Whilst the flow cytometry results show no accumulation of 
low molecular weight DNA, this tends to be a late stage apoptotic marker.  
3.4 Conclusions and Perspectives 
FEN1 has essential roles in DNA replications and repair. Over-expression of the wild type 
enzyme may therefore result in an increased level of DNA strand breaks. However, we are 
not seeing an obvious phenotype, so further analysis is essential. Assays such as TUNEL or 
Comet (Invitrogen) allow analysis of apoptotic DNA and DNA strand breaks respectively 
(Collins, 2004). It is possible that the over-expressed wild type FEN1 enzyme is not able to 
access DNA replication/repair sites because of another limiting factor. For example, the 
PCNA trimer acts as a processivity factor for HsFEN1, and loads and unloads the enzyme at 
the correct place, at the correct time (Li et al., 1995). It is possible that an increase in the 
wild type enzyme will only affect the cells when there is additional PCNA, for example if a 
DNA damage response has been activated. It would therefore be very interesting to look at 
the effect of the wild type over-expressing clones when exposed to DNA damaging agents 
such as UV radiation and methyl methanesulphonate (MMS).  
The FEN1 enzyme has a number of binding partners. As a consequence, the detrimental 
effect seen by over-expression of the D183K variant could be caused by the excess D183K 
FEN1 preventing these proteins from binding to any other potential binding partners, and 
therefore affecting their function. For example, FEN1 interacts with the C-terminus of WRN, 
specifically between residues 949-1092 (Brosh et al., 2001). It is the C-terminus of WRN that 
also interacts with DNA Pol β, specifically residues 949-1432 (Harrigan et al., 2003). Product 
formation from strand displacement by DNA Pol β increases from 10% to 25% in the 
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presence of WRN (Harrigan et al., 2003). Weak strand displacement, such as that seen in 
the absence of WRN, allows DNA Pol β to expand triplet repeats (Hartenstine et al., 2002), 
which can lead to detrimental phenotypes and clinical disease (Ashley & Warren, 1995). 
Over-expression of the D183K variant has a detrimental phenotype on the parasite, whilst 
the knock down clones do not. This may be due to insufficient knock down of the FEN1-
specific RNA, and based on the data presented here, this cannot be ruled out. It may also 
be due to functional redundancy between FEN1 and EXO1, as seen in other cell types 
(Tishkoff et al., 1997). The FEN1 protein may have a longer half-life, so even if the knock 
down has been successful, there may still be endogenous FEN1 persisting in the cells.  The 
data for the D183K FEN1 construct does indicate that the TbFEN protein has potential as a 
therapeutic target, but the RNAi knock down work needs to be repeated, and possibly for a 
longer time course. Clearly the presence of inactive FEN1 is detrimental to the cells, and is 
expressed at sufficient levels to swamp the endogenous FEN1. As a consequence, inhibiting 
the native TbFEN seems likely to lead to parasite death. This work provides the first 
evidence that FEN1 in a medically relevant protozoan pathogen has the potential to be a 
therapeutic target.
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4 Validating Previous FEN Inhibitors 
4.1 Introduction 
The previous chapter showed that the catalytically inert flap endonuclease D183K variant 
caused a detrimental phenotype in the Trypanosoma brucei bloodstream form cells. In this 
chapter, the wild type enzyme was tested against three previously identified flap 
endonuclease inhibitors, from both the Sayers laboratory and the literature. Two inhibitors 
described previously in the Sayers laboratory (Zhang, 2012), and myricetin, a commercially 
available flavonol with known anti-FEN properties, were selected (van Pel et al., 2013). In 
order to assess the inhibitory effects of these compounds, a low through-put gel based 
assay (designed and optimised in-house) was used. The compounds were tested against 
both the Trypanosoma brucei and human flap endonucleases. 
4.2 Results 
4.2.1 Construct Production and Purification of the HsFEN 
A synthetic HsFEN sequence, codon optimised for expression in Escherichia coli, was 
designed and supplied by Eurofins MWG Operon. This construct lacked the last 44 amino 
acid residues, and the aspartic acid codon for Asp 179 was mutated to a lysine (HsFEN 
D179K ΔC). In order to produce the wild type enzyme this construct was cloned into 
pET21a+, and the codon corresponding to Lys 179 was reverted back to the original aspartic 
acid by splicing by overlap extension PCR (Materials and Methods). Synthetic DNA encoding 
the C-terminal 44 amino acids was inserted using an oligonucleotide cassette by standard 
recombination DNA technology, producing the HsFEN wild type full-length construct (Figure 
4-1). This full-length, native construct was sub-cloned into the lactose inducible pET21a+ 
vector (Figure 4-1), and over-expressed (Figure 4-2). The protein sequence was analysed 
using Expasy ProtParam, an online resource that deduces a number of physico-chemical 
properties from the protein sequence only (Gasteiger E., 2005). Knowledge of the 
theoretical pI (8.80) was used to assist with protein purification. The success of the 
purification procedure was monitored by Coomassie-stained SDS-PAGE (Figure 4-3). 
Zymogram analysis of the wild type enzyme was carried out to detect nuclease activity 
(Figure 4-3). 
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Figure 4-1 Producing the wild type full length HsFEN construct 
The lysine residue at 179 was reverted to its original wild type aspartic acid (AAAGAT) by 
SOE-PCR. (A) The integrity of the wild type HsFENΔC gene was analysed by restriction digest 
using NdeI  and HindIII (NH). (B) The C-terminus of the HsFEN protein was optimised for 
expression in E. coli and ordered from Eurofins. This was removed from its vector backbone by 
restriction digest using BamHI and HindIII (BH). The resulting cassette was purified and 
introduced to pET-HsFEN ΔC, to produce the pET-HsFEN wild type full length construct. (C) The 
success of the procedure was determined by restriction digest with NdeI and HindIII and NdeI 
and BamHI (NB). Each step was monitored by gel electrophoresis (shown), and success was 
confirmed by DNA sequencing (Medical School Core Genomics Facility). Annotations: LK; 1 Kbp 
ladder (NEB), L; 100bp ladder (Norgen Biotek).
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Figure 4-2 SDS-PAGE analysis of the over-expression and cell lysis of the recombinant 
wild type HsFEN 
(A) Analysis of the un-induced (Un) and induced cell pellets at three time points post-induction 
(2 ½ hours, 5 hours and overnight (ON)).  Samples were normalised against A600.  (B) Analysis 
following lysis of the induced cell pellet, as described in the materials and methods. 
Annotations: M; low range protein marker (Bio-Rad), +; control of the empty pET21a+ vector in 
the same E. coli strain, R; sample following re-suspension of the cell pellet, SC; sample after 
sonication, SN and P; supernatant and pellet respectively, following centrifugation of the lysed, 
sonicated sample, P-SN and P-P; supernatant and the pellet respectively, from PEI precipitation 
and centrifugation step.
4.2.2 Solvent Effects and Compound Activity 
Previous optimisation of this low-throughput assay showed that the HsFEN cleaved the flap 
substrate at a lower rate than the TbFEN, and an incubation period three times longer was 
required for substrate hydrolysis (data not shown). The effect of 5% DMSO (a commonly 
used solvent in screening protocols) on the rate of substrate cleavage was tested (Figure 
4-4). Results were transformed using arcsine before being analysed by repeated measures T 
test (https://graphpad.com/support/faq/the-arcsin-function/; GraphPad Prism 6.0). Both 
enzymes displayed a significant increase in product formation in the presence of 5% DMSO. 
That increase was approximately 50% and 33% for the TbFEN and HsFEN respectively (p = 
0.0122 and 0.0045 respectively).  
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Figure 4-3 SDS-PAGE analysis of the purification of the recombinant, full length HsFEN 
Soluble HsFEN was purified using a variety of chromatography techniques. (A) HsFEN was 
eluted over a 0.05-0.75 M salt gradient from a Bio-Rad High S cation exchange chromatography 
column (pH 7.8). Fractions are shown in ascending order (white  pink). (B) Pooled fractions 
F4-6 were applied to a Bio-Rad High Q chromatography column coupled to a HiTrap heparin HP 
affinity chromatography column (pH 7.8). Fractions were eluted over a 0.05-0.75 M salt gradient 
from the heparin column only, and are shown in ascending order (white  pink). (C) Pooled 
fractions 11-22 were concentrated and further purified by size exclusion chromatography (GE 
Healthcare Superdex 200 10/300 GL, pH 6.7). Purified HsFEN was concentrated and analysed by 
zymogram and stained with both Coomassie blue (D) and ethidium bromide (E). Annotations: 
M; low range protein marker (Bio-Rad), S; sample from the dialysis bag, S2; supernatant from 
the dialysis bag following centrifugation and filtration to remove precipitation, 1-6; flow 
through samples collected during column loading, FT; flow through collected during column 
loading, W; column wash with the loading buffer, T5; T5Δ192CA positive control. 27/14; 
amount (in µg) of pure HsFEN loaded per well. 
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Figure 4-4 DMSO stimulates cleavage in both the TbFEN (top) and HsFEN (bottom) 
enzymes  
The raw gel image is shown for the two enzymes (A and C for TbFEN and HsFEN respectively). 
The upper band corresponds to undigested substrate, whilst the lower band corresponds to 
digested substrate. Densitometry results were converted to percentage substrate digestion, and 
are shown for both the TbFEN (B) and HsFEN (D). Error bars indicate standard deviation from 
three biological replicates. Values were transformed by arcsine before statistical analysis with a 
repeated measures T test (GraphPad Prism 6.0).  
C01 and D11 were previously identified as FEN inhibitors (Zhang, 2012). C01 selectively 
inhibits the T5 bacteriophage FEN, whilst D11 inhibits both the T5 and T7 bacteriophage 
FENs (Zhang, 2012). These were tested alongside myricetin, a commercially available HsFEN 
inhibitor (van Pel et al., 2013). The structures of the three compounds are shown in Figure 
4-5. Inhibitors were tested at an initial concentration of 50 μM, and compared against a 5% 
DMSO control. Results for both enzymes are shown in Figure 4-6. Results were transformed 
to arcsine before being analysed for statistical significance using a One-Way Repeated 
Measures ANOVA (https://graphpad.com/support/faq/the-arcsin-function/; GraphPad 
Prism 6.0). Myricetin causes a statistically significant decrease in product formation (p = 
0.0003 and 0.0009 for HsFEN and TbFEN respectively). D11 causes a statistically significant 
decrease in product formation (p = 0.009 and 0.0010 for HsFEN and TbFEN respectively). 
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Figure 4-5 Previously identified FEN inhibitors. 
D11 inhibits both the T5 and T7 bacteriophage FEN, whilst C01 inhibits the T5 FEN only (Zhang, 
2012). Myricetin inhibits the HsFEN (van Pel et al., 2013). Structures were rendered using 
Chemdraw 14. 
The lanes that contain the D11 compound show  three bands (Figure 4-6). One correlates to 
the undigested substrate, whilst the second corresponds to the cleavage product. However, 
a third band located above the undigested substrate was also present.  This low mobility 
band was also seen even when no DNA or protein was added, indicating that the compound 
is fluorescent (data not shown). Further analysis on the D11 compound was performed to 
assess its ability to interact with DNA. The absorbance profile of the compound was 
measured in the presence and absence of high molecular weight DNA (see Figure 4-7). The 
presence of DNA shifts the absorbance spectra by 10 nm to the red (Figure 4-7 C). This was 
compared to two molecules known to intercalate with DNA: ethidium bromide (Figure 
4-7A) and methylene blue (Figure 4-7 B). The presence of DNA shifts the absorbance 
spectra of ethidium bromide by 40 nm to the red and methylene blue by 10 nm to the red. 
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Figure 4-6 Analysis of the inhibitory effect of D11, C01 and myricetin on TbFEN (left) and 
HsFEN (right) 
The effect of 50 µM of each compound on DNA cleavage by 10 µg/mL of protein was compared 
to the DNA substrate alone (-), and in the presence of 10 µg/mL protein and 5% DMSO (+). (A, 
D) The raw gel image showing the effect of myricetin (My) on the TbFEN and HsFEN enzymes 
respectively. (B, E) The raw gel image showing the effect of D11 (D) and C01 (C) on the activity 
of the TbFEN and HsFEN enzymes respectively.  (C, F) Normalised substrate digestion of the 
DNA substrate by the TbFEN and HsFEN enzymes respectively. Error bars indicate standard 
deviation from three biological replicates. Values were transformed by arcsine before statistical 
analysis using a One Way Repeated Measures ANOVA (GraphPad Prism 6.0). Statistical 
significance is indicated by stars. 
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Figure 4-7 Analysis of the DNA intercalation properties of compound D11 
A wavelength scan of the absorbance of each compound in the presence/absence of high 
molecular weight herring sperm DNA (type XIV; Sigma). (A) The presence of DNA with ethidium 
bromide increased the max by approximately 40 nm, from 480 nm to 520 nm. (B) The presence 
of DNA with methylene blue increased the max by approximately 10 nm, from 660 nm to 670 
nm. (C) The presence of DNA with D11 increased the max by approximately 10 nm, from 345 to 
355 nm. Error bars are depicted as dotted lines, and indicate the standard deviation from the 
mean of three replicates. 
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4.2.3 Effect of Myricetin in vitro and in vivo  
The ability of myricetin to inhibit HsFEN is consistent with the previous literature (van Pel et 
al., 2013). The ability of myricetin to inhibit the TbFEN had not been reported previously, 
and was explored further. A dose response was performed against both enzymes to 
determine the IC50 (the concentration required to inhibit enzymatic activity by 50%). The 
IC50 for myricetin against the TbFEN was determined as 14.81 µM, compared to 12.03 µM 
for the human enzyme (see Figure 4-8).  
An attempt to identify binding sites for myricetin in both the TbFEN and HsFEN enzyme was 
performed using SwissDock (Grosdidier et al., 2011a; Grosdidier et al., 2011b). Myricetin 
(ZINC ID = zinc03874317) was docked onto the HsFEN structure (PDB 3Q8L; without DNA), 
and the Phyre2-predicted TbFEN structure described in Chapter Two. The top-ranked 
binding sites for both proteins are depicted in Figure 4-8 and described in Table 4-1. The 
myricetin binding site on the TbFEN enzyme is located close to the active site of the protein 
(Figure 4-8 B). The myricetin binding site on the HsFEN enzyme is located towards the back 
of the enzyme, near the helix-two turn-helix motif. 
The next step was to determine whether this inhibition in vitro corresponds to parasite cell 
death. A standard PrestoBlue assay was used to assess cell viability in the presence of 
different myricetin concentrations compared to a DMSO control (see Figure 4-9). A 
maximum concentration of 0.5% DMSO could be used before cell viability was significantly 
affected. A dose response curve was produced to determine the LD50 (the dose at which 
50% of the parasites are dead). The LD50 for myricetin was 23 µM for T. brucei blood stream 
form cells.  
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Figure 4-8 Dose dependent inhibition of TbFEN and HsFEN by myricetin 
(A) Myricetin inhibits both TbFEN and HsFEN in a dose dependent manner. (B) IC50 values are 
not significantly different between proteins (p = 0.3189), as determined by non-linear 
regression (GraphPad Prism 6.0). Molecular docking of myricetin (ZINC ID = zinc03874317) to 
the Phyre2-predicted structure of TbFEN (C) and to a known HsFEN structure (PDB 38QL; D) 
show that the top hit is located at different sites for the two enzymes. 
Table 4-1 The top binding sites of myricetin to the two eukaryotic FENs 
Protein Cluster Cluster Rank 
Full Fitness 
(kcal/mol) 
ΔG (kcal/mol) 
HsFEN 0 0 -2369.38 -7.35 
TbFEN 0 0 -3000.00 -7.46 
The Full Fitness and ΔG values for the most favourably ranked complex (Cluster Rank = 0) 
within the highest ranked cluster (Cluster 0) are shown. 
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Figure 4-9 Myricetin demonstrates dose dependent killing of the T. brucei parasite 
The resazurin-based PrestoBlue viability assay was used to determine the effect of myricetin on 
the T. brucei parasite. (A) The effect of different DMSO concentrations on cell viability was 
initially determined. The percentage change in fluorescence compared to a ‘cells only control’ 
was converted to arcsine for statistical analysis. A repeated measures one-way ANOVA, with a 
Dunnet’s post-hoc test were performed, and show only a DMSO concentration of 0.5% does not 
significantly affect cell viability (p = 0.1203). (B) The percentage cell death was calculated for 
nine myricetin concentrations.  The LD50 was calculated by non-linear regression in GraphPad 
6.0. The mean ± standard deviation of three biological replicates is shown. 
 
  
 96 
4.3 Discussion 
4.3.1 Construct Production and Purification of the HsFEN 
The HsFEN D179K ΔC construct contains the equivalent active site substitution to the TbFEN 
D183K variant described in Chapter Two. This construct, which is missing the C-terminal 44 
amino acids that constitute the flexible PCNA binding domain, was originally designed for 
crystallography work based on the published crystal structure from the Tainer laboratory 
(Tsutakawa et al., 2011). The lysine was reverted back to the original aspartic acid to create 
the wild type HsFEN ΔC construct. The E. coli codon-optimised C-terminal domain was used 
in conjunction with the HsFEN ΔC construct to produce the full-length HsFEN1 in the 
pET21a+ vector. The C-terminus is important in protein-protein interactions and in 
substrate binding, so creating the full length construct was essential for any drug discovery 
work (Stucki et al., 2001). 
4.3.2  Solvent Effects and Compound Activity 
DMSO is a dipolar aprotic molecule commonly used as a solvent (Santos et al., 2003).  It is 
efficient at dissolving water-insoluble compounds, and is considered the solvent of choice 
for use in drug screens (Santos et al., 2003; Tjernberg et al., 2006).  However, DMSO can 
have huge impacts on proteins, even at the low levels commonly used in drug screening.  
These effects include changes in binding properties, disordering of protein structures and 
decrease in thermal stability (Batista et al., 2013; Jackson & Mantsch, 1991; Tjernberg et al., 
2006). Knowing how DMSO affects both FEN proteins was crucial to ensure accurate 
interpretation of results from screening trials. As shown in Figure 4-4, the presence of 5% 
DMSO significantly increases the activity of both enzymes. Studies on the effect of DMSO 
on the thermal stability of the enzymes has been analysed briefly in Chapter Five, and 
indicates that 5% DMSO decreases the thermal stability. This decrease in stability could 
allow the enzyme to bind to the DNA substrate more easily, resulting in a reduced KM 
and/or an increased Kcat. Further work needs to be performed to understand how DMSO is 
affecting both the structure and function of the enzymes. This could include analysing the 
far-UV circular dichroism spectra of the enzymes in the presence of different DMSO 
concentrations, and performing a full catalytic screen to obtain the rate constants. For the 
purpose of this work, the effect of any compounds dissolved in DMSO must be compared to 
a protein-DMSO control, for accuracy. 
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Further analysis of the compounds previously identified in the Sayers laboratory has 
uncovered a false-positive result. Compound D11 is intrinsically fluorescent, and displays 
DNA intercalation properties. The DNA intercalation assay was tested on two compounds 
that are known to intercalate with DNA: ethidium bromide and methylene blue. The 
presence of DNA caused a shift in the λmax of the compounds by 40 nm and 10 nm 
respectively. These values are consistent with those previously reported in the literature 
(Hossain & Suresh Kumar, 2009; Waring, 1965). False positives are a major concern in 
screening methods (Thorne et al., 2010), and this highlights the importance of additional 
screening steps following the original hit identification. Whilst compound C01 showed 
promising results in the T5 FEN screen (Zhang, 2012), it is unable to inhibit the activity of 
either the TbFEN or HsFEN enzymes. Despite this, the fact that it can selectively inhibit the 
T5 enzyme over the T7 enzyme is still encouraging (Zhang, 2012), and provides optimism 
that selective inhibition between FEN enzymes can be achieved. 
4.3.3 Effect of Myricetin in vitro and in vivo  
SwissDock uses the EADock docking algorithm to identify and rank docking sites for a ligand 
on a particular protein (Grosdidier et al., 2007). The full fitness function evaluates clusters 
of complexes, which correspond to binding modes (Grosdidier et al., 2007). The most 
favourably ranked complex (with a Cluster Rank of 0) is taken as the centre of the first 
cluster, then the second most favourably ranked complex is chosen for the second cluster, 
and so on (Grosdidier et al., 2007). A negative ΔG value indicates that the reaction is 
favourable, or spontaneous, and does not require any external energy input. The Cluster 
Rank 0 for myricetin binding to the TbFEN is in a different location to that on the HsFEN 
enzyme. Whilst these binding models are only indicative of the actual binding site, they do 
imply that despite the TbFEN and HsFEN enzymes having a sequence identity of 51%, there 
may be slight structural variations that may impact compound interactions. Selective 
inhibition of FENs has been achieved between species, as shown with compound C01 
selectively inhibiting T5 FEN over T7 FEN (Zhang, 2012). It has also been achieved between 
FEN family members in the same species, as shown with HsFEN and HsXPG (Tumey et al., 
2005). 
The IC50 of myricetin against TbFEN in vitro is high at 14 μM. This is slightly higher than that 
obtained for the HsFEN enzyme using the same assay, but the difference was not significant 
(p = 0.3189). Previously obtained IC50 values for HsFEN and myricetin were considerably 
lower, specifically 0.09 μM (van Pel et al., 2013). This is likely due to assay variation, as van 
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Pel et al used a sensitive fluorescence based spectrophotometric assay. One of the benefits 
of using the less sensitive gel-based assay is that any abnormalities such as compound 
fluorescence can readily detected (Figure 4-6).  
The toxic effect of DMSO on T. brucei blood stream form cells has been documented 
previously (Sykes & Avery, 2009). The results shown here, where a maximum of 0.5% DMSO 
can be used, is consistent with those reported (Sykes & Avery, 2009). Testing myricetin on 
bloodstream form cells showed dose dependent killing of the T. brucei parasite. This result 
is not surprising given the trypanocidal activities of other flavonoids, such as quercetin 
(Dodson et al., 2011; Grecco et al., 2012; Mamani-Matsuda et al., 2004). Because the IC50 of 
both the HsFEN and TbFEN enzymes is so similar, it is reasonable to assume that myricetin 
would target and kill human cells as efficiently. Whilst time constraints prevented this from 
being investigated fully, reviewing the literature has shown some interesting results. 
Myricetin has been extensively studied in mammalian cell lines (and in mammals 
themselves), because it displays a number of beneficial properties. These include 
antioxidant (Wang et al., 2010; Zhang et al., 2011), antimicrobial (reviewed in (Cushnie & 
Lamb, 2005)), anticancer (reviewed in (Devi et al., 2015)), antiviral (reviewed in (Cushnie & 
Lamb, 2005)) and neuroprotective effects (Ma et al., 2015; Ma et al., 2007). During these 
investigations, mice were fed up to 50 mg/kg of myricetin with no ill effects (Ma et al., 
2015). This corresponds to approximately 2.7 mM of myricetin (based on a mouse weighing 
25 g, with a total blood volume of 1.46 mL) (NC3Rs, 2016).  
Because myricetin has such a wide range of beneficial properties, it raises concerns that the 
results seen against the T. brucei parasite are not due to myricetin: TbFEN interactions. A 
recent review assessed the molecular mechanisms underlying the anticancer effects of 
myricetin (Devi et al., 2015). Myricetin appears to target a number of proteins, including 
Akt, VGEF and Hif-I (Devi et al., 2015). This wide range of protein targets may be due to the 
ability of myricetin to act as a chelating agent (Fernandez et al., 2002). Sequestering metal 
ions that are required for protein function may explain how myricetin can act on such a 
wide range of protein targets. This may be the mechanism of action behind myricetin: FEN1 
inhibition. However, data derived from the thermal shift screen (Chapter Five) indicates 
that myricetin is interacting directly with the protein, and not just preventing metal ion 
binding. In addition,  earlier work on the inhibitory effect of myricetin on DNA polymerases 
(which have a FEN domain) from different organisms lend strength to the TbFEN being an 
actual target (Ono & Nakane, 1990; Shinozuka et al., 1988). Further work is required to fully 
understand myricetin and its mechanism of action against T. brucei. These experiments 
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could include over-expressing the TbFEN D183K variant in the parasite (Chapter Three), and 
observing whether the presence of myricetin could prevent or rescue the detrimental 
phenotype. Another method would be to produce myricetin-resistant T. brucei clones by 
culturing the cells in increasing concentrations of the compound. The genomic DNA could 
be harvested and sequenced, allowing the identification of any factors (such as point 
mutations or loss of a gene) that can identify the target. This technique has been 
successfully used to produce and characterise nifurtimox and fexinidazole resistant strains 
(Wyllie et al., 2016). Determining whether or not myricetin interacts directly with the 
TbFEN enzyme should also be investigated. Isothermal titration calorimetry would enable 
binding parameters to be determined directly for any such interaction. 
The trypanocidal effect of myricetin does validate it as a potential therapeutic. A patent for 
the use of myricetin against parasitic infections including T. brucei is in existence 
(Prendergast, 2001). The structure of myricetin could serve as a starting point for further 
structure-activity work aimed at improving selectivity and potency against TbFEN. Another 
approach is the ‘deconstruction-reconstruction’ method of fragment-based drug design 
(Chen et al., 2015). Target groups could be selected from a known inhibitor. These can then 
be optimised for certain characteristics, such as an ability to cross the blood brain barrier, 
or optimise its oral bioavailability, which is currently poor in myricetin (Chen et al., 2015; 
Devi et al., 2015).  
4.4 Conclusions and Perspectives 
The current data on compound D11 prevents it from being used for further screens. 
However, this does not detract from the results obtained for the C01 compound (Zhang, 
2012). The possibility of selecting a flap endonuclease from one organism over another is 
possible. Now it needs to be achieved in medically relevant flap endonucleases.  
The potential of the deconstruction-reconstruction method, using myricetin as a starting 
point, should be explored further. As myricetin has been shown to inhibit the TbFEN, and is 
(to this author’s knowledge) the first known compound to do so, it can be used in additional 
biochemical assays as a positive control. 
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5 Developing a Thermal Shift-Based High 
Throughput Screening Assay 
5.1 Introduction 
Developing compounds that specifically target the Trypanosoma brucei FEN over its human 
orthologue requires a sophisticated approach. One such approach is fragment-based drug 
design, which involves constructing a novel compound around fragments that bind the 
target protein. Fragment-based drug design has an excellent record of producing selective 
inhibitors for difficult targets (Baker, 2013). This chapter focuses on optimising a high 
throughput thermal shift-based assay for the identification of fragments.  
5.2 Assay Rationale 
Thermal shift assays require dyes that fluoresce when bound to hydrophobic protein 
regions (Pantoliano et al., 2001). Mixing the native protein and dye together at 
physiological temperatures produces low-level fluorescence. Heating the solution causes 
the protein to denature, exposing its hydrophobic core. The dye binds to the hydrophobic 
residues and fluorescence increases (Pantoliano et al., 2001). The signal will increase until 
all the protein is denatured, and the hydrophobic regions are saturated. From this, the 
melting temperature (TM) can be calculated. This is equivalent to the temperature at which 
50% of the protein is denatured.  Compounds (or fragments) that bind to the protein can 
either stabilise or destabilise it. Stabilising compounds increase the TM of the protein, whilst 
destabilising compounds decrease the TM. For the purpose of this assay, stabilising 
compounds are considered potential inhibitory compounds, therefore any 
compounds/fragments that increase the TM of the protein are considered positive hits 
(Pantoliano et al., 2001).  
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5.3 Results 
5.3.1 Enzyme Hydrophobicity 
The nature of the thermal shift assay requires the protein of interest to have hydrophobic 
regions that the dye can associate with. In order to assess the hydrophobicity of both the 
human and the Trypanosoma brucei flap endonucleases, hydropathicity plots were 
produced using the EXPASY ProtScale online tool (http://web.expasy.org/protscale/). Two 
scales were compared; the Kyte and Doolittle, and Cowan (pH 7.5) hydropathicity scales 
(Cowan & Whittaker, 1990; Kyte & Doolittle, 1982). Scales were normalised to between 0 
and 1, to allow for direct comparison (Figure 5-1). The plot was produced by grouping the 
protein sequence into clusters of seven consecutive amino acids, and producing an average 
hydropathicity score for each cluster (Gasteiger E., 2005). Both proteins display 
hydrophobic peaks, and the results for each scale are consistent.
 
 
Figure 5-1 Hydropathicity plots for the TbFEN (A) and HsFEN (B) 
The hydropathicity values were plotted against the amino acid sequence to generate protein-
specific hydropathicity plots. Two scales were used and normalised to allow comparison. Plots 
were produced using the EXPASY ProtScale online tool (http://web.expasy.org/protscale/) 
(Gasteiger E., 2005), and visualised using GraphPad Prism (6.0).  
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5.3.2 Assay Optimisation 
Thermal shift assays are commercially available, allowing easy optimisation. The kit used for 
this work was the Protein Thermal Shift™ kit from Invitrogen. Use of this kit with TbFEN and 
HsFEN required optimisation of the buffer conditions, specifically pH and additives, and 
protein concentration. 
5.3.2.1 Protein Concentration 
The protein concentration was the first parameter investigated. Assays were initially 
performed using the neutral, phosphate-based buffer supplied with the kit. Six protein 
concentrations (11, 2.3, 1.2, 0.6, 0.2 and 0.1 µM) were tested for both FEN proteins (Figure 
5-2). The denaturation profile for each enzyme displays three distinct stages, which are 
shown in Figure 5-2. Because of the presence of this third phase, the curves were truncated 
prior to fitting with the Boltzmann equation.  
Both proteins display a strong signal with a concentration of 11 µM. The TbFEN protein 
displayed a strong signal at 2.3 and 1.2 µM, with an R2 ≥ 0.9899 for the Boltzmann 
equation. The HsFEN protein had a weaker signal at a concentration of 2.3 µM, but still 
displayed excellent line fitting (R2 ≥ 0.9976). At lower concentrations of the two proteins, 
the signal quality and the line fitting accuracy is reduced. For some replicates, the 
Boltzmann equation could not be successfully fitted onto the curve, resulting in ambiguous 
results that were not included. Based on this, a minimum concentration of 1.2 µM and 2.3 
µM of TbFEN and HsFEN (respectively) was used. 
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Figure 5-2 Optimising protein concentration for the TbFEN (top) and HsFEN (bottom) 
Protein denaturation profiles for the TbFEN (A) and HsFEN (C) at six different protein 
concentrations. Each line depicts the mean of three biological replicates, with the dotted lines 
indicating the standard deviation from the mean. The denaturation profiles were used to 
calculate the melting temperature for the TbFEN (B) and HsFEN (D) using the Boltzmann 
equation (GraphPad Prism 6.0). Error bars indicate standard deviation from the mean.  
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Figure 5-3 Melting temperatures for the TbFEN (A) and HsFEN (B) at six different pH 
values 
Melting temperatures (TM) were calculated for each pH value using the Boltzmann equation 
(GraphPad 6.0). Error bars indicate standard deviation of the mean from three technical 
replicates.  
5.3.3.1 Buffer pH 
The pH at which the protein was most stable was determined. The HsFEN protein has 
previously been shown to be most active around pH 8.0 (Harrington & Lieber, 1994b), so 
four buffers (with a final concentration of 50 mM) at six different pH values were 
investigated (Figure 5-3). For the TbFEN protein, HEPES-NaOH buffer at pH 7.0 appeared to 
stabilise the protein the most, with a TM of 64.79
°C ± 0.87. This was significantly higher than 
for all other pH conditions (p ≤ 0.0001; determined by one-way ANOVA in GraphPad Prism 
(6.0)). For the HsFEN protein, HEPES-NaOH buffer at either pH 7.0 or 7.5 appeared to 
stabilise the protein the most, with a TM of 48.12
°C ± 1.02 and 47.83°C ± 0.61 respectively. 
The TM values for these two pH conditions were not significantly different (p = 0.9993; 
determined by one-way ANOVA in GraphPad Prism (6.0)).  
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Table 5-1 The effect of additives on the melting temperature of each protein  
Component  
Change in TM (%) P value 
HsFEN TbFEN HsFEN TbFEN 
NaCl (50 mM) -3.14 -3.94 0.1032 0.0031 
KCl (100 mM) -2.73 -8.37 0.1168 <0.0001 
MgCl2 (10 mM) 5.92 4.45 0.0011 0.0012 
MnCl2 (10 mM) 5.49 7.64 0.0020 <0.0001 
DTT (1 mM) -0.55 2.50 0.9811 0.0561 
Tween NA NA NA NA 
Triton X NA NA NA NA 
The melting temperature for each condition was compared to the melting temperature of the 
protein using a One Way ANOVA in GraphPad Prism (6.0). TM values were calculated from three 
technical replicates. NA = not applicable. 
5.3.3.2 Buffer Composition 
Buffer additives were carefully considered. The ultimate aim is to inhibit the TbFEN enzyme 
in vivo. The buffer conditions must mimic that environment as much as possible, whilst 
providing good, reproducible readings. The components tested are summarised in Table 
5-1. Both Tween and Triton X-100 could not be analysed as they displayed fluorescence in 
the absence of protein. The presence of both NaCl and KCl decreased the TM of both 
proteins, although this decrease was not significant for HsFEN (p = 0.1032 and 0.1168 
respectively). Both Mg2+ and Mn2+ increased the TM of both proteins significantly. DTT 
increased the TM of the TbFEN only although this was not significant (p = 0.0561). A final 
buffer composition of 50 mM HEPES-NaOH (pH 7.0), 1 mM DTT, 10 mM MgCl2, 50 mM NaCl, 
100 mM KCl was used. 
Both fragment and compound libraries tend to be dissolved in 100% DMSO, so the effect of 
5% DMSO on protein stability was analysed (Figure 5-4). The presence of 5% DMSO 
significantly decreases the melting temperature of the TbFEN by 2.6%, and HsFEN by 4.75% 
(p = 0.0220 and 0.0091 respectively, determined using an unpaired T test in GraphPad 
Prism 6.0). 
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Figure 5-4 Effect of 5% DMSO on the melting temperature of TbFEN (A) and HsFEN (B)  
Error bars depict standard deviation from the mean of two (HsFEN) and three (TbFEN) 
biological replicates. Statistical significance was analysed using an unpaired T test (GraphPad 
Prism 6.0). 
5.3.3.3 Pharmacological Relevance 
The sensitivity of the thermal shift assay was assessed using myricetin, a compound known 
to inhibit both the TbFEN (Chapter Four) and the HsFEN (van Pel et al., 2013). Three 
myricetin concentrations were tested: 10, 50 and 100 µM. The calculated TM values were 
compared to a DMSO control. The presence of myricetin significantly increases the TM of 
both the TbFEN and HsFEN (Figure 5-5). For the TbFEN, this increase is statistically 
significant at 50 and 100 µM (p = 0.0007 and p ≤ 0.0001 respectively). For the HsFEN, this is 
statistically significant at 100 µM only (p = 0.0111). This shows that the assay is capable of 
detecting known FEN inhibitors. 
A statistical test to analyse assay robustness was calculated, and the values described in 
Table 5-2 (Zhang et al., 1999). This value, called Zʹ, was calculated for the two myricetin 
concentrations that caused a shift in TM; 50 and 100 μM. Values between 0.5 and 1.0 
indicate that the assay is of sufficient quality, as there is detectable separation between the 
positive and negative controls (myricetin and DMSO respectively. Only one sample did not 
reach the required Zʹ value, and that was one replicate of TbFEN in the presence of 50 µM 
myricetin.  
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Figure 5-5 Effect of three concentrations of myricetin (10, 50 and 100 μM) on the melting 
temperature of TbFEN (A) and HsFEN (B) when compared to the DMSO only control (0). 
The presence of 50 and 100 µM myricetin significantly increases the melting temperature of the 
TbFEN. The presence of both 50 and 100 µM myricetin increases the melting temperature of the 
hFEN, but this is only significant with the higher myricetin concentration. Error bars indicate the 
standard deviation from the mean of three biological replicates for the TbFEN, and two for the 
HsFEN. Statistical significance was analysed using a One Way ANOVA (GraphPad Prism 6.0).
Table 5-2 Calculated Zʹ values for the myricetin control 
Protein Replicate 
Myricetin 
Concentration (µM) 
Zʹ 
TbFEN 
1 
50 0.69 
100 0.84 
2 
50 0.74 
100 0.86 
3 
50 0.17 
100 0.70 
HsFEN 
1 
50 0.69 
100 0.60 
2 
50 0.51 
100 0.69 
Zʹ values were calculated as described in Section 7.8. 
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5.4 Discussion 
5.4.1 Enzyme Hydrophobicity 
Both the TbFEN and HsFEN were initially checked for assay compatibility by producing 
hydropathicity plots. Both enzymes display hydrophobic peaks. This was expected, as 36 
and 37% of the amino acid sequence comprised of hydrophobic residues in HsFEN and 
TbFEN respectively. Other proteins with a similar percentage of hydrophobic residues have 
been successfully analysed by thermal shift, including human α-oestrogen receptor (37% 
hydrophobic residues) and bovine dihydrofolate reductase (35% hydrophobic residues) 
(Pantoliano et al., 2001). 
5.4.2 Assay Optimisation 
5.4.2.1 Protein Concentration 
The dye used in the assay has excitation and emission maxima of ~ 575 and 602nm 
respectively. This high excitation wavelength is beneficial as it minimises any intrinsic 
fluorescence properties of the fragments from interfering with the screen (Niesen et al., 
2007). Initial assays show that denaturation curves for both enzymes display three distinct 
stages; a stable stage, a denaturing stage and an aggregation stage (Figure 5-2). In the first 
stage, the protein is stable, and the fluorescent signal remains constant. In the second 
stage, the protein becomes denatured, allowing the dye to access and bind to hydrophobic 
regions in the protein core. This causes an increase in the fluorescence signal. The third 
stage is where the protein has fully denatured, but the fluorescent signal begins to 
decrease. This third stage was unexpected, but has been observed previously (Lo et al., 
2004; Niesen et al., 2007), and has been attributed to the denatured proteins aggregating 
together to form plaques. This results in the fluorescence signal being quenched. Because 
of this, the denaturation plots were truncated prior to fitting with the Boltzmann equation. 
This results in a better fit for the line equation, as well as a more accurate TM calculation. 
Determining the appropriate protein concentration for the assay is essential. A high enough 
protein concentration needs to be used for a good, reproducible signal, whilst being low 
enough to maximise the number of assays per protein batch. Six protein concentrations 
were picked for analysis (11, 2.3, 1.2, 0.6, 0.2 and 0.1 µM). No statistically significant 
difference in TM was calculated. For the TbFEN, a protein concentration below 1.2 µM 
displayed greater variability between replicates, despite the R2 ≥ 0.9227. This is most likely 
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caused by a lower signal intensity producing more variable readings. For the HsFEN, the 
signal produced when the protein concentration was less than or equal to 0.2 µM was very 
low. Because of this, higher protein concentrations were thought to be more accurate, and 
a minimum of 1.2 μM and 2.3 μM for the TbFEN and HsFEN respectively was picked. For the 
TbFEN, this protein concentration is similar to those used in the literature (1 µM and 1.5 
µM; (Lo et al., 2004; Pantoliano et al., 2001)). The concentration of the HsFEN used is 
higher, and highlights the importance of optimising the assay on a protein-to-protein basis.  
In the neutral phosphate buffer, the TM of the TbFEN is higher than that of the HsFEN (~ 
59°C and ~ 52°C respectively). This increased stability was not expected, but may be a 
consequence of the range of temperatures the Trypanosoma brucei parasite is exposed to 
throughout its life cycle. It would be interesting to determine if the enzymes are active at 
higher temperatures. This could be analysed by measuring the effect of temperature on 
substrate binding and cleavage using the assays described in Chapter Two. 
5.4.2.2 Buffer pH 
Analysing which pH is optimal for both proteins in this assay format is essential, as pH can 
have major effects on protein stability (Alber, 1989). The buffering agents picked were MES 
(pH 6.5), HEPES (pH 7.0, 7.5, 8.0) and Tris (pH 8.5, 9.0). MES, HEPES and Tris are classed as 
Good’s buffers, as they do not make complexes with cations, do not interfere with 
enzymatic reactions, have minimal absorbance in UV and visible spectra, and changes in 
temperature have minimal effect on buffer dissociation (Good et al., 1966). The pH of Tris-
based buffers can change with temperature, but because of the other beneficial properties, 
this was still used. All pH values for the buffers were accurate at 37°C.  For the TbFEN 
protein, a pH of 7.0 is the optimal, with the TM reaching ~65
°C. This was interesting as a pH 
of 7.5 was expected to be the optimal. This is because the intracellular pH of the 
bloodstream trypomastigotes is 7.4, mimicking the pH of the human blood (Scott et al., 
1995). For the HsFEN protein either pH 7.0 or 7.5 were the optimal (Figure 5-3). This was 
interesting, as the optimal pH of catalytic activity is 8.0. However, this may be due to the 
additives included in the reaction buffer.  
5.4.2.3 Buffer Composition 
A KCl concentration of 100 mM was tested because the literature indicates that, whilst KCl 
decreased HsFEN substrate cleavage (Harrington & Lieber, 1994b), its presence increases 
DNA binding by ExoIX (Anstey-Gilbert et al., 2013). Potassium ions have been observed in 
complex with both the HsFEN and E. coli ExoIX bound to the helix-two turn-helix motif and 
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helix-three turn-helix motif respectively (Anstey-Gilbert et al., 2013; Tsutakawa et al., 
2011). Binding of K+ in the HsFEN is coordinated by S237, I238 and I241 (Tsutakawa et al., 
2011). Both isoleucine residues are conserved in the TbFEN, but an arginine residue is 
found in place of the serine. The results shown here indicate that KCl causes a decrease in 
the TM of the enzyme, implying that it decreases stability. This may provide a potential 
reason as to why it increases DNA binding (Anstey-Gilbert et al., 2013). Destabilising the 
protein may allow the DNA substrate to associate more readily, resulting in an increase in 
Kd. However, this needs to be analysed further in both the HsFEN and TbFEN, using either 
the fluorescence DNA anisotropy assay, or the bio-layer interferometry assay detailed in 
Chapter Two. Sodium chloride was included for protein stabilisation. The presence of 50 
mM NaCl does decrease the TM of both enzymes, but this is only significant for the TbFEN. 
NaCl was used for its protective properties, to prevent the protein from precipitating (Kelly 
et al., 2005).  
Two divalent metal cations were tested in this system: Mg2+ and Mn2+. Previous work in this 
thesis has shown that the presence of Mn2+ increases product formation by two-fold 
compared to the same concentration of Mg2+ (Chapter Two). Interestingly, Mn2+ increases 
the TM of the TbFEN by 7.6%, whilst Mg
2+ increases the TM by 4.5%. For the HsFEN, both 
metal ions increase the TM by a similar percentage (5.9 and 5.5% for Mg
2+ and Mn2+ 
respectively). This increase in TM may be due to the actual binding of two/three metal ions 
to the active site of the enzyme itself, therefore stabilising the enzyme further. This raises 
the question as to why the potential incorporation of the K+ causes a decrease in protein 
stability, if this is also incorporated into the HsFEN structure. Despite MnCl2 stabilising the 
protein more, MgCl2 was incorporated into the buffer. There are two reasons for this. 
Firstly, Mg2+ is the pharmacologically relevant divalent metal cation, and secondly, the 
background signal is lower (data not shown). 
DTT is commonly added to enzymatic reactions to keep the cysteine residues in the 
reduced state that is typical of the functional protein. Both the TbFEN and HsFEN contain 
cysteine residues (three and six respectively). With the addition of DTT in the buffer there is 
no significant change in the TM of the two proteins. This may be because DTT is present in 
all buffers throughout the purification process, so there should be no change in oxidation 
state of the cysteine residues when added to the buffer.  
Two non-ionic detergents were tested in this assay format. This was attempted because 
certain compounds can self-aggregate. This can sequester the target protein onto the 
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surface of these aggregates, causing false positive results (Thorne et al., 2010). It has been 
shown that the inclusion of these non-ionic detergents can decrease the number of hits by 
up to fifteen times when compared to that without detergent (Jadhav et al., 2010). There is 
past precedent for using detergents in FEN screens: 0.01% v/v Tween-20 was used in a 
HsFEN screen (McWhirter et al., 2013). However, attempts to incorporate either Tween-20 
or Triton X-100 were not successful, as both interacted with the dye, producing significant 
background noise (data not shown). Based on this, the shift buffer was composed of 50 mM 
HEPES-NaOH pH 7.0, 1 mM DTT, 50 mM NaCl, 100 mM KCl and 10 mM MgCl2.  
Most commercially available fragment/compound libraries are dissolved in 100% DMSO, so 
analysing the effect of DMSO in this assay is essential. A concentration of 5% was analysed 
as this was used previously, and shown to stimulate enzyme activity two fold (Chapter 
Four). DMSO significantly decreases the TM of both proteins. This negative effect of DMSO 
has been described previously (Giugliarelli et al., 2012; Tjernberg et al., 2006). As a 
consequence, the effect of any compound/fragments on the TM of the protein must be 
compared to a DMSO-containing control to ensure all potential hits are identified.  
5.4.2.4 Pharmacological Relevance 
In order to ensure that the assay is able to detect fragment/compound binding, the two 
proteins were tested using a known inhibitor: myricetin. A dose response can be seen, with 
an increase in TM for both proteins with increasing concentrations of myricetin. This data 
implies that myricetin is interacting directly with the proteins, rather than with any buffer 
additives. This indicates that the assay can be used to detect a known inhibitor. However, it 
is important to normalise against a negative, no protein control, as myricetin does display 
fluorescence in the presence of the dye (data not shown). The Zʹ statistic was used to assess 
how robust the assay is by analysing the mean and standard deviation for the TM values in 
the presence and absence of myricetin. This statistic was only calculated for the two 
myricetin concentrations where a shift in TM was observed (50 µM and 100 µM). As shown 
in Table 5-2, all Zʹ values fall within the expected range (1> Zʹ≥0.5) for both proteins, with 
one exception. One TbFEN replicate in the presence of 50 µM myricetin, had a Zʹ value of 
0.17. This is most likely caused by pipetting errors. Despite this, myricetin should still be 
considered a good positive control, but at concentrations of 100 μM for either TbFEN or 
HsFEN. 
Whilst the reaction conditions have been optimised, the assay has not been fully validated. 
Coma et al (2009) describe steps to achieve full HTS validation that includes assessing 
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machine operation by running empty plates , and testing quality of the assay by performing 
multiple runs of control plates (protein with either 5% DMSO or 100 µM myricetin) (Coma 
et al., 2009). Whilst the assay appears reproducible on a small scale, this needs to be 
analysed in detail to ensure the data gathered is robust. Time commitments prevented this 
from being performed, but should be a priority before any fragment libraries are screened 
using this method.
5.5 Conclusions and Perspectives 
Selective inhibition of the TbFEN over the HsFEN will be difficult to achieve because the 
enzymes are 51% identical at the sequence level. However, fragment based drug design has 
yielded selective inhibitors against proteins with a similar level of sequence identity. One 
such example is selective inhibition of Jak-2 over Jak-3 (Antonysamy et al., 2009). Jak-2 
(accession number O60674) and Jak-3 (accession number P52333) display 50% sequence 
similarity, as determined by (Altschul et al., 1990).  
The current assay has been optimised for use with both the TbFEN and HsFEN. Successful 
optimisation will allow screening of fragment libraries. Screening of a 1000 fragment library 
(purchased from MayBridge) was attempted, but the concentration used for the fragments 
was too low to draw any meaningful conclusions from the data set. A minimum of 1 mM 
should be used in further screens, compared to the 50 μM used initially. Time constraints 
prevented this work from being repeated with the higher fragment concentration. Any 
fragment binding identified by this method will need to be analysed further. Potential 
techniques include nuclear magnetic resonance, surface plasmon resonance and isothermal 
calorimetry. These techniques will provide further information on the association and 
dissociation of the fragments with the protein. Successful fragments from these steps 
should then be taken forward for the labour and time intensive process of X-ray 
crystallography.  Identification of the binding site will allow successful fragments to 
progress through to the compound production process. In this step, the fragments are 
joined to produce a compound with the desired properties. These properties include 
selective inhibition of the TbFEN, ability to cross the blood-brain barrier, and ability to enter 
the parasite.  
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6 Summary and Context in Trypanosoma brucei 
Drug Development 
6.1 Summary 
Flap endonucleases have been intensively studied for nearly fifty years (Klett et al., 1968; 
Liu et al., 2004). The potential of these enzymes as drug targets has been highlighted for 
the human homologue relatively recently (Dorjsuren et al., 2011; McManus et al., 2009; 
McWhirter et al., 2013; Panda et al., 2009; Tumey et al., 2005; Tumey et al., 2004; van Pel 
et al., 2013). However, research into the potential of flap endonucleases from medically 
relevant protozoans has been neglected. The work described in this thesis is classed as 
‘target re-purposing’ , whereby a protein in a different species (HsFEN) is used to identify a 
parasitic orthologue (TbFEN) (Klug et al., 2016). Using a target-based approach is 
advantageous over phenotypic assays because the protein that is inhibited is already known 
(Plouffe et al., 2008). However, this may not correlate to cell death in vivo (Plouffe et al., 
2008). Despite this, target-based drug design against human African trypanosomiasis (HAT) 
is widely reported, and has been reviewed recently (Scotti et al., 2016). Of the enzymes 
reviewed in this paper, only two are involved in nucleic acid processing (RNA editing ligase I 
and Leucyl-tRNA synthase), whilst none are involved directly in DNA replication (Scotti et 
al., 2016). This work highlights the potential of a DNA replication and repair protein as 
potential therapeutic target. 
The production of the TbFEN D183K variant was initially performed in order to obtain a 
protein: substrate complex in the presence of biologically relevant cations. This catalytically 
inert variant binds to DNA with similar affinity to the wild type enzyme (Chapter Two). The 
finding that the substitution of aspartic acid 183 with a lysine results in a catalytically inert 
protein supports work previously performed on the homologous T5 bacteriophage protein 
(Zhang, 2012). However, the equivalent mutation in the T5FEN protein (D153K) resulted in 
an approximately 10-fold increase in affinity for the same DNA substrate compared to the 
wild type T5FEN (Zhang, 2012). Additional investigation needs to be performed to 
determine if this observation is substrate-specific, or if mutating other active site residues 
to lysines has a similar effect. It is likely that mutating the aspartic acid residue to lysine has 
resulted in steric clashes that, whilst they don’t affect the protein folding (Chapter Two), 
may affect the binding ability of the enzyme (Figure 6-1). 
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Figure 6-1 Potential steric clashes in the D183K active site 
The Phyre2 model of TbFEN (described in Chapter 2) was used to visualise the effect of the 
D183K variant (yellow) on the protein (gray). The PyMol mutagenesis wizard was used to 
display potential steric clashes (red discs). Two potential conformations are shown. The images 
were rendered by the author using The PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC. 
This inactive variant was hypothesised to cause a detrimental phenotype if over-expressed 
in T. brucei. This was tested and compared to RNAi knockdown of the FEN1 mRNA, and 
over-expression of the wild type enzyme (Chapter Three). Whilst the success of the RNAi 
knock down was inconclusive, the effect of the D183K variant on cell growth was striking, 
with a significant effect on cumulative cell growth observed after 48 hours post-induction, 
and a morphological change apparent after 72 hours post-induction. However, the 
phenotype caused by over-expression of the wild type FEN1 was not detrimental. A 
hypothetical scenario explaining this is described in Figure 6-2, where the effect of FEN1 is 
limited by loading to PCNA. Disrupting the TbFEN clearly affects the cells, but additional 
investigation needs to be performed to fully understand the mechanism. Not only might 
this work be informative from a drug development perspective, it may also provide tools 
for investigating DNA metabolism.  
Nuclear DNA replication within the T. brucei parasite has received little attention. That is 
shifting, but the most recent papers focus on the origin of replication, rather than the 
replication machinery itself (Marques et al., 2016; Stanojcic et al., 2016). Gaining an 
understanding of the parasite’s nuclear DNA replication processes could highlight novel 
therapeutic targets, and the work in this thesis provides a starting point for this.  
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Figure 6-2 Hypothesised effect of FEN1 over-expression in T. brucei blood stream form 
cells 
PCNA may act as a limiting factor for TbFEN activity. Three FEN1 proteins can bind to the PCNA 
trimer, which recruits FEN1 to the site of cleavage (Chen et al., 1996; Li et al., 1995). Any effects 
caused by over-expression of wild type FEN1 may be limited by this step. Over-expression of the 
D183K variant may be swamping endogenous FEN1, and become loaded onto PCNA. This 
prevents successful DNA replication at the lagging strand, resulting in the detrimental 
phenotype observed. 
The results from the cell-based work were promising, so we progressed to drug 
development, and tested known FEN inhibitors against the TbFEN. Three previously 
identified compounds (D11, C01 and myricetin) that are known to inhibit other FEN 
proteins were tested. Only myricetin inhibited the TbFEN, with an IC50 similar to the HsFEN 
in this assay (Chapter Four). Critically, myricetin also caused cell death when tested against 
the parasite. Whether this is a result of a direct FEN1-myricetin interaction, or a broader, 
non-specific interaction, remains to be elucidated, and is discussed further in Chapter Four. 
Whilst it is unlikely that myricetin will be used as a therapeutic, it provides a starting point 
and a positive control. A typical drug design/development process takes several years, but 
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having a known FEN inhibitor will aid this, because functional groups can be identified, and 
potentially used in fragment-based approaches. 
Another strategy employed in this thesis was to optimise a thermal shift-based assay to 
screen a fragment library (Chapter Five). The ability of this assay to detect known FEN 
inhibitors was tested against myricetin, and yielded positive results (Chapter Five). This type 
of assay is increasing in popularity as part of fragment-based screening process. It typically 
acts as the first step, to narrow down the number of fragments that get taken forward to 
more labour- and consumable-intensive techniques (Mashalidis et al., 2013).  
This thesis adds to the body of knowledge by identifying FEN1 as a potential therapeutic 
target that can be inhibited. A thermal shift-based assay has been optimised and a control 
compound identified to allow for compound/fragment based drug screening. 
6.2 Future Work 
6.2.1 Characterisation of the TbFEN  
The work presented in Chapter Two has highlighted a number of avenues for further 
exploration. Lysine substitutions for the remaining six active site amino acids were 
produced, but not analysed due to time constraints. This should be a priority, as we are still 
lacking that elusive protein: substrate crystal structure. The enzyme kinetics performed on 
the TbFEN employed a simple model substrate, so only limited conclusions could be drawn 
from this in comparison with other FEN enzymes which have been more extensively studied 
(Anstey-Gilbert et al., 2013; Finger et al., 2009; Friedrich-Heineken & Hübscher, 2004; 
Garforth et al., 2001; Harrington & Lieber, 1994b; Sayers & Eckstein, 1990; Tsutakawa et al., 
2011). However, the low-throughput DNA cleavage assay used in Chapter Three showed 
that the TbFEN required a shorter incubation time than the HsFEN for the same flap 
substrate (one hour and three hours respectively). As a consequence, performing a number 
of comparative kinetic experiments on a variety of different substrates for the TbFEN and 
HsFEN would be very interesting. In addition, preliminary work performed on the binding 
specificity of the TbFEN enzyme with different substrate structures showed that the TbFEN 
can bind to single-stranded DNA, 3ʹ overhangs and blunt-ended substrates (data not 
shown). This should be explored further to determine if binding correlates with substrate 
cleavage. If the TbFEN has greater substrate promiscuity than the HsFEN, it could indicate 
additional roles for TbFEN that are currently unknown.  
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6.2.2 Understanding the role of the FEN enzyme in Trypanosoma brucei 
and other kinetoplastids 
The work presented in Chapter Three indicates that having a functional flap endonuclease 
is essential for cell growth. However, initial attempts to elucidate why were not successful. 
There is no current literature on the role of flap endonucleases within T. brucei. If this 
enzyme is to be considered a drug target, more work needs to be performed to understand 
how targeting the enzyme will disrupt normal cellular functions, resulting in cell death. 
Another avenue that should be pursued is the role of the FEN in telomere maintenance 
(Gilson & Géli, 2007; Sampathi et al., 2009). This could provide insights into telomeres in all 
organisms, especially as using trypanosomes as model organisms for telomere study was 
proposed in 2007 (Dreesen et al., 2007). It would also be prudent to consider the potential 
of FEN1 to be involved with variant surface glycoprotein (VSG) switching. VSG genes are 
located adjacent to telomeres, and recombination is a key process for producing different 
VSG variants (Horn, 2014). Rad27 (the FEN1 orthologue in yeast) has been linked to 
restricting short sequence recombination in Saccharomyces cerevisiae (Negritto et al., 
2001). Analysis of FENs from other kinetoplastid parasites, specifically Leishmania spp and 
Trypanosoma cruzi would also be of interest. A paper published in 2008 highlighted a 
potential new role for L. donovanni FEN in a DNA ‘degradesome’ involved in programmed 
cell death, which should be explored further (BoseDasgupta et al., 2008).  
6.2.3 Screening Fragment Libraries 
The optimised thermal-shift based assay for the TbFEN recombinant protein provides a 
starting point for a drug development programme. This assay should be further validated, 
then used to screen fragment libraries (at a concentration of 1-10 mM) against both the 
TbFEN and HsFEN enzymes. This will allow hits to be identified, and select for those that are 
specific to the TbFEN. This is essential given the level of conservation seen between the two 
FEN orthologues. Compounds that interact with the TbFEN and not the HsFEN should be 
taken forward for further analysis of protein: fragment binding using nuclear magnetic 
resonance spectroscopy, isothermal titration calorimetry and/or surface plasmon 
resonance (Dalvit, 2009; Harner et al., 2013; Holdgate & Ward, 2005; Mashalidis et al., 
2013). Identification of the binding sites by X-ray crystallography is also essential to identify 
independent binding site to inform how the fragments can be used to create a novel 
compound. Given the high sequence identity between flap endonuclease from T. brucei and 
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T. cruzi (76%), and Leishmania spp (73%), any compounds produced from developing 
fragment hits against TbFEN should be tested against the flap endonucleases from these 
other kinetoplastid parasites.  
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7 Materials and Methods 
7.1 Cloning 
Three Trypanosoma brucei flap endonuclease (TbFEN) constructs were produced (Table 
7-1). These were modelled on the T. brucei FEN gene (NCBI Gene ID: 3656016), but were 
codon optimised for improved expression in Escherichia coli. Three additional T. brucei 
constructs were produced for over-expression/knock out in vivo. These were modelled on 
the same gene, but the native T. brucei coding sequence was used. Three human flap 
endonuclease (HsFEN) constructs were used. These were modelled on the FEN gene (NCBI 
Gene ID: 2237), but were codon optimised for improved expression in E. coli. 
Table 7-1 Constructs produced and used for this thesis 
Name Experiment  Production 
TbFEN-pET Chapter 2, 4 and 5 Synthesised by Eurofins MWG Operon. 
Cloned into pET21a+ as part of this thesis. 
TbFEN D183K ΔC-
pET 
Production of TbFEN 
D183K-pET 
Synthesised by Eurofins MWG Operon. 
Cloned into pET21a+ as part of this thesis. 
TbFEN D183K-
pET 
Chapter 2 Produced from TbFEN-pET and TbFEN 
D183K ΔC-pET as part of this thesis. 
TbFEN-p2McN Chapter 3 Isolated from genomic DNA and cloned into 
p2McN as part of this thesis. 
TbFEN D183K-
p2McN 
Chapter 3 Produced from TbFEN-p2McN as part of 
this thesis. 
TbFEN-p2T7ti Chapter 3 Produced from TbFEN-p2McN and cloned 
into p2T7ti as part of this thesis. 
HsFEN-pET Chapter 4 Produced from HsFEN D179K-pET as part 
of this thesis. 
HsFEN D179K-
pET 
Production of HsFEN-pET C-terminus cassette was synthesised by 
Eurofins MWG Operon. Full length HsFEN 
D179K-pET produced as part of this thesis. 
HsFEN D179K ΔC-
pET 
Production of HsFEN-pET Synthesised by Eurofins MWG Operon. 
Cloned into pET21a+ as part of this thesis. 
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7.1.1 Bacterial Strains and Plasmids 
Three E. coli strains were used in this work (Table 7-2). The first two strains, XLI blue and 
DH5α, were used to store recombinant plasmids at -80°C (Bullock et al., 1987; Grant et al., 
1990). The third strain, BL21(DE3), was used for the over-expression of the gene of interest 
(Studier & Moffatt, 1986).  
The pET21a+ plasmid (Novagen) was used for expression of all E. coli-produced protein. 
Two plasmids were used for in vivo work with T. brucei blood stream form cells; p2McN and 
p2T7ti provided by Dr Helen Price, originally from D. Horn and S. Alsford).  
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Table 7-2 Escherichia coli strains used, and their genotypes 
Strain Genotype 
XLI 
Blue 
(recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 
(Tetr)]) 
DH5 α 
(F– endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG purB20 φ80dlacZΔM15 Δ 
(lacZYA-argF) U169, hsdR17 (rK–mK+), λ–) 
BL21 
(DE3) 
(B F– ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
[malB+]K-12(λS)) 
7.1.2 Chemically Competent E. coli Cells 
A single E. coli colony was picked from a lysogeny broth (LB) agar plate containing 
appropriate selection marker/s. This was placed in 3 mL of LB media containing appropriate 
selection marker/s, and incubated overnight at 37°C. The culture was diluted 1:100 in LB 
media containing appropriate selection marker/s (100 mL). Cells were grown at 37°C until 
an A600nm of 0.5-0.7 was reached. The culture was centrifuged at 215 xg for ten minutes at 
4°C. The cell pellet was re-suspended in pre-chilled 100 mM CaCl2 (BDH), in a volume 
equivalent to 10% of the original LB media (10 mL) and incubated on ice for thirty minutes. 
The cell suspension was centrifuged as above. The cell pellet was gently re-suspended in 
pre-chilled 100 mM CaCl2 containing 25% glycerol (v/v), at a volume equivalent to 4% of the 
initial LB media (4 mL). The cells were stored in 250 μL aliquots at -80°C. 
LB-agar: 1 % (w/v) tryptone (Fisher), 0.5% (w/v) yeast extract (Oxoid), 0.5% (w/v) NaCl 
(Acros Organics), and 1.5% (w/v) of BactoAgar (BD) 
LB media: 1.0% (w/v) tryptone, 0.5% (w/v) yeast extract and 0.5% (w/v) NaCl
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7.1.3 Preparing Plasmid DNA 
Plasmid DNA was isolated and purified from E. coli cells using commercial kits (Sigma, 
Qiagen and E.Z.N.A.). LB agar plates, containing appropriate selection marker/s, were 
streaked with the appropriate transgenic E. coli, and incubated at 37°C overnight. A single 
colony was isolated and inoculated into 3 mL LB media containing appropriate selection 
markers, and incubated at 37°C overnight. Overnight culture was diluted 1:50 in LB media, 
containing appropriate selection marker/s, and incubated at 37°C overnight. Bacterial cells 
were harvested by centrifugation at 16 000 xg for 10 minutes at room temperature, and 
purified by a modified alkaline-SDS lysis procedure, following the manufacturer’s 
instructions. 
7.1.4 Sub-Cloning 
Plasmid DNA was digested by appropriate restriction enzymes (NEB or Promega) according 
to the manufacturer’s protocol.  Typically, 1 µg of DNA was incubated with 10 units of 
enzyme (enzyme units are defined by the manufacturer) in the appropriate buffer and 
incubated for one hour at 37°C. DNA fragments were separated by 1% agarose 
electrophoresis (see section 7.4.1 for details), and the desired band was excised and 
purified using the GenEluteTM Gel Extraction Kit (Sigma). The DNA fragments were ligated 
into pET21a+ using T4 DNA Ligase (Thermo Scientific) according to the manufacturer’s 
protocol. An example reaction is described in Table 7-3. Chemically competent E. coli cells 
were thawed on ice, and 50 μL of cells was incubated with 5 μL of the ligation product for 
one hour on ice. The cells were heat shocked at 42°C for thirty seconds, followed by ten 
minute incubation on ice. DH5α cells were plated directly onto LB agar plates containing 
appropriate selection marker/s. XLI blue cells were incubated for one hour at 37°C in fresh 
LB media (without antibiotic selection) before being plated onto LB agar plates containing 
appropriate selection marker/s. 
The plasmid was isolated from the colonies as described in Section 7.1.3. Glycerol stocks of 
the bacterial cells were also produced by adding 20% glycerol to bacterial culture to a final 
volume of 1 mL. Glycerol stocks were stored at -80°C. Plasmid DNA was initially analysed by 
restriction enzyme digest and sequence identities were confirmed by DNA sequencing 
(Core Genomics Facility, The University of Sheffield) using appropriate primers (Table 7-7). 
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Table 7-3 Example ligation reaction 
Components Volume/Quantities 
Digested vector 20-100 ng 
Digested insert 2: 1 molar ratio (insert: vector) 
10x Ligase buffer 1 µL 
T4 DNA Ligase 0.5 Unit 
Nuclease free water To 10 µL 
7.2 Site Directed Mutagenesis 
Polymerase chain reaction (PCR) was used to create the necessary point mutations in all 
constructs. Two methods were used: splicing by overlap extension (SOE) PCR, and whole 
plasmid PCR. 
7.2.1 Splicing by Overlap Extension PCR 
This method was used to produce active site mutations in both the human and T. brucei 
flap endonucleases. The SOE-PCR reaction was performed using the following high fidelity 
polymerases; Phusion High Fidelity Polymerase (NEB), KAPA high fidelity polymerase (KAPA 
Biosystems) or Q5 high fidelity polymerase (NEB). Reactions were set up as described in the 
manufacturer’s protocols. Typically 10 ng template DNA was used in a 25 µL reaction, with 
0.3 µM of each oligonucleotide primer and 1 unit of polymerase.  The PCR annealing 
temperature was dependent on the oligonucleotide (see Table 7-7). PCR products were 
analysed on a 1% agarose gel and band-purified using the GenEluteTM Gel Extraction Kit 
(Sigma). The two fragments from the first round of PCR (1 µL of each) were used as the 
template for the second round. All other reaction conditions remained the same. The PCR 
product was analysed on a 1% agarose gel and band purified as before. The PCR product 
was then sub-cloned into pET21a+, and inserted into appropriate E. coli cells (Section 7.1.4).  
7.2.2 Whole Plasmid Site- Directed Mutagenesis 
This technique was used to remove the internal HindIII site from the endogenous T. brucei 
FEN in order to insert it into the p2McN over-expression vector. This technique is based on 
the NEB Q5 mutagenesis kit protocol (NEB). Primers were designed using the 
NEBaseChanger online tool (http://nebasechanger.neb.com/), and are listed in Table 7-7. 
This creates two oligonucleotide primers, a forward primer that contains the desired 
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mutation, and a reverse primer that begins on the complementary DNA sequence where 
the mutation primer begins.  PCR was performed using the KAPA high fidelity polymerase 
(KAPA Biosystems), and set up as described in the manufacturer’s protocol. An additional 
30 seconds per 1kbp of DNA was used for the elongation steps. PCR products were PCR 
purified (Qiagen) and treated with DpnI (Promega) to remove methylated template DNA, as 
described by the manufacturer’s protocol. DpnI was heat inactivated by incubating at 80°C 
for 20 minutes. The sample was then 5ʹ-phosphorylated with T4 polynucleotide kinase 
(PNK, supplied by NEB). PNK was heat inactivated by incubating at 65°C for 20 minutes. This 
was followed by treatment with T4 DNA Ligase (NEB), to ligate the linear plasmid to 
produce closed circular DNA. This was then inserted into appropriate E. coli cells (Section 
7.1.4). 
7.3 Protein Over-Expression and Purification 
7.3.1 Protein Over-Expression 
All recombinant genes were expressed from the pET21a+ vector in the E. coli BL21(DE3) 
strain using either Studier’s auto-inductive method or by the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Studier, 2005). For the Studier method, the cells were grown 
in 500 mL of ZYM-5052 media containing 100 µg/mL of carbenicillin, at 27°C. The culture 
was incubated until the A600nm plateaued, typically between an A600nm of 4-6. Cells were 
recovered by centrifugation at 4000 xg for twenty minutes at 10°C, thoroughly re-
suspended in 25 mM Tris (pH 8.0), 100 mM NaCl and 5 mM EDTA, then centrifuged as 
before. Typically, 4-8 g of cell paste was harvested per litre of culture. Cells were stored at -
80°C. 
For the IPTG induction method, cells were grown in 4 L of 2YT media (1.6% (w/v) tryptone, 
1% (w/v) yeast and 0.5% (w/v) NaCl) containing 0.1% glucose, at 37°C until the A600 reached 
0.4. The temperature was then decreased to 25°C, and the cells were induced by adding 0.1 
mM IPTG. The cells were grown overnight. Cells were recovered by centrifugation at 4000 
xg for twenty minutes at 10°C, washed in 25 mM Tris (pH 8.0), 100 mM NaCl and 5 mM 
EDTA, then centrifuged as before. Typically 5-10 g of cell paste per litre of culture was 
obtained. Cells were stored at -80°C. 
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ZYM-5052: 1% (w/v) tryptone, 0.5% yeast, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM 
NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2 x trace metals, 0.5% glycerol (v/v), 0.05% 
glucose (w/v), 0.2% α-lactose (w/v). 
1000x trace metals: 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2-4H2O, 10 mM ZnSO4-7H2O, 
2 mM CoCl2-6H2O, 2 mM CuCl2-2H2O, 2 mM NiCl2-6H2O, 2 mM Na2MoO4-2H2O, 2 
mM Na2SeO3-5H2O, 2 mM H3BO3. 
2 YT: 1.6 % (w/v) tryptone, 1% (w/v) yeast and 0.5% (w/v) NaCl 
7.3.2 Cell Lysis 
Frozen cell paste was re-suspended in lysis buffer (50 mM Tris pH 8.0, 2 mM 
ethylenediaminetetraacetic acid (EDTA), 200 mM NaCl, 5% (v/v) glycerol) at a volume of 5 
mL per gram of cells. Lysozyme (Sigma) was added to a final concentration of 200 µg/mL, 
and incubated at 4°C for twenty minutes. Phenylmethanesulfonyl fluoride (PMSF; Sigma), 
freshly prepared as a concentrated stock solution, was added to a final concentration of 23 
µg/mL. This was followed by a forty minute incubation at 4°C, or until the solution had 
turned viscous. Sodium deoxycholate (Acros Organic) was added to a final concentration of 
500 µg/mL, and incubated at 4°C for twenty minutes. Dithiothreitol (DTT) (1 mM) was 
added, and incubated at 4°C for five minutes. The solution was sonicated at 20% maximum 
amplitude for thirty second pulses as required to reduce viscosity and using a Jencons 
Ultrasonic Processor (GE-50) sonicator. The preparation was kept on ice throughout. 
Cellular debris was then removed via centrifugation at 75600 xg at 4°C for twenty minutes. 
The soluble fraction was analysed using SDS-PAGE to locate the protein, which was typically 
found in the supernatant. Ammonium sulphate (0.5 M) was added to the supernatant. The 
supernatant was stored on ice whilst a 5% polyethylenimine (PEI; Sigma) (w/v) precipitation 
was performed to precipitate the nucleic acids. The amount of 5% PEI used was determined 
by serial precipitation performed on 1 mL of supernatant. Initially, 10 µL of 5% PEI was 
added, vortexed and centrifuged down at 15000 xg at room temperature for ten minutes. 
This was repeated until no further pelleting occurred. This was scaled up for the bulk of the 
sample, which was stirred for ten minutes at 4°C, then centrifuged at 75600 xg for fifteen 
minutes at 4°C. The supernatant was then removed and placed on ice, whilst the pellet was 
discarded. 
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7.3.3 Ion Exchange and Affinity Chromatography 
Purification was performed using a combination of cation exchange, anion exchange and 
affinity chromatography. All columns were run at 4°C. Either a phosphate buffer (20 mM 
K2HPO4, 20 mM KH2PO4, 1 mM DTT (Melford), 2 mM EDTA and 5% glycerol (v/v)) or a Tris-
based buffer (20 mM Tris pH 8.0, 1 mM DTT, 2 mM EDTA, 5% glycerol ) was used, 
depending on the pH required. All samples were dialysed using 50 mM NaCl, and loaded 
onto the column in the same buffer. Proteins were then eluted from the packed column 
bed under a salt gradient in appropriate buffer. Elution was performed over 20x the volume 
of the column itself. Fractions (one column volume) were collected, and the elution profile 
was monitored using denaturing SDS-PAGE gel. All proteins were purified to a minimum of 
98% purity, as measured by densitometry using Image J. 
7.3.4 Size Exclusion Chromatography 
Size exclusion chromatography was used to further purify the protein samples, using the 
Superdex 200 10/300 GL column. Samples were concentrated down to a maximum volume 
of 500 µL using a centrifugal diafiltration device (Sartorius Stedim Biotech) at 4°C, with a 
molecular weight cut off of 5 kDa. The concentrated sample was injected into the column 
using an AKTA Prime system. Samples were eluted in 0.5 mL fractions in 20 mM K2HPO4, 20 
mM KH2PO4, 1 mM DTT, 2 mM EDTA, 150 mM NaCl and 5% glycerol. The elution of the 
protein from the column was monitored using both UV and denaturing SDS-PAGE. 
7.3.5 Protein Storage and Quantification 
Purified proteins were concentrated to a maximum volume of 1 mL, using a centrifugal 
diafiltration device (Sartorius Stedim Biotech) at 4°C, with a molecular weight cut off of 5 
kDa. Concentrated protein was stored in 50% glycerol at -20°C. The protein concentration 
was determined using the Bio-Rad Protein Assay, a colourmetric assay based on the 
Bradford assay. A standard curve was generated from bovine serum albumin (BSA; Sigma) 
standards ranging from 20-100 µg/mL (in duplicate). Protein samples and BSA standards 
were diluted 1:10 in diluted dye reagent (one part dye, four parts deionised water) and 
incubated at room temperature for 10 minutes. The absorbance at 595 nm was measured. 
The concentration of the unknown protein sample was calculated using the following 
equation: 
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Protein concentration (mg/mL) =
𝑦−𝑐
𝑚∗𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
∗ 1000 
Where y is the absorbance at 595 nm, c is the intercept and m is the gradient (both c and m 
are determined from the standard curve). 
7.4  Electrophoresis Methods 
7.4.1 DNA Electrophoresis 
DNA was separated based on size using 1% (w/v) agarose gels. Powdered agarose (Web 
Scientific) was dissolved in TAE running buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, 
pH 8.0), containing 0.1 µg/mL of ethidium bromide, and set at room temperature. The gel 
was transferred to an electrophoresis tank containing TAE buffer and run between 2.6 – 4.2 
V/cm (equivalent to 50-80 mA) until the DNA samples had migrated sufficiently. This was 
determined by full separation of the DNA ladder. The DNA bands were then visualised using 
the DC290 camera and the Kodak 1D 3.6.2 imaging software on a UV trans-illuminator. 
7.4.2 Denaturing SDS-PAGE 
SDS-PAGE gels were used to visualise proteins by separating them out based on size. Gels 
containing 10% acrylamide were used unless stated otherwise in the figure legends. 
Samples were mixed 1:1 with sodium dodecyl sulphate (SDS) loading dye and incubated for 
three minutes at 95°C. Samples were loaded into wells in the stacking gel  and run at 20 
V/cm (equivalent to 30 mA) until the dye line reached the edge of the resolving gel. The 
protein was stained using Coomassie Brilliant Blue stain, followed by a de-staining solution 
to remove excess dye. The gels were visualised using the DC290 camera and the Kodak 1D 
3.6.2 imaging software on the FLA-3000 Imager. 
SDS Loading Buffer: 0.2% SDS, 2.5% glycerol, 75 mM Tris-HCl (pH 6.8), 0.5% 
bromophenol blue (BDH), 5 mM EDTA and 1 mM DTT. 
SDS-PAGE Stacking Gel: 120 mM Tris-HCl (pH 6.9), 10% acrylamide (30:1 acrylamide: 
bisacrylamide), 0.1% SDS, 0.5 mg/mL ammonium persulphate (APS) and 0.003% 
(v/v) tetramethylethylenediamine (TEMED). 
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SDS-PAGE Resolving Gel: 100 mM Tris-Bicine (pH 8.0), 10% acrylamide (30:1 acrylamide: 
bisacrylamide) (National Diagnostics), 0.1% SDS, 0.5 mg/mL APS (BDH) and 
0.15% TEMED. 
SDS-PAGE Running Buffer: 50 mM Tris-Bicine (pH 8.3) and 0.1% SDS. 
Coomassie Brilliant Blue Stain: 40% (v/v) methanol (BDH), 10% (v/v) acetic acid and 2 
mg/mL Coomassie Brilliant Blue R250 (Sigma). 
SDS-PAGE De-stain Solution: 20% (v/v) methanol and 10% (v/v) acetic acid. 
7.4.3 SDS-PAGE Substrate Gel 
Nuclease activity of the FEN proteins (and any contaminants) was visualised using an SDS-
PAGE substrate gel. The gel was prepared in the same way as a standard SDS-PAGE gel (see 
section 7.4.2), but 200 µg of Type XIV Herring sperm DNA (Sigma) was added to the 
resolving gel. Samples were prepared and run as described in section 7.4.2. The gel was 
washed thrice with 100 mL of TBG buffer  for thirty minutes in total. The gel was incubated 
overnight in 200 mL of incubation buffer. The nuclease reaction was terminated by the 
removal of the incubation buffer, and washed once with 100 mL TBG.  The gel was washed 
once with 100 mL TBG supplemented with 0.25 µg/mL of ethidium bromide, then washed 
in 100 mL TBG. Gels were visualised using the DC290 camera and the Kodak 1D 3.6.2 
imaging software on a UV trans-illuminator. Nuclease activity was depicted as an area of 
reduced fluorescence. The substrate gel was stained with Coomassie Brilliant Blue and de-
stained as a typical SDS-PAGE gel (Section 7.4.2) to visualise the protein. 
TBG: 100 mM Tris-Bicine pH 8.0, 0.04 mM EDTA and 10% glycerol (v/v). 
Incubation Buffer: 100 mM Tris-Bicine pH 8.0, 50 mM NaCl, 1 mM DTT, 10 mM MgCl2, 
100 mM KCl and 10% glycerol (v/v). 
7.4.4 Low Through-Put Inhibitor Assay 
This assay was developed by Dr Sarbendra L Pradhananga, a post-doctoral researcher in the 
Sayers laboratory. This assay allows the visualisation of a specific, single-labelled DNA 
substrate, from which the cleavage capability of the enzyme can be determined in the 
presence of potential inhibitors. These gels contain 25% acrylamide unless otherwise 
stated. The flap endonuclease of interest was mixed with assay buffer  to give a final 
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concentration of 10 µg/mL. The candidate compounds were added to a final concentration 
of 50 µM (the DMSO percentage was kept constant at 5%). Compounds C01 and D11 were 
originally purchased on a “fee-for-service” basis from Sygnature Discovery Ltd 
(Nottingham), whilst Myricetin was purchased from Sigma Aldrich. Samples were incubated 
for five minutes at 37°C in a light protected amber tube (Eppendorf). The DNA substrate 
(Table 7-8) was annealed by diluting to a final concentration of 2.5 pmol/µL in assay buffer, 
and incubating at 95°C for five minutes, followed by five minute incubation on ice. The 
annealed substrate was added to the enzyme/inhibitor solution to a final concentration of 
0.6 pmol/µL. This solution was incubated at 37°C for either one or three hours for the 
TbFEN or HsFEN respectively. This was diluted 1:1 in DNA loading dye, and incubated for 
five minutes at 70°C. Samples were loaded onto the 25% DNA-PAGE gel . and run at 22 
V/cm (equivalent to 150 V) for ninety minutes in the dark.  Gels were visualised using the 
DC290 camera and the Kodak 1D 3.6.2 imaging software on a UV trans-illuminator. 
Assay Buffer: 25 mM HEPES, 0.5 mM EDTA, 100 mM NaCl, 10 mM MgCl2, 100 mM KCl, 2 
mM DTT, 0.1 mg/ml BSA, pH 7.0. 
DNA Loading Dye: 30% (v/v) glycerol, 0.2% (w/v) xylene cyanol, 1% (w/v) SDS and 250 mM 
EDTA. 
25% DNA Gel: 5 mL 30% acrylamide/bisacrylamide (19:1), 0.6 mL 10x TBE, 0.3 mL water, 0.1 
mL 10% (w/v) APS and 0.01 mL TEMED. 
7.5 Antibody Production 
Antibodies against the N-terminus of the TbFEN protein were raised in rabbits by a contract 
research organisation, Generon (www.generon.co.uk). Briefly, one New Zealand rabbit was 
injected subcutaneously with 450 µg of purified protein in complete Freund’s adjuvant on 
days 1, 21, 51 and 81. Test sera were gathered on days 28 and 58, with final sera collection 
on day 88. The antibodies were purified using Zeba desalting columns (Thermo Scientific), 
buffer exchanged into PBS, and stored at -20°C. 
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7.6 Spectroscopy-Based Methods 
7.6.1 UV Exonuclease Assay 
The exonuclease activity of the enzyme was determined using a spectrophotometric 
method (Sayers & Eckstein, 1990). Reactions containing 25 mM HEPES-NaOH (pH 7.5), 10 
mM MgCl2, 100 mM KCl, 1 mM DTT and 667 µg/mL of herring sperm type XIV DNA were 
pre-warmed at 37°C for ten minutes. The recombinant FEN1 proteins were added and 
incubated at 37°C. Aliquots (100 µL) were taken during over a time course and quenched 
with equal volumes of 6% HClO4. These were incubated on ice for ten minutes and 
centrifuged at 14000 xg for five minutes. The supernatant (150 µL) was added to 850 µL of 
H2O and the absorbance measured at 260 nm in a 1 cm path length quartz cuvette. Increase 
in absorbance were plotted against time, and fitted by linear regression. One unit is defined 
as the amount of enzyme required to release 1 nmole of acid soluble nucleotides in thirty 
minutes at 37°C (1 A260 corresponds to 1.2 = 100 nmole nucleotide). 
7.6.2 Circular Dichroism 
Proteins were exchanged into circular dichroism (CD) buffer (20 mM K2HPO4, 20 mM 
KH2PO4, 1 mM DTT, 50 mM NaCl and 5% glycerol, pH 7.0) using a diafiltration device 
(Sartorius Stedim Biotech) with a molecular weight cut off of 5 kDa. Proteins were 
quantified by near UV absorption, as described by Kelly, Jess and Price (2005). Briefly, 
proteins were diluted into 6 M guanidine hydrochloride, pH 7.1, and the absorbance at 280 
nm was recorded. The absorbance at 280 nm of a 1 mg/mL solution was defined as (Kelly et 
al., 2005): 
𝐴280 (1 𝑚𝑔/𝑚𝐿) =
5690𝑤 +  1280𝑦 +  60𝑐
𝑀𝑎𝑠𝑠 (𝐷𝑎)
 
Where w is the number of tryptophan residues present in the protein, y the number of 
tyrosine residues and c the number of cysteine residues (Kelly et al., 2005). 
The measured absorbance at A280 was then divided by the calculated A280 value for 1 
mg/mL, to give the actual protein concentration, in mg/mL. Samples were diluted to 
between 0.1-0.5 mg/mL for analysis. Samples were run in the JASCO J-810 spectrometer. 
Run parameters are described in Table 7-4. Readings were measured in ellipticity 
(commonly called millidegrees). This was converted to molar ellipticity ([Ɵ]Molarλ) using the 
following equation (Kelly et al., 2005): 
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[Ɵ]𝑀𝑜𝑙𝑎𝑟𝜆 =
100 ∗  Ɵ𝜆
𝑚 ∗ 𝑑
 
Where Ɵλ is ellipticity (or millidegrees) at wavelength λ, m is the molar concentration of the 
protein and d is the path length (cm) (Kelly et al., 2005). 
Table 7-4 Parameters used on the JASCO J-810 spectrometer                                       
Parameter Setting 
Start wavelength (nm) 250 
End wavelength (nm) 195 
Data pitch (nm) 1 
Scanning mode Continuous 
Scanning speed (nm/minute) 20 
Response (seconds) 8 
Band width 1 
Accumulation 3 
7.6.3 Förster Resonance Energy Transfer Cleavage Assay 
Förster resonance energy transfer (FRET) occurs when the emission spectra of a donor 
fluorophore overlaps with the absorption spectra of a quencher (Lakowicz, 2006). In this 
assay, a dual-labelled DNA substrate is incubated with enzyme. Cleavage of the quencher 
dye allows the increased fluorescence of the excited fluorophore to be detected.  
Dual fluorescently-labelled oligonucleotides were used as the template for FRET substrates. 
Unlabelled, partially complementary oligonucleotides were used to create the flap 
substrates preferred by the FEN enzymes. The oligonucleotides used are shown in Table 
7-8. Double-stranded oligonucleotide substrates were prepared to a final concentration of 
0.5 µM in 25 mM HEPES-NaOH (pH 7.5), 1 mM EDTA and 0.5 M NaCl. The solution was 
heated to 85°C for five minutes, and was then left to cool slowly to room temperature. 
Annealed products were then stored at -20°C. 
Substrate at the required concentration was prepared in 25 mM HEPES-NaOH pH 7.5, 100 
mM KCl, 0.5 mM EDTA, 2 mM DTT and 0.1 mg/mL BSA. The enzyme was diluted to the 
appropriate concentration in the same buffer. The enzyme and substrate solution were pre-
warmed to 37°C, and the reaction initiated by the addition of 10 mM MgCl2. The 
fluorescence intensity data collection began ~ 10 seconds after the addition of MgCl2 at one 
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second intervals using a HITACHI F-2500 FL spectrophotometer at 496 nm/519 nm 
(excitation/emission).  
7.7 Bio-Layer Interferometry 
This assay uses the principle of optical interferometry to detect protein binding to an 
immobilized DNA substrate. This binding causes a change in optical thickness, causing a 
wavelength shift (Sultana & Lee, 2015). This allows interactions to be monitored in real-
time. The oligonucleotide substrate (Table 7-8) was diluted to a final concentration of 5 
pmol/µL in binding buffer (25 mM HEPES-NaOH pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 0.1 mg/mL BSA, 5 mM CaCl2). The annealed substrate was produced by incubating the 
diluted oligonucleotide at 95°C for five minutes, then incubating on ice for five minutes. 
Binding experiments were performed on the FortѐBIO BLItz machine, using streptavidin 
based probes. The process is described in Table 7-5. Probes were hydrated for a minimum 
of ten minutes in 200 µL of reaction buffer and 20 pmol of annealed biotinylated 
oligonucleotide was loaded over 120 seconds, and washed for a further 120 seconds. 
Baseline measurements were obtained using 250 µL of reaction buffer. Protein-DNA 
association was measured by loading 4 µL of freshly diluted protein onto the DNA bound 
probe over 120 seconds. Dissociation rates were measured by placing the protein-DNA 
bound probe into 250 µL of reaction buffer for 120 seconds. Data was corrected for system 
artefacts between the association and dissociation steps, and was analysed using global 
(1:1) curve fitting. This calculated the rate constants for association (kon) and dissociation 
(koff), and the dissociation constant (Kd). 
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Table 7-5 Run conditions for binding experiments on the Forte Bio BLItz machine 
Stage Time (mins) Volume (µL) 
Hydration 10 200 
Initial Baseline 0.5 250 
Association 2 4 
Dissociation 2 250 
7.8 Thermal Shift Assay 
This assay uses a dye that fluoresces when it binds to hydrophobic regions of proteins. 
Denaturing the protein by increasing the temperature produces a melting curve, from 
which the melting temperature (TM) can be calculated. The TM is the temperature at which 
50% of the protein is unfolded. 
The assay was set up as described by the manufacturer (Life Technologies). Briefly, protein 
was diluted to a minimum of 1.2 μM and 2.3 μM (TbFEN or HsFEN respectively) in shift 
buffer (50 mM HEPES-NaOH pH 7.0, 1 mM DTT, 50 mM NaCl, 100 mM KCl, 10 mM MgCl2 
and 1x dye). Samples were loaded on to a MicroAmp® Optical 384 well plate (Applied 
Biosystems). Plates were sealed with a MicroAmp® Optical Adhesive Film (applied 
Biosystems) and centrifuged for one minute at 1000 rpm in a Sorvall® Legend T centrifuge. 
Plates were loaded onto an Applied Biosystems 7900 Real Time PCR machine. Using the SDS 
software (version 2.1 or 2.4), a dissociation stage was set up to increase from 25°C to 95°C, 
with a ramp rate of 2%. Data was exported into Microsoft Excel, and the melt curve was 
inserted into GraphPad Prism (version 6.0). Data was normalised against the negative 
controls, and analysed using the Boltzmann equation in GraphPad Prism (6.0). The Zʹ factor, 
a statistical test to assess assay robustness, was calculated using the following equation  
(Zhang et al., 1999): 
𝑍ʹ = 1 −
3(𝜎𝑝 +  𝜎𝑛)
(𝜇𝑝 −  𝜇𝑛)
 
Where μp and σp are the mean and standard deviation of the positive control, and μn and σn 
are the mean and standard deviation of the negative control (Zhang et al., 1999). 
7.9 In Vivo Parasitology 
This work was performed in collaboration with Dr Helen Price, at Keele University. 
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7.9.1 Parasite Growth and Maintenance 
The Trypanosoma brucei brucei bloodstream form (BSF), strain Lister 427 (Single Marker 
Lister) was maintained in HMI9 media (18.3 mg/mL HM19 powder (Gibco), 36 mM sodium 
hydrogen carbonate (Sigma), 14.3 µL/L β-mercaptoethanol (Sigma), 2 mM L-glutamine 
(Gibco), 100 U/mL penicillin (Gibco) and 100 µg/mL streptomycin) supplemented with 10% 
heat-inactivated tetracycline-free foetal calf serum (Bioline). Neomycin (2.5 µg/mL) was 
added to maintain the phage-derived T7 RNA polymerase and tetracycline repressor. BSF 
cells were grown at 37°C with 5% CO2.  
7.9.2 Transfection of T. brucei blood stream forms 
BSF cells were transfected by electroporation. Briefly, 6 x105 cells/mL were collected by 
centrifugation at 800 xg at 20°C for ten minutes. Cells were washed in 10 mL of PBS and 
centrifuged as before. Cells were washed in 1 mL PBS and centrifuged at 4000 xg for five 
minutes at 20°C. The cell pellet was re-suspended in 100 μL T-cell Nucleofector ® solution 
(Lonza), and transferred to an Amaxa cuvette. Electroporation was performed using 
programme X-001 on the Amaxa Nucleofector ® machine (Lonza), with 4 μg, 3.5 μg and 4.5 
μg of NotI digested p2T7ti-FEN, p2McN-FEN and p2McN-FEND183K respectively. Transfected 
cells were diluted into 20 mL of pre-warmed HMI9 media, and plated out onto 24-well 
plates neat, or after a 1:10 dilution. Stable transfectants were selected for by the addition 
of 2.5 μg/mL phelomycin (Sigma) for the p2T7ti plasmid, or 10 μg/mL hygromycin for the 
p2McN plasmid, 16 hours post-transfection. 
7.9.3 Cumulative Growth Curves 
Mid log phase BSF cells (transformed or parental) were grown and then counted using a 
haemocytometer. Fresh flasks of HMI9 media with the appropriate additives were seeded 
with 5 x104 cells/mL. Expression of double stranded RNA, or the FEN1 wild type or D183K 
variant proteins, were induced by the addition of 1 μg/mL tetracycline. Cumulative growth 
was plotted against time (hours post induction). 
7.9.4 Total RNA Extraction and Quantification 
Cells were harvested by centrifugation at 800 xg at 20°C for ten minutes, washed in PBS 
(equal to one fifth of the original culture volume) and centrifuged at 800 xg at 20°C for ten 
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minutes. Cells were washed in PBS (equal to one hundredth of the original culture volume) 
and centrifuged at 4000 xg at 20°C for five minutes. The cell pellet was re-suspended in an 
equal volume of TRIsure and incubated at 20°C for five minutes. Chloroform was added (0.2 
mL/1 mL TRIsure), mixed vigorously, incubated at room temperature for three minutes, 
then centrifuged for fifteen minutes at 12 000 xg at 4°C. The top aqueous layer was 
harvested, isopropanol added (0.5 mL/ 1 mL of TRIsure), and mixed by inversion. Samples 
were incubated at 20°C for ten minutes, then centrifuged for fifteen minutes at 12 000 xg at 
4°C. The supernatant was discarded, and the pellet washed in 75% ethanol (1 mL per mL of 
TRIsure). Samples were vortexed and centrifuged at 7500 xg for five minutes at 4°C. The 
supernatant was discarded and the pellet air dried. RNA was re-suspended in 50 μL 
nuclease-free water and incubated at 60°C until the pellet had dissolved. The RNA 
concentration and purity was determined using the Nanodrop 1000, then stored at -80°C. 
7.9.5 Reverse Transcription Quantitative PCR (RT-qPCR) 
Two-step RT-qPCR was carried out on harvested RNA (Section 7.9.4). The first step converts 
the RNA to cDNA (reverse transcription), whilst the second step involves absolute 
quantification of the total RNA by comparing threshold cycles (CT) against a standard curve. 
RNA was treated with DNase (Ambion) to remove genomic DNA, according to the 
manufacturer’s protocol. Briefly, 4 µg RNA was treated with 1 unit of DNase for fifteen 
minutes at 37°C. Inactivation buffer (equal to 10% of the reaction volume) was added, and 
incubated at 20°C for two minutes. The sample was centrifuged at 10 000 xg for one minute 
at 20°C, and the supernatant harvested. Reverse transcription (RT) was performed using the 
Omniscript RT kit (Qiagen). Two reactions were set up per RNA sample, one with and one 
without the Omniscript RT enzyme. Reactions were performed according to the 
manufacturer’s protocol. Briefly, 4 µg DNase-treated RNA was incubated with 0.5 U/µL of 
RNaseOUT ™ (Invitrogen) inhibitor, 0.2 U/µL of Omniscript RT enzyme, 20 ng/µL oligo-dT 
(Qiagen) and 0.5 mM each dNTP (dA, dG, dC and dT). Samples were incubated at 37°C for 
sixty minutes to produce cDNA. Samples were stored at -20°C until required for PCR. 
Quantitative PCR was performed using Applied Biosystems 7900HT thermocycler, with the 
PowerUpTM SYBR® Green Master Mix (Life Technologies). Oligonucleotides were designed 
as described by Thornton and Basu (2011), except PerlPrimer was used instead of Beacon 
DesignerTM (Thornton & Basu, 2011). The FEN1 specific oligonucleotide pair used is 
described in Table 7-8. Standards of p2McN- FEN1 were produced, beginning with 1x109 
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molecules per µL, then serially diluted 1:10 down to 1x103 molecules per µL. Reactions 
were set up according to the manufacturer’s protocol. Briefly FEN1-specific 
oligonucleotides were diluted to a final concentration of 125 nM, whilst α-tubulin specific 
oligonucleotides (kindly provided by Dr Helen Price) were diluted to 300 nM. A final 
concentration of 40 ng of cDNA was used (assuming 100% conversion and recovery of RNA 
to cDNA). MicroAmp® optical 384 well plates (Life Technologies) were sealed with a 
MicroAmp® Optical Adhesive Film and centrifuged for one minute at 1000 rpm in a Sorvall® 
Legend T centrifuge. The computer programme SDS (version 2.1 or 2.4) was used with the 
Applied Biosystems 7900HT thermocycler, and was programmed as described in Table 7-6. 
Table 7-6 qPCR parameters 
Stage Number Temperature (°C) Time (seconds) Number of Repeats 
One 50 120 1 
Two 95 300 1 
Three 
95 15 
40 
60 60 
Four 
95 15 
1 60 30 
95 15 
7.9.6 Immunofluorescent Confocal Microscopy 
Mid log phase BSF cells were counted using a haemocytometer. Cells (5 x106 cells) were 
harvested by centrifugation at 800 xg for ten minutes at 20°C. The cell pellet was re-
suspended in 10 mL vPBS (137 mM NaCl, 3 mM KCl, 16 mM Na2HPO4, 3 mM HK2PO4, 46 mM 
sucrose, 10 mM glucose) and centrifuged, as before. The cell pellet was re-suspended in 4% 
paraformaldehyde/PBS, and incubated on ice for sixty minutes. The paraformaldehyde was 
diluted 1:10 in ice cold PBS, and centrifuged at 4°C for ten minutes at 800 xg. The cell pellet 
was re-suspended in 1 mL PBS, and centrifuged at 3000 xg for three minutes at 20°C. The 
cell pellet was re-suspended in 50 µL of PBS, applied to a polysine slide and left at room 
temperature for twenty minutes. Excess liquid was removed from the slides, cells were 
permeabilised in 0.1% Triton-X 100 in PBS, and incubated at room temperature for ten 
minutes. Slides were washed once in PBS, Image iT FX signal enhancer (Life Technologies) 
was applied per sample and incubated at room temperature for thirty minutes. Excess 
liquid was removed and replaced with 100 µL of diluted primary antibody (rabbit α-FEN1; 
1:100 and mouse α-TAT1; 1:200, provided by Dr Helen Price, originally a gift from Professor 
 137 
Keith Gull). Slides were incubated at room temperature for one hour. Excess liquid was 
removed, and slides washed thrice in PBS for five minutes each time, under gentle 
agitation. Slides were dried, and 100 µL of diluted secondary antibody (goat α-mouse IgG 
Alexa Fluor 488 and goat α-rabbit IgG Alexa Fluor 594, both 1:250 (Life Technologies)) was 
added, and incubated in the dark at room temperature for one hour. Excess liquid was 
removed and slides washed as before, but in the dark. Excess liquid was removed and the 
coverslip was added using ProShield mounting medium (Life Technologies). Slides were left 
overnight in the dark, at room temperature, to allow the mounting medium to set, then 
stored at 4°C until visualised. Slides were examined using the Zeiss LSM 510 NLO inverted 
confocal microscope with a 63x/1.4 oil lens. Images were acquired using the LSM 510 
software. 
7.9.7 Flow Cytometry 
Propidium iodide is a DNA intercalating agent that enters dead cells. Using this on dead 
cells allows the cell cycle progression of the cell population to be analysed, and any defects 
in the cell cycle, can be detected. Cells were harvested by centrifugation at 800 xg at 20°C 
for ten minutes, and then washed once in PBS. Cells were re-suspended in 70% methanol, 
30% PBS and incubated at 4°C overnight. Cells were washed once in 10 mL cold PBS, the 
centrifuged at 400 xg at 20°C for twenty minutes. Cells were re-suspended in 1 mL PBS 
containing 10 µg/mL propidium iodide (Sigma) and 10 µg/mL RNase A (Thermo Scientific) at 
a cell density of 5 x106 cells/mL. Samples were incubated at 37°C for thirty minutes. Cell 
cycle analysis was performed on the Becton Dickinson FACSCalibur, using the FL3-A 
detector. Data for 10 000 cells was collected per sample. Data was analysed using FlowJo, 
version 10.0.7v2. 
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Table 7-7 Oligonucleotides used in all sub-cloning, site directed mutagenesis and 
sequencing protocols 
Name Sequence (5ʹ - 3ʹ) Technique 
For_Xba tttTCTAGATGGGTGTTCTTGGCCTTTCG Sub-cloning 
Rev_Bam tttGGATCCCTACTTTTTGACAGCCTTTTTGTGTCC Sub-cloning 
For_KK TGGCCTTTCGaaaCTTCTGTACG Site directed mutagenesis 
Rev_KK AGAACACCCATCTAGAGTCG Site directed mutagenesis 
For_Hind tttAAGCTTATGGGTGTTCTTGGCCTTTCG Sub-cloning 
For_D183K GGAACAGAGAAGATGGATGGAT Site directed mutagenesis 
Rev_D183K GGCATCCATCTTCTCTGTTCCTAC Site directed mutagenesis 
RNA_Xba_for ttgtTCTAGAGGATCAGATGGAGGAGGTGA Sub-cloning 
RNA_Hind_rev ttgtAAGCTTTTCGTAAGTGCGTCACGAAG Sub-cloning 
D34K_for CGTATCGCGATTAAAGCCAGTATGGCCG Site directed mutagenesis 
M13_for AGGGTTTTCCCAGTCACGACGTT Site directed mutagenesis 
M13_rev GAGCGGATAACAATTTCACACAGG Site directed mutagenesis 
K179D_for TGCAGCAGCCACCGAAGATATGGATTGTCTGACCTTT Site directed mutagenesis 
K179D_rev CCAAAGGTCAGACAATCCATATCTTCGGTGGCTGCTGCA Site directed mutagenesis 
D34K_rev CGGCCATACTGGCTTTAATCGCGATACGACG Site directed mutagenesis 
New_for TATACATATGGGCGTCCTTGGGCTGFTCTAAACTGTTGTATG Site directed mutagenesis 
New_rev CGCAAGCTTATCATTTTTTCACTGCTTTTTTATGG Site directed mutagenesis 
T7_for TAATACGACTCACTATAGGG Sequencing 
T7_term GCTAGTTATTGCTCAGCGG Sequencing 
Codons involved in site directed mutagenesis are underlined and in bold. Restriction enzyme 
sequences are shown in italics. 
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Table 7-8 Oligonucleotides used in analytical techniques 
Name Sequence (5ʹ - 3ʹ) Modification Technique 
Bio_OHP2 CTCTGTCGAACACACGCZTGCGTGTGTTC 6-BDT BLI 
Aniso_sub TAAACGCTGTCTCGCTGAAAGCGAGACAGCGAAAGACGCTCGT 6 FLUDT Inhibitor 
Aniso_flap ACGAGCGTCTTT NA Inhibitor 
Assay3 TTTTCGCTGTCTCGCTGAGT 5ʹ CY3, 3ʹFLU FRET 
Assay3_flap ACTCAGCGAGACAGCGCCGGAACACACGCTGCGTGTGTTCCGG NA FRET 
RT_FEN1_for TGGCCGTATATCAGTTCGTC NA RT-qPCR 
RT_FEN1_rev CGTAACATCCCCAGCTTCAT NA RT-qPCR 
RT_TUB_for CGTGAGGCTATCTGCATCCA NA RT-qPCR 
RT_TUB_rev CCCAGCAGGCGTTACCAA NA RT-qPCR 
 
 
  
 140 
8 References 
Alber, T. (1989). Mutational effects on protein stability. Annu Rev Biochem, 58, 765-798. doi: 
10.1146/annurev.bi.58.070189.004001. 
Alleva, J. L. and Doetsch, P. W. (1998). Characterization of Schizosaccharomyces pombe Rad2 
protein, a FEN-1 homolog. Nucleic Acids Res, 26, 3645-3650. 
Altschul, S. F., Gish, W., Miller, W., Myers, E. W. and Lipman, D. J. (1990). Basic local alignment 
search tool. J Mol Biol, 215, 403-410. doi: 10.1016/S0022-2836(05)80360-2. 
Anene, B. M., Onah, D. N. and Nawa, Y. (2001). Drug resistance in pathogenic African 
trypanosomes: what hopes for the future? Vet Parasitol, 96, 83-100. 
Anstey-Gilbert, C. S., Hemsworth, G. R., Flemming, C. S., Hodskinson, M. R., Zhang, J., Sedelnikova, 
S. E., Stillman, T. J., Sayers, J. R. and Artymiuk, P. J. (2013). The structure of Escherichia coli 
ExoIX--implications for DNA binding and catalysis in flap endonucleases. Nucleic Acids Res, 
41, 8357-8367. doi: 10.1093/nar/gkt591. 
Antonysamy, S., Hirst, G., Park, F., Sprengeler, P., Stappenbeck, F., Steensma, R., Wilson, M. and 
Wong, M. (2009). Fragment-based discovery of JAK-2 inhibitors. Bioorg Med Chem Lett, 19, 
279-282. doi: 10.1016/j.bmcl.2008.08.064. 
Ashley, C. T. and Warren, S. T. (1995). Trinucleotide repeat expansion and human disease. Annu 
Rev Genet, 29, 703-728. doi: 10.1146/annurev.ge.29.120195.003415. 
Bae, S. H. and Seo, Y. S. (2000). Characterization of the enzymatic properties of the yeast dna2 
Helicase/endonuclease suggests a new model for Okazaki fragment processing. J Biol Chem, 
275, 38022-38031. doi: M006513200 [pii] 10.1074/jbc.M006513200. 
Baker, M. (2013). Fragment-based lead discovery grows up. Nat Rev Drug Discov, 12, 5-7. doi: 
10.1038/nrd3926. 
Baker, N., de Koning, H. P., Mäser, P. and Horn, D. (2013). Drug resistance in African 
trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol, 29, 110-118. 
doi: 10.1016/j.pt.2012.12.005. 
Baker, N., Glover, L., Munday, J. C., Aguinaga Andrés, D., Barrett, M. P., de Koning, H. P. and Horn, 
D. (2012). Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in 
African trypanosomes. Proc Natl Acad Sci U S A, 109, 10996-11001. doi: 
10.1073/pnas.1202885109. 
Balakrishnan, L. and Bambara, R. A. (2013). Flap endonuclease 1. Annu Rev Biochem, 82, 119-138. 
doi: 10.1146/annurev-biochem-072511-122603. 
Baldwin, G. S., Sessions, R. B., Erskine, S. G. and Halford, S. E. (1999). DNA cleavage by the EcoRV 
restriction endonuclease: roles of divalent metal ions in specificity and catalysis. J Mol Biol, 
288, 87-103. doi: 10.1006/jmbi.1999.2672. 
Barnes, C. J., Wahl, A. F., Shen, B., Park, M. S. and Bambara, R. A. (1996). Mechanism of tracking 
and cleavage of adduct-damaged DNA substrates by the mammalian 5'- to 3'-
exonuclease/endonuclease RAD2 homologue 1 or flap endonuclease 1. J Biol Chem, 271, 
29624-29631. 
Barrett, M. P. and Croft, S. L. (2012). Management of trypanosomiasis and leishmaniasis. Br Med 
Bull, 104, 175-196. doi: 10.1093/bmb/lds031. 
 141 
Barrett, M. P., Vincent, I. M., Burchmore, R. J., Kazibwe, A. J. and Matovu, E. (2011). Drug 
resistance in human African trypanosomiasis. Future Microbiol, 6, 1037-1047. doi: 
10.2217/fmb.11.88. 
Batista, A. N., Batista, J. M., Bolzani, V. S., Furlan, M. and Blanch, E. W. (2013). Selective DMSO-
induced conformational changes in proteins from Raman optical activity. Phys Chem Chem 
Phys, 15, 20147-20152. doi: 10.1039/c3cp53525h. 
Bellofatto, V., Fairlamb, A. H., Henderson, G. B. and Cross, G. A. (1987). Biochemical changes 
associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma 
brucei. Mol Biochem Parasitol, 25, 227-238. 
Berg, J. M., Tymoczko, J. L. and Stryer, L. (2002a). Proteins Are Built from a Repertoire of 20 Amino 
Acids. In Biochemistry W H Freeman, New York. 
Berg, J. M., Tymoczko, J. L. and Stryer, L. (2002b). Restriction Enzymes: Performing Highly Specific 
DNA-Cleavage Reactions. In Biochemistry W H Freeman, New York. 
Blackburn, E. H., Greider, C. W. and Szostak, J. W. (2006). Telomeres and telomerase: the path 
from maize, Tetrahymena and yeast to human cancer and aging. Nat Med, 12, 1133-1138. 
doi: 10.1038/nm1006-1133. 
Bornarth, C. J., Ranalli, T. A., Henricksen, L. A., Wahl, A. F. and Bambara, R. A. (1999). Effect of flap 
modifications on human FEN1 cleavage. Biochemistry, 38, 13347-13354. 
BoseDasgupta, S., Das, B. B., Sengupta, S., Ganguly, A., Roy, A., Dey, S., Tripathi, G., Dinda, B. and 
Majumder, H. K. (2008). The caspase-independent algorithm of programmed cell death in 
Leishmania induced by baicalein: the role of LdEndoG, LdFEN-1 and LdTatD as a DNA 
'degradesome'. Cell Death Differ, 15, 1629-1640. doi: 10.1038/cdd.2008.85. 
Bray, P. G., Barrett, M. P., Ward, S. A. and de Koning, H. P. (2003). Pentamidine uptake and 
resistance in pathogenic protozoa: past, present and future. Trends Parasitol, 19, 232-239. 
Breda, A., Valadares, N., Norberto de Souza, O. and Garratt, R. (2006). Protein Structure, 
Modelling and Applications. In Bioinformatics in Tropical Disease Research: A Practical and 
Case-Study Approach (eds. Gruber, A., Durham, A., Huynh, C., and al., e.), National Centre 
for Biotechnology Information, Bethesda. 
Brenndörfer, M. and Boshart, M. (2010). Selection of reference genes for mRNA quantification in 
Trypanosoma brucei. Mol Biochem Parasitol, 172, 52-55. doi: 
10.1016/j.molbiopara.2010.03.007. 
Bridges, D. J., Gould, M. K., Nerima, B., Mäser, P., Burchmore, R. J. and de Koning, H. P. (2007). 
Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-
resistance between arsenical and diamidine drugs in African trypanosomes. Mol Pharmacol, 
71, 1098-1108. doi: 10.1124/mol.106.031351. 
Brosh, R. M., Jr., Driscoll, H. C., Dianov, G. L. and Sommers, J. A. (2002). Biochemical 
characterization of the WRN-FEN-1 functional interaction. Biochemistry, 41, 12204-12216. 
Brosh, R. M., Jr., von Kobbe, C., Sommers, J. A., Karmakar, P., Opresko, P. L., Piotrowski, J., 
Dianova, I., Dianov, G. L. and Bohr, V. A. (2001). Werner syndrome protein interacts with 
human flap endonuclease 1 and stimulates its cleavage activity. EMBO J, 20, 5791-5801. 
doi: 10.1093/emboj/20.20.5791. 
Bruce, D. (1895). Preliminary report on the tsetse fly disease or nagana in Zululand, Bennett and 
Davis, Durban. 
Brun, R., Blum, J., Chappuis, F. and Burri, C. (2010). Human African trypanosomiasis. Lancet, 375, 
148-159. doi: 10.1016/S0140-6736(09)60829-1. 
 142 
Bullock, W., Fernandex, J. and Short, J. (1987). XL1-Blue: a high efficiency 
plasmid transforming recA Escherichia coli strain with β-galactosidase selection. Biotechniques, 5, 
376-378. 
Bustos, P. L., Perrone, A. E., Milduberger, N., Postan, M. and Bua, J. (2015). Oxidative stress 
damage in the protozoan parasite Trypanosoma cruzi is inhibited by Cyclosporin A. 
Parasitology, 142, 1024-1032. doi: 10.1017/S0031182015000232. 
Campillo, N. and Carrington, M. (2003). The origin of the serum resistance associated (SRA) gene 
and a model of the structure of the SRA polypeptide from Trypanosoma brucei 
rhodesiense. Mol Biochem Parasitol, 127, 79-84. 
Cao, W. and Barany, F. (1998). Identification of TaqI endonuclease active site residues by Fe2+-
mediated oxidative cleavage. J Biol Chem, 273, 33002-33010. 
Carter, N. S., Berger, B. J. and Fairlamb, A. H. (1995). Uptake of diamidine drugs by the P2 
nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J 
Biol Chem, 270, 28153-28157. 
Carter, N. S. and Fairlamb, A. H. (1993). Arsenical-resistant trypanosomes lack an unusual 
adenosine transporter. Nature, 361, 173-176. doi: 10.1038/361173a0. 
CDC (2015). Parasites - African Trypanosomiasis (also known as Sleeping Sickness). 
Chatr-Aryamontri, A., Breitkreutz, B. J., Oughtred, R., Boucher, L., Heinicke, S., Chen, D., Stark, C., 
Breitkreutz, A., Kolas, N., O'Donnell, L., Reguly, T., Nixon, J., Ramage, L., Winter, A., Sellam, 
A., Chang, C., Hirschman, J., Theesfeld, C., Rust, J., Livstone, M. S., Dolinski, K. and Tyers, M. 
(2015). The BioGRID interaction database: 2015 update. Nucleic Acids Res, 43, D470-478. 
doi: 10.1093/nar/gku1204. 
Chen, H., Zhou, X., Wang, A., Zheng, Y., Gao, Y. and Zhou, J. (2015). Evolutions in fragment-based 
drug design: the deconstruction-reconstruction approach. Drug Discov Today, 20, 105-113. 
doi: 10.1016/j.drudis.2014.09.015. 
Chen, U., Chen, S., Saha, P. and Dutta, A. (1996). p21Cip1/Waf1 disrupts the recruitment of 
human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex. Proc 
Natl Acad Sci U S A, 93, 11597-11602. 
Collins, A. R. (2004). The comet assay for DNA damage and repair: principles, applications, and 
limitations. Mol Biotechnol, 26, 249-261. doi: 10.1385/MB:26:3:249. 
Coma, I., Clark, L., Diez, E., Harper, G., Herranz, J., Hofmann, G., Lennon, M., Richmond, N., 
Valmaseda, M. and Macarron, R. (2009). Process validation and screen reproducibility in 
high-throughput screening. J Biomol Screen, 14, 66-76. doi: 10.1177/1087057108326664. 
Cong, Y. S., Wright, W. E. and Shay, J. W. (2002). Human telomerase and its regulation. Microbiol 
Mol Biol Rev, 66, 407-425, table of contents. 
Connor, R. (1992). The Diagnosis, Treatment and Prevention of Animal Trypanosomiasis Under 
Field Conditions. In Programme for the control of African animal trypanosomiasis and 
related development: Ecological and technical aspects Food and Agriculture Organisation of 
the United Nations. 
Corpet, F. (1988). Multiple sequence alignment with hierarchical clustering. Nucl. Acids Res., 16. 
Costa, R. M., Chiganças, V., Galhardo, R. a. S., Carvalho, H. and Menck, C. F. (2003). The eukaryotic 
nucleotide excision repair pathway. Biochimie, 85, 1083-1099. 
Cowan, J. A. (1998). Metal Activation of Enzymes in Nucleic Acid Biochemistry. Chem Rev, 98, 
1067-1088. 
 143 
Cowan, R. and Whittaker, R. G. (1990). Hydrophobicity indices for amino acid residues as 
determined by high-performance liquid chromatography. Pept Res, 3, 75-80. 
Cushnie, T. P. and Lamb, A. J. (2005). Antimicrobial activity of flavonoids. Int J Antimicrob Agents, 
26, 343-356. 
Dalvit, C. (2009). NMR methods in fragment screening: theory and a comparison with other 
biophysical techniques. Drug Discov Today, 14, 1051-1057. doi: 
10.1016/j.drudis.2009.07.013. 
Damper, D. and Patton, C. L. (1976). Pentamidine transport and sensitivity in brucei-group 
trypanosomes. J Protozool, 23, 349-356. 
Dao-pin, S., Söderlind, E., Baase, W. A., Wozniak, J. A., Sauer, U. and Matthews, B. W. (1991). 
Cumulative site-directed charge-change replacements in bacteriophage T4 lysozyme 
suggest that long-range electrostatic interactions contribute little to protein stability. J Mol 
Biol, 221, 873-887. 
de Boer, J. and Hoeijmakers, J. H. (2000). Nucleotide excision repair and human syndromes. 
Carcinogenesis, 21, 453-460. 
de Koning, H. P. (2008). Ever-increasing complexities of diamidine and arsenical crossresistance in 
African trypanosomes. Trends Parasitol, 24, 345-349. doi: 10.1016/j.pt.2008.04.006. 
de Raadt, P. (2005). The history of sleeping sickness. 
Delespaux, V., Geysen, D., Van den Bossche, P. and Geerts, S. (2008). Molecular tools for the rapid 
detection of drug resistance in animal trypanosomes. Trends Parasitol, 24, 236-242. doi: 
10.1016/j.pt.2008.02.006. 
Desquesnes, M. and Gardiner, P. R. (1993). [Epidemiology of bovine trypanosomiasis 
(Trypanosoma vivax) in French Guiana]. Rev Elev Med Vet Pays Trop, 46, 463-470. 
Devi, K. P., Rajavel, T., Habtemariam, S., Nabavi, S. F. and Nabavi, S. M. (2015). Molecular 
mechanisms underlying anticancer effects of myricetin. Life Sci, 142, 19-25. doi: 
10.1016/j.lfs.2015.10.004. 
Devos, J. M., Tomanicek, S. J., Jones, C. E., Nossal, N. G. and Mueser, T. C. (2007). Crystal structure 
of bacteriophage T4 5' nuclease in complex with a branched DNA reveals how flap 
endonuclease-1 family nucleases bind their substrates. J Biol Chem, 282, 31713-31724. doi: 
10.1074/jbc.M703209200. 
Dianova, I., Bohr, V. A. and Dianov, G. L. (2001). Interaction of human AP endonuclease 1 with flap 
endonuclease 1 and proliferating cell nuclear antigen involved in long-patch base excision 
repair. Biochemistry, 40, 12639-12644. 
DNDi (2015). Oxaborole SCYX-7158 (HAT). In Human African Trypanosomiasis: Translation, Vol. 
2016. 
DNDi (2016). DNDi Strategy. 
Dodson, H. C., Lyda, T. A., Chambers, J. W., Morris, M. T., Christensen, K. A. and Morris, J. C. 
(2011). Quercetin, a fluorescent bioflavanoid, inhibits Trypanosoma brucei hexokinase 1. 
Exp Parasitol, 127, 423-428. doi: 10.1016/j.exppara.2010.10.011. 
Dorjsuren, D., Kim, D., Maloney, D. J., Wilson, D. M. and Simeonov, A. (2011). Complementary 
non-radioactive assays for investigation of human flap endonuclease 1 activity. Nucleic 
Acids Res, 39, e11. doi: gkq1082 [pii] 
10.1093/nar/gkq1082. 
 144 
Dreesen, O., Li, B. and Cross, G. A. (2007). Telomere structure and function in trypanosomes: a 
proposal. Nat Rev Microbiol, 5, 70-75. doi: 10.1038/nrmicro1577. 
Duxin, J. P., Dao, B., Martinsson, P., Rajala, N., Guittat, L., Campbell, J. L., Spelbrink, J. N. and 
Stewart, S. A. (2009). Human Dna2 is a nuclear and mitochondrial DNA maintenance 
protein. Mol Cell Biol, 29, 4274-4282. doi: MCB.01834-08 [pii] 
10.1128/MCB.01834-08. 
FAO (2015). The Disease. In Programme Against African Trypanosomiasis (PAAT). 
Federhen, S. (2012). The NCBI Taxonomy database. Nucleic Acids Res, 40, D136-143. doi: 
10.1093/nar/gkr1178. 
Feng, M., Patel, D., Dervan, J. J., Ceska, T., Suck, D., Haq, I. and Sayers, J. R. (2004). Roles of 
divalent metal ions in flap endonuclease-substrate interactions. Nat Struct Mol Biol, 11, 
450-456. doi: 10.1038/nsmb754. 
Fernandez, M. T., Mira, M. L., Florêncio, M. H. and Jennings, K. R. (2002). Iron and copper 
chelation by flavonoids: an electrospray mass spectrometry study. J Inorg Biochem, 92, 105-
111. 
Finger, L. D., Atack, J. M., Tsutakawa, S., Classen, S., Tainer, J., Grasby, J. and Shen, B. (2012). The 
wonders of flap endonucleases: structure, function, mechanism and regulation. Subcell 
Biochem, 62, 301-326. doi: 10.1007/978-94-007-4572-8_16. 
Finger, L. D., Blanchard, M. S., Theimer, C. A., Sengerova, B., Singh, P., Chavez, V., Liu, F., Grasby, J. 
A. and Shen, B. (2009). The 3'-flap pocket of human flap endonuclease 1 is critical for 
substrate binding and catalysis. J Biol Chem, 284, 22184-22194. doi: 
10.1074/jbc.M109.015065. 
Fox, K. R., Sansom, C. E. and Stevens, M. F. (1990). Footprinting studies on the sequence-selective 
binding of pentamidine to DNA. FEBS Lett, 266, 150-154. 
Frearson, J. A., Brand, S., McElroy, S. P., Cleghorn, L. A., Smid, O., Stojanovski, L., Price, H. P., 
Guther, M. L., Torrie, L. S., Robinson, D. A., Hallyburton, I., Mpamhanga, C. P., Brannigan, J. 
A., Wilkinson, A. J., Hodgkinson, M., Hui, R., Qiu, W., Raimi, O. G., van Aalten, D. M., Brenk, 
R., Gilbert, I. H., Read, K. D., Fairlamb, A. H., Ferguson, M. A., Smith, D. F. and Wyatt, P. G. 
(2010). N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 
464, 728-732. doi: 10.1038/nature08893. 
Friedrich-Heineken, E., Henneke, G., Ferrari, E. and Hubscher, U. (2003). The acetylatable lysines 
of human Fen1 are important for endo- and exonuclease activities. J Mol Biol, 328, 73-84. 
Friedrich-Heineken, E. and Hubscher, U. (2004). The Fen1 extrahelical 3'-flap pocket is conserved 
from archaea to human and regulates DNA substrate specificity. Nucleic Acids Res, 32, 
2520-2528. doi: 10.1093/nar/gkh576. 
Friedrich-Heineken, E. and Hübscher, U. (2004). The Fen1 extrahelical 3'-flap pocket is conserved 
from archaea to human and regulates DNA substrate specificity. Nucleic Acids Res, 32, 
2520-2528. doi: 10.1093/nar/gkh576. 
Frosina, G., Fortini, P., Rossi, O., Carrozzino, F., Raspaglio, G., Cox, L. S., Lane, D. P., Abbondandolo, 
A. and Dogliotti, E. (1996). Two pathways for base excision repair in mammalian cells. J Biol 
Chem, 271, 9573-9578. 
Fukushima, S., Itaya, M., Kato, H., Ogasawara, N. and Yoshikawa, H. (2007). Reassessment of the 
in vivo functions of DNA polymerase I and RNase H in bacterial cell growth. J Bacteriol, 189, 
8575-8583. doi: JB.00653-07 [pii] 10.1128/JB.00653-07. 
 145 
Garforth, S. J., Patel, D., Feng, M. and Sayers, J. R. (2001). Unusually wide co-factor tolerance in a 
metalloenzyme; divalent metal ions modulate endo-exonuclease activity in T5 exonuclease. 
Nucleic Acids Res, 29, 2772-2779. 
Garg, P., Stith, C. M., Sabouri, N., Johansson, E. and Burgers, P. M. (2004). Idling by DNA 
polymerase delta maintains a ligatable nick during lagging-strand DNA replication. Genes 
Dev, 18, 2764-2773. doi: 10.1101/gad.1252304. 
Gary, R., Ludwig, D. L., Cornelius, H. L., MacInnes, M. A. and Park, M. S. (1997). The DNA repair 
endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence 
elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor 
p21. J Biol Chem, 272, 24522-24529. 
Gasteiger E., H. C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A (2005). Protein 
Identification and Analysis Tools on the ExPASy Server. In The Proteomics Protocols 
Handbook (ed. Walker, J.), pp. 571-607. Humana Press. 
Gibson, W. C. (2005). The SRA gene: the key to understanding the nature of Trypanosoma brucei 
rhodesiense. Parasitology, 131, 143-150. 
Gilson, E. and Géli, V. (2007). How telomeres are replicated. Nat Rev Mol Cell Biol, 8, 825-838. doi: 
10.1038/nrm2259. 
Giugliarelli, A., Paolantoni, M., Morresi, A. and Sassi, P. (2012). Denaturation and preservation of 
globular proteins: the role of DMSO. J Phys Chem B, 116, 13361-13367. doi: 
10.1021/jp308655p. 
González, V. M., Pérez, J. M. and Alonso, C. (1997). The berenil ligand directs the DNA binding of 
the cytotoxic drug Pt-berenil. J Inorg Biochem, 68, 283-287. 
Good, N. E., Winget, G. D., Winter, W., Connolly, T. N., Izawa, S. and Singh, R. M. (1966). Hydrogen 
ion buffers for biological research. Biochemistry, 5, 467-477. 
Goulian, M., Richards, S. H., Heard, C. J. and Bigsby, B. M. (1990). Discontinuous DNA synthesis by 
purified mammalian proteins. J Biol Chem, 265, 18461-18471. 
Grant, S. G., Jessee, J., Bloom, F. R. and Hanahan, D. (1990). Differential plasmid rescue from 
transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. Proc Natl 
Acad Sci U S A, 87, 4645-4649. 
Grazú, V., Silber, A. M., Moros, M., Asín, L., Torres, T. E., Marquina, C., Ibarra, M. R. and Goya, G. 
F. (2012). Application of magnetically induced hyperthermia in the model protozoan 
Crithidia fasciculata as a potential therapy against parasitic infections. Int J Nanomedicine, 
7, 5351-5360. doi: 10.2147/IJN.S35510. 
Grecco, S. o. S., Reimão, J. Q., Tempone, A. G., Sartorelli, P., Cunha, R. L., Romoff, P., Ferreira, M. 
J., Fávero, O. A. and Lago, J. H. (2012). In vitro antileishmanial and antitrypanosomal 
activities of flavanones from Baccharis retusa DC. (Asteraceae). Exp Parasitol, 130, 141-145. 
doi: 10.1016/j.exppara.2011.11.002. 
Greenfield, N. J. (2006a). Using circular dichroism collected as a function of temperature to 
determine the thermodynamics of protein unfolding and binding interactions. Nat Protoc, 
1, 2527-2535. doi: 10.1038/nprot.2006.204. 
Greenfield, N. J. (2006b). Using circular dichroism spectra to estimate protein secondary 
structure. Nat Protoc, 1, 2876-2890. doi: 10.1038/nprot.2006.202. 
Greenwood, D., Finch, R., Davey, P. and Wilcox, M. (2007). Historical Introduction. In 
Antimicrobial Chemotherapy pp. 1-10. Oxford University Press, New York. 
 146 
Grimsley, G. R., Shaw, K. L., Fee, L. R., Alston, R. W., Huyghues-Despointes, B. M., Thurlkill, R. L., 
Scholtz, J. M. and Pace, C. N. (1999). Increasing protein stability by altering long-range 
coulombic interactions. Protein Sci, 8, 1843-1849. doi: 10.1110/ps.8.9.1843. 
Grosdidier, A., Zoete, V. and Michielin, O. (2007). EADock: docking of small molecules into protein 
active sites with a multiobjective evolutionary optimization. Proteins, 67, 1010-1025. doi: 
10.1002/prot.21367. 
Grosdidier, A., Zoete, V. and Michielin, O. (2011a). Fast docking using the CHARMM force field 
with EADock DSS. J Comput Chem. doi: 10.1002/jcc.21797. 
Grosdidier, A., Zoete, V. and Michielin, O. (2011b). SwissDock, a protein-small molecule docking 
web service based on EADock DSS. Nucleic Acids Res, 39, W270-277. doi: 
10.1093/nar/gkr366. 
Hall, B. S., Bot, C. and Wilkinson, S. R. (2011). Nifurtimox activation by trypanosomal type I 
nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem, 286, 13088-13095. doi: 
10.1074/jbc.M111.230847. 
Harner, M. J., Frank, A. O. and Fesik, S. W. (2013). Fragment-based drug discovery using NMR 
spectroscopy. J Biomol NMR, 56, 65-75. doi: 10.1007/s10858-013-9740-z. 
Harrigan, J. A., Opresko, P. L., von Kobbe, C., Kedar, P. S., Prasad, R., Wilson, S. H. and Bohr, V. A. 
(2003). The Werner syndrome protein stimulates DNA polymerase beta strand 
displacement synthesis via its helicase activity. J Biol Chem, 278, 22686-22695. doi: 
10.1074/jbc.M213103200. 
Harrington, J. J. and Lieber, M. R. (1994a). Functional domains within FEN-1 and RAD2 define a 
family of structure-specific endonucleases: implications for nucleotide excision repair. 
Genes Dev, 8, 1344-1355. 
Harrington, J. J. and Lieber, M. R. (1994b). The characterization of a mammalian DNA structure-
specific endonuclease. EMBO J, 13, 1235-1246. 
Hartenstine, M. J., Goodman, M. F. and Petruska, J. (2002). Weak strand displacement activity 
enables human DNA polymerase beta to expand CAG/CTG triplet repeats at strand breaks. J 
Biol Chem, 277, 41379-41389. doi: 10.1074/jbc.M207013200. 
Hasan, S., Stucki, M., Hassa, P. O., Imhof, R., Gehrig, P., Hunziker, P., Hubscher, U. and Hottiger, M. 
O. (2001). Regulation of human flap endonuclease-1 activity by acetylation through the 
transcriptional coactivator p300. Mol Cell, 7, 1221-1231. 
Henneke, G., Koundrioukoff, S. and Hübscher, U. (2003). Multiple roles for kinases in DNA 
replication. EMBO Rep, 4, 252-256. doi: 10.1038/sj.embor.embor774. 
Henry, C. M., Hollville, E. and Martin, S. J. (2013). Measuring apoptosis by microscopy and flow 
cytometry. Methods, 61, 90-97. doi: 10.1016/j.ymeth.2013.01.008. 
Hodgson, B., Calzada, A. and Labib, K. (2007). Mrc1 and Tof1 regulate DNA replication forks in 
different ways during normal S phase. Mol Biol Cell, 18, 3894-3902. doi: 10.1091/mbc.E07-
05-0500. 
Hodskinson, M. R., Allen, L. M., Thomson, D. P. and Sayers, J. R. (2007). Molecular interactions of 
Escherichia coli ExoIX and identification of its associated 3'-5' exonuclease activity. Nucleic 
Acids Res, 35, 4094-4102. doi: 10.1093/nar/gkm396. 
Holdgate, G. A. and Ward, W. H. (2005). Measurements of binding thermodynamics in drug 
discovery. Drug Discov Today, 10, 1543-1550. doi: 10.1016/S1359-6446(05)03610-X. 
 147 
Horn, D. (2014). Antigenic variation in African trypanosomes. Mol Biochem Parasitol, 195, 123-
129. doi: 10.1016/j.molbiopara.2014.05.001. 
Horton, H., Moran, L., Scrimgeor, K., Perry, M. and Rawn, J. (2006). Chemical Modes of Enzymatic 
Catalysis. In Principles of Biochemistry (ed. Carlson, G.), pp. 162-167. Pearson Education Ltd, 
London. 
Hossain, M. and Suresh Kumar, G. (2009). DNA intercalation of methylene blue and quinacrine: 
new insights into base and sequence specificity from structural and thermodynamic studies 
with polynucleotides. Mol Biosyst, 5, 1311-1322. doi: 10.1039/b909563b. 
Imboden, M. A., Laird, P. W., Affolter, M. and Seebeck, T. (1987). Transcription of the intergenic 
regions of the tubulin gene cluster of Trypanosoma brucei: evidence for a polycistronic 
transcription unit in a eukaryote. Nucleic Acids Res, 15, 7357-7368. 
Iten, M., Mett, H., Evans, A., Enyaru, J. C., Brun, R. and Kaminsky, R. (1997). Alterations in 
ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei 
rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chemother, 41, 1922-
1925. 
Jackson, M. and Mantsch, H. H. (1991). Beware of proteins in DMSO. Biochim Biophys Acta, 1078, 
231-235. 
Jackson, S. P. and Bartek, J. (2009). The DNA-damage response in human biology and disease. 
Nature, 461, 1071-1078. doi: 10.1038/nature08467. 
Jacobs, R. T., Nare, B., Wring, S. A., Orr, M. D., Chen, D., Sligar, J. M., Jenks, M. X., Noe, R. A., 
Bowling, T. S., Mercer, L. T., Rewerts, C., Gaukel, E., Owens, J., Parham, R., Randolph, R., 
Beaudet, B., Bacchi, C. J., Yarlett, N., Plattner, J. J., Freund, Y., Ding, C., Akama, T., Zhang, Y. 
K., Brun, R., Kaiser, M., Scandale, I. and Don, R. (2011). SCYX-7158, an orally-active 
benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop 
Dis, 5, e1151. doi: 10.1371/journal.pntd.0001151. 
Jadhav, A., Ferreira, R. S., Klumpp, C., Mott, B. T., Austin, C. P., Inglese, J., Thomas, C. J., Maloney, 
D. J., Shoichet, B. K. and Simeonov, A. (2010). Quantitative analyses of aggregation, 
autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med 
Chem, 53, 37-51. doi: 10.1021/jm901070c. 
Jennings, F. W. and Urquhart, G. M. (1983). The use of the 2 substituted 5-nitroimidazole, 
Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z 
Parasitenkd, 69, 577-581. 
Jiricny, J. (2006). The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol, 7, 335-346. doi: 
10.1038/nrm1907. 
Johnson, C. M. (2013). Differential scanning calorimetry as a tool for protein folding and stability. 
Arch Biochem Biophys, 531, 100-109. doi: 10.1016/j.abb.2012.09.008. 
Jones, T. W. and Dávila, A. M. (2001). Trypanosoma vivax--out of Africa. Trends Parasitol, 17, 99-
101. 
Joyce, C. M. and Grindley, N. D. (1984). Method for determining whether a gene of Escherichia 
coli is essential: application to the polA gene. J Bacteriol, 158, 636-643. 
Kabani, S., Fenn, K., Ross, A., Ivens, A., Smith, T. K., Ghazal, P. and Matthews, K. (2009). Genome-
wide expression profiling of in vivo-derived bloodstream parasite stages and dynamic 
analysis of mRNA alterations during synchronous differentiation in Trypanosoma brucei. 
BMC Genomics, 10, 427. doi: 10.1186/1471-2164-10-427. 
 148 
Kazak, L., Reyes, A., He, J., Wood, S. R., Brea-Calvo, G., Holen, T. T. and Holt, I. J. (2013). A cryptic 
targeting signal creates a mitochondrial FEN1 isoform with tailed R-Loop binding properties. 
PLoS One, 8, e62340. doi: 10.1371/journal.pone.0062340. 
Keating, J., Yukich, J. O., Sutherland, C. S., Woods, G. and Tediosi, F. (2015). Human African 
trypanosomiasis prevention, treatment and control costs: a systematic review. Acta Trop, 
150, 4-13. doi: 10.1016/j.actatropica.2015.06.003. 
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. and Sternberg, M. J. (2015). The Phyre2 web 
portal for protein modeling, prediction and analysis. Nat Protoc, 10, 845-858. doi: 
10.1038/nprot.2015.053. 
Kelly, S. M., Jess, T. J. and Price, N. C. (2005). How to study proteins by circular dichroism. Biochim 
Biophys Acta, 1751, 119-139. doi: 10.1016/j.bbapap.2005.06.005. 
Kennedy, P. G. (2013). Clinical features, diagnosis, and treatment of human African 
trypanosomiasis (sleeping sickness). Lancet Neurol, 12, 186-194. doi: 10.1016/S1474-
4422(12)70296-X. 
Kieft, R., Capewell, P., Turner, C. M., Veitch, N. J., MacLeod, A. and Hajduk, S. (2010). Mechanism 
of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome lytic factor. 
Proc Natl Acad Sci U S A, 107, 16137-16141. doi: 10.1073/pnas.1007074107. 
Kinabo, L. D. (1993). Pharmacology of existing drugs for animal trypanosomiasis. Acta Trop, 54, 
169-183. 
Klett, R. P., Cerami, A. and Reich, E. (1968). Exonuclease VI, a new nuclease activity associated 
with E. coli DNA polymerase. Proc Natl Acad Sci U S A, 60, 943-950. 
Klug, D. M., Gelb, M. H. and Pollastri, M. P. (2016). Repurposing strategies for tropical disease 
drug discovery. Bioorg Med Chem Lett. doi: 10.1016/j.bmcl.2016.03.103. 
Kucherlapati, M., Yang, K., Kuraguchi, M., Zhao, J., Lia, M., Heyer, J., Kane, M. F., Fan, K., Russell, 
R., Brown, A. M., Kneitz, B., Edelmann, W., Kolodner, R. D., Lipkin, M. and Kucherlapati, R. 
(2002). Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression. 
Proc Natl Acad Sci U S A, 99, 9924-9929. doi: 152321699 [pii] 10.1073/pnas.152321699. 
Kumar, S. and Subramanian, S. (2002). Mutation rates in mammalian genomes. Proc Natl Acad Sci 
U S A, 99, 803-808. doi: 10.1073/pnas.022629899. 
Kuzoe, F. A. (1993). Current situation of African trypanosomiasis. Acta Trop, 54, 153-162. 
Kyte, J. and Doolittle, R. F. (1982). A simple method for displaying the hydropathic character of a 
protein. J Mol Biol, 157, 105-132. 
Labib, K. and Hodgson, B. (2007). Replication fork barriers: pausing for a break or stalling for time? 
EMBO Rep, 8, 346-353. doi: 10.1038/sj.embor.7400940. 
LaCount, D. J., Bruse, S., Hill, K. L. and Donelson, J. E. (2000). Double-stranded RNA interference in 
Trypanosoma brucei using head-to-head promoters. Mol Biochem Parasitol, 111, 67-76. 
Lakowicz, J. R. (2006). Principles of fluorescence spectroscopy, Third edn. Springer Science and 
Business Media, LLC. 
Langousis, G. and Hill, K. L. (2014). Motility and more: the flagellum of Trypanosoma brucei. Nat 
Rev Microbiol, 12, 505-518. doi: 10.1038/nrmicro3274. 
Lanteri, C. A., Stewart, M. L., Brock, J. M., Alibu, V. P., Meshnick, S. R., Tidwell, R. R. and Barrett, 
M. P. (2006). Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and 
resistance. Mol Pharmacol, 70, 1585-1592. doi: 10.1124/mol.106.024653. 
 149 
Lavinder, J. J., Hari, S. B., Sullivan, B. J. and Magliery, T. J. (2009). High-throughput thermal 
scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am 
Chem Soc, 131, 3794-3795. doi: 10.1021/ja8049063. 
Le Gall, T., Romero, P. R., Cortese, M. S., Uversky, V. N. and Dunker, A. K. (2007). Intrinsic disorder 
in the Protein Data Bank. J Biomol Struct Dyn, 24, 325-342. doi: 
10.1080/07391102.2007.10507123. 
Leach, T. M. and Roberts, C. J. (1981). Present status of chemotherapy and chemoprophylaxis of 
animal trypanosomiasis in the Eastern hemisphere. Pharmacol Ther, 13, 91-147. 
Lee, K. H., Kim, D. W., Bae, S. H., Kim, J. A., Ryu, G. H., Kwon, Y. N., Kim, K. A., Koo, H. S. and Seo, Y. 
S. (2000). The endonuclease activity of the yeast Dna2 enzyme is essential in vivo. Nucleic 
Acids Res, 28, 2873-2881. 
Lee, O. H., Kim, H., He, Q., Baek, H. J., Yang, D., Chen, L. Y., Liang, J., Chae, H. K., Safari, A., Liu, D. 
and Songyang, Z. (2011). Genome-wide YFP fluorescence complementation screen 
identifies new regulators for telomere signaling in human cells. Mol Cell Proteomics, 10, 
M110 001628. doi: 10.1074/mcp.M110.001628. 
Li, X., Li, J., Harrington, J., Lieber, M. R. and Burgers, P. M. (1995). Lagging strand DNA synthesis at 
the eukaryotic replication fork involves binding and stimulation of FEN-1 by proliferating 
cell nuclear antigen. J Biol Chem, 270, 22109-22112. 
Lieber, M. R. (1997). The FEN-1 family of structure-specific nucleases in eukaryotic DNA 
replication, recombination and repair. Bioessays, 19, 233-240. doi: 
10.1002/bies.950190309. 
Liu, Y., Kao, H. I. and Bambara, R. A. (2004). Flap endonuclease 1: a central component of DNA 
metabolism. Annu Rev Biochem, 73, 589-615. doi: 
10.1146/annurev.biochem.73.012803.092453. 
Lo, M. C., Aulabaugh, A., Jin, G., Cowling, R., Bard, J., Malamas, M. and Ellestad, G. (2004). 
Evaluation of fluorescence-based thermal shift assays for hit identification in drug 
discovery. Anal Biochem, 332, 153-159. doi: 10.1016/j.ab.2004.04.031. 
Lodish, H., Berk, A., Matsudaira, P., Kaiser, C. A., Krieger, M., Scott, M. P., Zipursky, S. L. and 
Darnell, J. (2004). Molecular Cell Biology.  pp. 131-137. W.H. Freeman and Company. 
Lopes, M., Cotta-Ramusino, C., Pellicioli, A., Liberi, G., Plevani, P., Muzi-Falconi, M., Newlon, C. S. 
and Foiani, M. (2001). The DNA replication checkpoint response stabilizes stalled replication 
forks. Nature, 412, 557-561. doi: 10.1038/35087613. 
Louis-Jeune, C., Andrade-Navarro, M. A. and Perez-Iratxeta, C. (2012). Prediction of protein 
secondary structure from circular dichroism using theoretically derived spectra. Proteins, 
80, 374-381. doi: 10.1002/prot.23188. 
Lüscher, A., Nerima, B. and Mäser, P. (2006). Combined contribution of TbAT1 and TbMRPA to 
drug resistance in Trypanosoma brucei. Mol Biochem Parasitol, 150, 364-366. doi: 
10.1016/j.molbiopara.2006.07.010. 
Ma, Z., Wang, G., Cui, L. and Wang, Q. (2015). Myricetin Attenuates Depressant-Like Behavior in 
Mice Subjected to Repeated Restraint Stress. Int J Mol Sci, 16, 28377-28385. doi: 
10.3390/ijms161226102. 
Ma, Z. G., Wang, J., Jiang, H., Liu, T. W. and Xie, J. X. (2007). Myricetin reduces 6-
hydroxydopamine-induced dopamine neuron degeneration in rats. Neuroreport, 18, 1181-
1185. doi: 10.1097/WNR.0b013e32821c51fe. 
 150 
Mamani-Matsuda, M., Rambert, J., Malvy, D., Lejoly-Boisseau, H., Daulouède, S., Thiolat, D., 
Coves, S., Courtois, P., Vincendeau, P. and Mossalayi, M. D. (2004). Quercetin induces 
apoptosis of Trypanosoma brucei gambiense and decreases the proinflammatory response 
of human macrophages. Antimicrob Agents Chemother, 48, 924-929. 
Marques, C. A., Tiengwe, C., Lemgruber, L., Damasceno, J. D., Scott, A., Paape, D., Marcello, L. and 
McCulloch, R. (2016). Diverged composition and regulation of the Trypanosoma brucei 
origin recognition complex that mediates DNA replication initiation. Nucleic Acids Res. doi: 
10.1093/nar/gkw147. 
Mashalidis, E. H., Śledź, P., Lang, S. and Abell, C. (2013). A three-stage biophysical screening 
cascade for fragment-based drug discovery. Nat Protoc, 8, 2309-2324. doi: 
10.1038/nprot.2013.130. 
Matovu, E., Stewart, M. L., Geiser, F., Brun, R., Mäser, P., Wallace, L. J., Burchmore, R. J., Enyaru, J. 
C., Barrett, M. P., Kaminsky, R., Seebeck, T. and de Koning, H. P. (2003). Mechanisms of 
arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell, 2, 
1003-1008. 
Matsuzaki, Y., Adachi, N. and Koyama, H. (2002). Vertebrate cells lacking FEN-1 endonuclease are 
viable but hypersensitive to methylating agents and H2O2. Nucleic Acids Res, 30, 3273-
3277. 
McManus, K. J., Barrett, I. J., Nouhi, Y. and Hieter, P. (2009). Specific synthetic lethal killing of 
RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci U S A, 
106, 3276-3281. doi: 10.1073/pnas.0813414106. 
McWhirter, C., Tonge, M., Plant, H., Hardern, I., Nissink, W. and Durant, S. T. (2013). Development 
of a high-throughput fluorescence polarization DNA cleavage assay for the identification of 
FEN1 inhibitors. J Biomol Screen, 18, 567-575. doi: 10.1177/1087057113476551. 
Melaku, A. and Birasa, B. (2013). Drugs and Drug Resistance in African Animal Trypanosomosis: A 
Review. In European Journal of Applied Sciences, Vol. 5 pp. 84-91. 
Meyskens, F. L. and Gerner, E. W. (1999). Development of difluoromethylornithine (DFMO) as a 
chemoprevention agent. Clin Cancer Res, 5, 945-951. 
Mirkin, E. V. and Mirkin, S. M. (2007). Replication fork stalling at natural impediments. Microbiol 
Mol Biol Rev, 71, 13-35. doi: 10.1128/MMBR.00030-06. 
Moritoh, S., Miki, D., Akiyama, M., Kawahara, M., Izawa, T., Maki, H. and Shimamoto, K. (2005). 
RNAi-mediated silencing of OsGEN-L (OsGEN-like), a new member of the RAD2/XPG 
nuclease family, causes male sterility by defect of microspore development in rice. Plant 
Cell Physiol, 46, 699-715. doi: 10.1093/pcp/pci090. 
Motyka, S. A. and Englund, P. T. (2004). RNA interference for analysis of gene function in 
trypanosomatids. Curr Opin Microbiol, 7, 362-368. doi: 10.1016/j.mib.2004.06.004. 
Murante, R. S., Huang, L., Turchi, J. J. and Bambara, R. A. (1994). The calf 5'- to 3'-exonuclease is 
also an endonuclease with both activities dependent on primers annealed upstream of the 
point of cleavage. J Biol Chem, 269, 1191-1196. 
Murante, R. S., Rust, L. and Bambara, R. A. (1995). Calf 5' to 3' exo/endonuclease must slide from 
a 5' end of the substrate to perform structure-specific cleavage. J Biol Chem, 270, 30377-
30383. 
NC3Rs (2016). Decision tree: How much blood does a mouse have? In Blood Sampling: Mouse. 
NCI (2015). Cancer Terms. In NCI Dictionary. 
 151 
Negritto, M. C., Qiu, J., Ratay, D. O., Shen, B. and Bailis, A. M. (2001). Novel function of Rad27 
(FEN-1) in restricting short-sequence recombination. Mol Cell Biol, 21, 2349-2358. doi: 
10.1128/MCB.21.7.2349-2358.2001. 
Niesen, F. H., Berglund, H. and Vedadi, M. (2007). The use of differential scanning fluorimetry to 
detect ligand interactions that promote protein stability. Nat Protoc, 2, 2212-2221. doi: 
10.1038/nprot.2007.321. 
Oli, M. W., Cotlin, L. F., Shiflett, A. M. and Hajduk, S. L. (2006). Serum resistance-associated 
protein blocks lysosomal targeting of trypanosome lytic factor in Trypanosoma brucei. 
Eukaryot Cell, 5, 132-139. doi: 10.1128/EC.5.1.132-139.2006. 
Ono, K. and Nakane, H. (1990). Mechanisms of inhibition of various cellular DNA and RNA 
polymerases by several flavonoids. J Biochem, 108, 609-613. 
Oredsson, S., Anehus, S. and Heby, O. (1980). Inhibition of cell proliferation by DL-alpha-
difluoromethylornithine, a catalytic irreversible inhibitor of ornithine decarboxylase. Acta 
Chem Scand B, 34, 457-458. 
Osório, A. L., Madruga, C. R., Desquesnes, M., Soares, C. O., Ribeiro, L. R. and Costa, S. C. (2008). 
Trypanosoma (Duttonella) vivax: its biology, epidemiology, pathogenesis, and introduction 
in the New World--a review. Mem Inst Oswaldo Cruz, 103, 1-13. 
Otte, M. J., Abuabara, J. Y. and Wells, E. A. (1994). Trypanosoma vivax in Colombia: epidemiology 
and production losses. Trop Anim Health Prod, 26, 146-156. 
Pace, C. N., Alston, R. W. and Shaw, K. L. (2000). Charge-charge interactions influence the 
denatured state ensemble and contribute to protein stability. Protein Sci, 9, 1395-1398. doi: 
10.1110/ps.9.7.1395. 
Paine, M. F., Wang, M. Z., Generaux, C. N., Boykin, D. W., Wilson, W. D., De Koning, H. P., Olson, C. 
A., Pohlig, G., Burri, C., Brun, R., Murilla, G. A., Thuita, J. K., Barrett, M. P. and Tidwell, R. R. 
(2010). Diamidines for human African trypanosomiasis. Curr Opin Investig Drugs, 11, 876-
883. 
Panda, H., Jaiswal, A. S., Corsino, P. E., Armas, M. L., Law, B. K. and Narayan, S. (2009). Amino acid 
Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development. 
Biochemistry, 48, 9952-9958. doi: 10.1021/bi9010754. 
Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., 
Asel, E., Springer, B. A., Lane, P. and Salemme, F. R. (2001). High-density miniaturized 
thermal shift assays as a general strategy for drug discovery. J Biomol Screen, 6, 429-440. 
doi: 10.1089/108705701753364922. 
Pascucci, B., D'Errico, M., Parlanti, E., Giovannini, S. and Dogliotti, E. (2011). Role of nucleotide 
excision repair proteins in oxidative DNA damage repair: an updating. Biochemistry (Mosc), 
76, 4-15. doi: BCM76010008 [pii]. 
Patel, N., Atack, J. M., Finger, L. D., Exell, J. C., Thompson, P., Tsutakawa, S., Tainer, J. A., Williams, 
D. M. and Grasby, J. A. (2012). Flap endonucleases pass 5'-flaps through a flexible arch using 
a disorder-thread-order mechanism to confer specificity for free 5'-ends. Nucleic Acids Res, 
40, 4507-4519. doi: 10.1093/nar/gks051. 
Pearce, L. (1921). STUDIES ON THE TREATMENT OF HUMAN TRYPANOSOMIASIS WITH 
TRYPARSAMIDE (THE SODIUM SALT OF N-PHENYLGLYCINEAMIDE-p-ARSONIC ACID). J Exp 
Med, 34, 1-104. 
Phillips, M. A. and Wang, C. C. (1987). A Trypanosoma brucei mutant resistant to alpha-
difluoromethylornithine. Mol Biochem Parasitol, 22, 9-17. 
 152 
Pimentel, D. e. S., Ramos, C. A., Ramos, R. A., de Araújo, F. R., Borba, M. L., Faustino, M. A. and 
Alves, L. C. (2012). First report and molecular characterization of Trypanosoma vivax in 
cattle from state of Pernambuco, Brazil. Vet Parasitol, 185, 286-289. doi: 
10.1016/j.vetpar.2011.10.019. 
Plouffe, D., Brinker, A., McNamara, C., Henson, K., Kato, N., Kuhen, K., Nagle, A., Adrián, F., 
Matzen, J. T., Anderson, P., Nam, T. G., Gray, N. S., Chatterjee, A., Janes, J., Yan, S. F., 
Trager, R., Caldwell, J. S., Schultz, P. G., Zhou, Y. and Winzeler, E. A. (2008). In silico activity 
profiling reveals the mechanism of action of antimalarials discovered in a high-throughput 
screen. Proc Natl Acad Sci U S A, 105, 9059-9064. doi: 10.1073/pnas.0802982105. 
Prendergast, P. (2001). Use of flavones, coumarins and related compounds to treat infections. 
Price, P. A. (1975). The essential role of Ca2+ in the activity of bovine pancreatic 
deoxyribonuclease. J Biol Chem, 250, 1981-1986. 
Qiu, J., Bimston, D. N., Partikian, A. and Shen, B. (2002). Arginine residues 47 and 70 of human flap 
endonuclease-1 are involved in DNA substrate interactions and cleavage site 
determination. J Biol Chem, 277, 24659-24666. doi: 10.1074/jbc.M111941200. 
Qiu, J., Li, X., Frank, G. and Shen, B. (2001). Cell cycle-dependent and DNA damage-inducible 
nuclear localization of FEN-1 nuclease is consistent with its dual functions in DNA 
replication and repair. J Biol Chem, 276, 4901-4908. doi: 10.1074/jbc.M007825200. 
Queiroz, R., Benz, C., Fellenberg, K., Hoheisel, J. D. and Clayton, C. (2009). Transcriptome analysis 
of differentiating trypanosomes reveals the existence of multiple post-transcriptional 
regulons. BMC Genomics, 10, 495. doi: 10.1186/1471-2164-10-495. 
Raether, W. and Seidenath, H. (1983). The activity of fexinidazole (HOE 239) against experimental 
infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Ann Trop Med 
Parasitol, 77, 13-26. 
Reuner, B., Vassella, E., Yutzy, B. and Boshart, M. (1997). Cell density triggers slender to stumpy 
differentiation of Trypanosoma brucei bloodstream forms in culture. Mol Biochem 
Parasitol, 90, 269-280. 
Riou, G. and Benard, J. (1980). Berenil induces the complete loss of kinetoplast DNA sequences 
in Trypanosoma equiperdum. In Biochemical and Biophysical Research Communications, 
Vol. 96 pp. 350-354. 
Robertson, A. B., Klungland, A., Rognes, T. and Leiros, I. (2009). DNA repair in mammalian cells: 
Base excision repair: the long and short of it. Cell Mol Life Sci, 66, 981-993. doi: 
10.1007/s00018-009-8736-z. 
Robins, P., Pappin, D. J., Wood, R. D. and Lindahl, T. (1994). Structural and functional homology 
between mammalian DNase IV and the 5'-nuclease domain of Escherichia coli DNA 
polymerase I. J Biol Chem, 269, 28535-28538. 
Sahin, A., Asencio, C., Izotte, J., Pillay, D., Coustou, V., Karembe, H. and Baltz, T. (2014). The 
susceptibility of Trypanosoma congolense and Trypanosoma brucei to isometamidium 
chloride and its synthetic impurities. Vet Parasitol, 203, 270-275. doi: 
10.1016/j.vetpar.2014.04.002. 
Sampathi, S., Bhusari, A., Shen, B. and Chai, W. (2009). Human flap endonuclease I is in complex 
with telomerase and is required for telomerase-mediated telomere maintenance. J Biol 
Chem, 284, 3682-3690. doi: 10.1074/jbc.M805362200. 
 153 
Santos, N. C., Figueira-Coelho, J., Martins-Silva, J. and Saldanha, C. (2003). Multidisciplinary 
utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem 
Pharmacol, 65, 1035-1041. 
Sayers, J. R. and Eckstein, F. (1990). Properties of overexpressed phage T5 D15 exonuclease. 
Similarities with Escherichia coli DNA polymerase I 5'-3' exonuclease. J Biol Chem, 265, 
18311-18317. 
Sayers, J. R. and Eckstein, F. (1991). A single-strand specific endonuclease activity copurifies with 
overexpressed T5 D15 exonuclease. Nucleic Acids Res, 19, 4127-4132. 
Schad, G. J., Allanson, A., Mackay, S. P., Cannavan, A. and Tettey, J. N. (2008). Development and 
validation of an improved HPLC method for the control of potentially counterfeit 
isometamidium products. J Pharm Biomed Anal, 46, 45-51. doi: 10.1016/j.jpba.2007.08.026. 
Scott, D. A., Moreno, S. N. and Docampo, R. (1995). Ca2+ storage in Trypanosoma brucei: the 
influence of cytoplasmic pH and importance of vacuolar acidity. Biochem J, 310 ( Pt 3), 789-
794. 
Scotti, L., Mendonça, F. J., da Silva, M. S. and Scotti, M. T. (2016). Enzymatic Targets in 
Trypanosoma brucei. Curr Protein Pept Sci, 17, 243-259. 
Seidl, A., Dávila, A. M. and Silva, R. A. (1999). Estimated financial impact of Trypanosoma vivax on 
the Brazilian pantanal and Bolivian lowlands. Mem Inst Oswaldo Cruz, 94, 269-272. 
Sharma, S., Otterlei, M., Sommers, J. A., Driscoll, H. C., Dianov, G. L., Kao, H. I., Bambara, R. A. and 
Brosh, R. M., Jr. (2004a). WRN helicase and FEN-1 form a complex upon replication arrest 
and together process branchmigrating DNA structures associated with the replication fork. 
Mol Biol Cell, 15, 734-750. doi: 10.1091/mbc.E03-08-0567. 
Sharma, S., Sommers, J. A., Wu, L., Bohr, V. A., Hickson, I. D. and Brosh, R. M., Jr. (2004b). 
Stimulation of flap endonuclease-1 by the Bloom's syndrome protein. J Biol Chem, 279, 
9847-9856. doi: 10.1074/jbc.M309898200. 
Shen, B., Nolan, J. P., Sklar, L. A. and Park, M. S. (1997). Functional analysis of point mutations in 
human flap endonuclease-1 active site. Nucleic Acids Res, 25, 3332-3338. doi: gka532 [pii]. 
Shinozuka, K., Kikuchi, Y., Nishino, C., Mori, A. and Tawata, S. (1988). Inhibitory effect of 
flavonoids on DNA-dependent DNA and RNA polymerases. Experientia, 44, 882-885. 
Silva, R. A., Morales, G., Eulert, E., Montenegro, A. and Ybañez, R. (1998). Outbreaks of 
trypanosomosis due to Trypanosoma vivax in cattle in Bolivia. Vet Parasitol, 76, 153-157. 
Silva, T. M., Olinda, R. G., Rodrigues, C. M., Câmara, A. C., Lopes, F. C., Coelho, W. A., Ribeiro, M. 
F., Freitas, C. I., Teixeira, M. M. and Batista, J. S. (2013). Pathogenesis of reproductive failure 
induced by Trypanosoma vivax in experimentally infected pregnant ewes. Vet Res, 44, 1. 
doi: 10.1186/1297-9716-44-1. 
Singh, P., Yang, M., Dai, H., Yu, D., Huang, Q., Tan, W., Kernstine, K. H., Lin, D. and Shen, B. (2008). 
Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other 
cancers. Mol Cancer Res, 6, 1710-1717. doi: 10.1158/1541-7786.mcr-08-0269. 
Sokolova, A. Y., Wyllie, S., Patterson, S., Oza, S. L., Read, K. D. and Fairlamb, A. H. (2010). Cross-
resistance to nitro drugs and implications for treatment of human African trypanosomiasis. 
Antimicrob Agents Chemother, 54, 2893-2900. doi: 10.1128/AAC.00332-10. 
Stanojcic, S., Sollelis, L., Kuk, N., Crobu, L., Balard, Y., Schwob, E., Bastien, P., Pagès, M. and 
Sterkers, Y. (2016). Single-molecule analysis of DNA replication reveals novel features in the 
divergent eukaryotes Leishmania and Trypanosoma brucei versus mammalian cells. Sci Rep, 
6, 23142. doi: 10.1038/srep23142. 
 154 
Steverding, D. (2008). The history of African trypanosomiasis. In Parasites and vectors, Vol. 1. 
Steverding, D. (2010). The development of drugs for treatment of sleeping sickness: a historical 
review. Parasit Vectors, 3, 15. doi: 10.1186/1756-3305-3-15. 
Stewart, J. A., Chaiken, M. F., Wang, F. and Price, C. M. (2012). Maintaining the end: roles of 
telomere proteins in end-protection, telomere replication and length regulation. Mutat Res, 
730, 12-19. doi: 10.1016/j.mrfmmm.2011.08.011. 
Stewart, M. L., Burchmore, R. J., Clucas, C., Hertz-Fowler, C., Brooks, K., Tait, A., Macleod, A., 
Turner, C. M., De Koning, H. P., Wong, P. E. and Barrett, M. P. (2010). Multiple genetic 
mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. 
Eukaryot Cell, 9, 336-343. doi: 10.1128/EC.00200-09. 
Stucki, M., Jónsson, Z. O. and Hübscher, U. (2001). In eukaryotic flap endonuclease 1, the C 
terminus is essential for substrate binding. J Biol Chem, 276, 7843-7849. doi: 
10.1074/jbc.M008829200. 
Studier, F. W. (2005). Protein production by auto-induction in high density shaking cultures. 
Protein Expr Purif, 41, 207-234. 
Studier, F. W. and Moffatt, B. A. (1986). Use of bacteriophage T7 RNA polymerase to direct 
selective high-level expression of cloned genes. J Mol Biol, 189, 113-130. doi: 0022-
2836(86)90385-2 [pii]. 
Sultana, A. and Lee, J. E. (2015). Measuring protein-protein and protein-nucleic Acid interactions 
by biolayer interferometry. Curr Protoc Protein Sci, 79, 19.25.11-19.25.26. doi: 
10.1002/0471140864.ps1925s79. 
Sykes, M. L. and Avery, V. M. (2009). Development of an Alamar Blue viability assay in 384-well 
format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream 
form strain 427. Am J Trop Med Hyg, 81, 665-674. doi: 10.4269/ajtmh.2009.09-0015. 
Syson, K., Tomlinson, C., Chapados, B. R., Sayers, J. R., Tainer, J. A., Williams, N. H. and Grasby, J. 
A. (2008). Three metal ions participate in the reaction catalyzed by T5 flap endonuclease. J 
Biol Chem, 283, 28741-28746. doi: 10.1074/jbc.M801264200. 
Teka, I. A., Kazibwe, A. J., El-Sabbagh, N., Al-Salabi, M. I., Ward, C. P., Eze, A. A., Munday, J. C., 
Mäser, P., Matovu, E., Barrett, M. P. and de Koning, H. P. (2011). The diamidine diminazene 
aceturate is a substrate for the high-affinity pentamidine transporter: implications for the 
development of high resistance levels in trypanosomes. Mol Pharmacol, 80, 110-116. doi: 
10.1124/mol.111.071555. 
Tercero, J. A. and Diffley, J. F. (2001). Regulation of DNA replication fork progression through 
damaged DNA by the Mec1/Rad53 checkpoint. Nature, 412, 553-557. doi: 
10.1038/35087607. 
Thorne, N., Auld, D. S. and Inglese, J. (2010). Apparent activity in high-throughput screening: 
origins of compound-dependent assay interference. Curr Opin Chem Biol, 14, 315-324. doi: 
10.1016/j.cbpa.2010.03.020. 
Thornton, B. and Basu, C. (2011). Real-time PCR (qPCR) primer design using free online software. 
Biochem Mol Biol Educ, 39, 145-154. doi: 10.1002/bmb.20461. 
Tishkoff, D. X., Boerger, A. L., Bertrand, P., Filosi, N., Gaida, G. M., Kane, M. F. and Kolodner, R. D. 
(1997). Identification and characterization of Saccharomyces cerevisiae EXO1, a gene 
encoding an exonuclease that interacts with MSH2. Proc Natl Acad Sci U S A, 94, 7487-7492. 
Tjernberg, A., Markova, N., Griffiths, W. J. and Hallén, D. (2006). DMSO-related effects in protein 
characterization. J Biomol Screen, 11, 131-137. doi: 10.1177/1087057105284218. 
 155 
Tock, M. R., Frary, E., Sayers, J. R. and Grasby, J. A. (2003). Dynamic evidence for metal ion 
catalysis in the reaction mediated by a flap endonuclease. EMBO J, 22, 995-1004. doi: 
10.1093/emboj/cdg098. 
Torreele, E., Bourdin Trunz, B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., Bray, M. A. and Pécoul, 
B. (2010). Fexinidazole--a new oral nitroimidazole drug candidate entering clinical 
development for the treatment of sleeping sickness. PLoS Negl Trop Dis, 4, e923. doi: 
10.1371/journal.pntd.0000923. 
Tsutakawa, S. E., Classen, S., Chapados, B. R., Arvai, A. S., Finger, L. D., Guenther, G., Tomlinson, C. 
G., Thompson, P., Sarker, A. H., Shen, B., Cooper, P. K., Grasby, J. A. and Tainer, J. A. (2011). 
Human flap endonuclease structures, DNA double-base flipping, and a unified 
understanding of the FEN1 superfamily. Cell, 145, 198-211. doi: 10.1016/j.cell.2011.03.004. 
Tumey, L. N., Bom, D., Huck, B., Gleason, E., Wang, J., Silver, D., Brunden, K., Boozer, S., Rundlett, 
S., Sherf, B., Murphy, S., Dent, T., Leventhal, C., Bailey, A., Harrington, J. and Bennani, Y. L. 
(2005). The identification and optimization of a N-hydroxy urea series of flap endonuclease 
1 inhibitors. Bioorg Med Chem Lett, 15, 277-281. doi: 10.1016/j.bmcl.2004.10.086. 
Tumey, L. N., Huck, B., Gleason, E., Wang, J., Silver, D., Brunden, K., Boozer, S., Rundlett, S., Sherf, 
B., Murphy, S., Bailey, A., Dent, T., Leventhal, C., Harrington, J. and Bennani, Y. L. (2004). 
The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 
inhibitors. Bioorg Med Chem Lett, 14, 4915-4918. doi: 10.1016/j.bmcl.2004.07.028. 
Uilenberg, G. (1998). A field guide for the diagnosis, treatment and prevention of african animal 
trypanosomiasis.  Food and Agriculture Organisation (FAO) of the United Nations, Rome, 
Italy. 
Vallur, A. C. and Maizels, N. (2010). Distinct activities of exonuclease 1 and flap endonuclease 1 at 
telomeric g4 DNA. PLoS One, 5, e8908. doi: 10.1371/journal.pone.0008908. 
van Pel, D. M., Barrett, I. J., Shimizu, Y., Sajesh, B. V., Guppy, B. J., Pfeifer, T., McManus, K. J. and 
Hieter, P. (2013). An evolutionarily conserved synthetic lethal interaction network identifies 
FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet, 9, 
e1003254. doi: 10.1371/journal.pgen.1003254. 
Vansterkenburg, E. L., Coppens, I., Wilting, J., Bos, O. J., Fischer, M. J., Janssen, L. H. and 
Opperdoes, F. R. (1993). The uptake of the trypanocidal drug suramin in combination with 
low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop, 
54, 237-250. 
Viadiu, H. and Aggarwal, A. K. (1998). The role of metals in catalysis by the restriction 
endonuclease BamHI. Nat Struct Biol, 5, 910-916. doi: 10.1038/2352. 
Vincent, I. M., Creek, D., Watson, D. G., Kamleh, M. A., Woods, D. J., Wong, P. E., Burchmore, R. J. 
and Barrett, M. P. (2010). A molecular mechanism for eflornithine resistance in African 
trypanosomes. PLoS Pathog, 6, e1001204. doi: 10.1371/journal.ppat.1001204. 
Vipond, I. B., Baldwin, G. S. and Halford, S. E. (1995). Divalent metal ions at the active sites of the 
EcoRV and EcoRI restriction endonucleases. Biochemistry, 34, 697-704. 
Wang, Z. H., Ah Kang, K., Zhang, R., Piao, M. J., Jo, S. H., Kim, J. S., Kang, S. S., Lee, J. S., Park, D. H. 
and Hyun, J. W. (2010). Myricetin suppresses oxidative stress-induced cell damage via both 
direct and indirect antioxidant action. Environ Toxicol Pharmacol, 29, 12-18. doi: 
10.1016/j.etap.2009.08.007. 
Warbrick, E., Lane, D. P., Glover, D. M. and Cox, L. S. (1997). Homologous regions of Fen1 and 
p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-
 156 
ordinate DNA replication and repair. Oncogene, 14, 2313-2321. doi: 
10.1038/sj.onc.1201072. 
Waring, M. J. (1965). Complex formation between ethidium bromide and nucleic acids. J Mol Biol, 
13, 269-282. 
Watkins, T. I. and Woolfe, G. (1952). Effect of changing the quaternizing group on the trypanocidal 
activity of dimidium bromide. Nature, 169, 506-507. 
Wenzler, T., Boykin, D. W., Ismail, M. A., Hall, J. E., Tidwell, R. R. and Brun, R. (2009). New 
treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of 
aza analogs of DB289. Antimicrob Agents Chemother, 53, 4185-4192. doi: 
10.1128/AAC.00225-09. 
Wenzler, T., Yang, S., Braissant, O., Boykin, D. W., Brun, R. and Wang, M. Z. (2013). 
Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of 
DB829, a preclinical candidate for treatment of second-stage human African 
trypanosomiasis. Antimicrob Agents Chemother, 57, 5330-5343. doi: 10.1128/AAC.00398-
13. 
WHO (2013). Control and surveillance of human African trypanosomiasis: report of a WHO expert 
committee. In WHO technical report series World Health Organisation. 
WHO (2015a). Global Health Observatory Data Repository. In Human African Trypanosomiasis, 
Vol. 2016. 
WHO (2015b). Trypanosomiasis, human African (sleeping sickness).  pp. Fact Sheet No 259. 
Wlodkowic, D., Skommer, J. and Darzynkiewicz, Z. (2009). Flow cytometry-based apoptosis 
detection. Methods Mol Biol, 559, 19-32. doi: 10.1007/978-1-60327-017-5_2. 
Wragg, W. R., Washbourn, K., Brown, K. N. and Hill, J. (1958). Metamidium: a new trypanocidal 
drug. Nature, 182, 1005-1006. 
Wyllie, S., Foth, B. J., Kelner, A., Sokolova, A. Y., Berriman, M. and Fairlamb, A. H. (2016). 
Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei. J Antimicrob 
Chemother, 71, 625-634. doi: 10.1093/jac/dkv376. 
Xu, Y., Potapova, O., Leschziner, A. E., Grindley, N. D. and Joyce, C. M. (2001). Contacts between 
the 5' nuclease of DNA polymerase I and its DNA substrate. J Biol Chem, 276, 30167-30177. 
doi: 10.1074/jbc.M100985200. 
Yang, W. (2008). An equivalent metal ion in one- and two-metal-ion catalysis. Nat Struct Mol Biol, 
15, 1228-1231. doi: 10.1038/nsmb.1502. 
Yang, W., Lee, J. Y. and Nowotny, M. (2006). Making and breaking nucleic acids: two-Mg2+-ion 
catalysis and substrate specificity. Mol Cell, 22, 5-13. doi: 10.1016/j.molcel.2006.03.013. 
Youssif, F., Mohamed, O., Gameel, A. and Hassan, T. (2010). Efficacy and toxicity of homidium 
bromide (ethidium) in goats infected with T. vivax. In Small Ruminant Research, Vol. 89 pp. 
36-41. 
Zhang, J. (2012). Biochemical Studies on T5 Exonuclease. In Medical School, Vol. Doctor of 
Philosophy pp. 154. The University of Sheffield, Sheffield. 
Zhang, J. H., Chung, T. D. and Oldenburg, K. R. (1999). A Simple Statistical Parameter for Use in 
Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen, 4, 67-73. 
Zhang, K., Ma, Z., Wang, J., Xie, A. and Xie, J. (2011). Myricetin attenuated MPP(+)-induced 
cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells. 
Neuropharmacology, 61, 329-335. doi: 10.1016/j.neuropharm.2011.04.021. 
 157 
Zheng, L., Dai, H., Zhou, M., Li, M., Singh, P., Qiu, J., Tsark, W., Huang, Q., Kernstine, K., Zhang, X., 
Lin, D. and Shen, B. (2007). Fen1 mutations result in autoimmunity, chronic inflammation 
and cancers. Nat Med, 13, 812-819. doi: nm1599 [pii] 
10.1038/nm1599. 
Zheng, L. and Shen, B. (2011). Okazaki fragment maturation: nucleases take centre stage. J Mol 
Cell Biol, 3, 23-30. doi: mjq048 [pii] 10.1093/jmcb/mjq048. 
Zheng, L., Zhou, M., Chai, Q., Parrish, J., Xue, D., Patrick, S. M., Turchi, J. J., Yannone, S. M., Chen, 
D. and Shen, B. (2005). Novel function of the flap endonuclease 1 complex in processing 
stalled DNA replication forks. EMBO Rep, 6, 83-89. doi: 7400313 [pii] 
10.1038/sj.embor.7400313. 
Zheng, L., Zhou, M., Guo, Z., Lu, H., Qian, L., Dai, H., Qiu, J., Yakubovskaya, E., Bogenhagen, D. F., 
Demple, B. and Shen, B. (2008). Human DNA2 is a mitochondrial nuclease/helicase for 
efficient processing of DNA replication and repair intermediates. Mol Cell, 32, 325-336. doi: 
10.1016/j.molcel.2008.09.024. 
 
 
  
 158 
Appendix A – Vector Maps 
 
 
All vector maps were created using SnapGene® Viewer 2.8.3. 
pET21a+ Vector Map 
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pUC19 Vector Map 
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p2McN Vector Map 
 
  
 161 
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Appendix B – Detailed Statistical Analysis for RT-
qPCR 
Table B-1 Detailed Statistical Analysis Performed on FEN1-specific mRNA Levels 
Clone Time 
Homogeneity 
of Variance 
Sphericity 
Greenhouse 
Geisser 
Correction? 
Test Statistic Post Hoc test  
427::fen1
D183K 
0 Yes; p = 0.240 
Violated; 
p = 0.0005 
Yes 
F (3.4, 9.0) = 44.7  
p = 0.0005  
partial ƞ2 = 0.944 
Tukey 
24 Yes; p = 0.056 Tukey 
48 No; p = 0.023 Games-Howell 
72 Yes; p = 0.770 Tukey 
427:: 
FEN1 
0 No; p = 0.008 
Not 
violated; 
p = 0.344 
No 
F (9, 21) = 20.93  
p = 0.0005  
partial ƞ2 = 0.900 
Games-Howell 
24 No; p = 0.032 Games-Howell 
48 No; p = 0.007 Games-Howell 
72 No; p = 0.008 Games-Howell 
427‡ 
FEN1 
0 No; p = 0.042 
Violated; 
p = 0.0005 
Yes 
F (2.1, 6.3) = 2.062  
p = 0.204  
partial ƞ2 = 0.407 
NA 
24 No; p = 0.004 NA 
48 No; p = 0.004 NA 
72 No; p = 0.009 NA 
Transgenic clones were compared with the 427 parental controls using a Repeated Measures 
mixed ANOVA (IBM SPSS statistics 22). 
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Appendix C – Line Fitting for Thermal Shift Assays 
Table C-1 Melting temperature and R2 values for protein concentration checks 
Protein Repeat Concentration Tm Mean SD R2 
TbFEN 
1 
5 
60.15 
59.68 0.48 
0.9983 
2 59.19 0.9995 
3 59.69 0.9985 
1 
1 
60.95 
60.82 0.12 
0.9967 
2 60.71 0.9966 
3 60.8 0.9965 
1 
0.5 
60.56 
59.92 0.68 
0.9936 
2 59.99 0.9963 
3 59.21 0.9898 
1 
0.25 
60.17 
59.14 1.72 
0.9898 
2 57.16 0.9879 
3 60.1 0.9905 
1 
0.1 
60.05 
59.05 1.57 
0.9869 
2 57.24 0.9624 
3 59.86 0.9900 
1 
0.05 
59.66 
57.50 2.96 
0.9621 
2 54.13 0.9227 
3 58.71 0.9789 
hFEN 
1 
5 
53.36 
52.72 1.05 
0.9948 
2 51.5 0.994 
3 53.29 0.9957 
1 
1 
53.29 
52.94 0.71 
0.9937 
2 52.12 0.9983 
3 53.4 0.9944 
1 
0.5 
53.4 
52.37 1.56 
0.9945 
2 50.58 0.9812 
3 53.13 0.9946 
1 
0.25 
52.88 
52.91 0.24 
0.9936 
2 52.68 0.7492 
3 53.16 0.9965 
1 
0.1 
53.87 
53.48 0.56 
0.9496 
2 Amb 0.1575 
3 53.08 0.9944 
1 
0.05 
53.12 
55.38 4.43 
0.9773 
2 60.48 0.6005 
3 52.54 0.9914 
Amb; ambiguous 
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pH Optimisation 
Table C-2 Melting temperature and R2 values for pH comparison 
Protein Repeat pH Tm Mean SD R2 
TbFEN 
1 
6.5 
54.73 
55.15 0.38 
0.9972 
2 55.46 0.9977 
3 55.26 0.9975 
1 
7.0 
63.85 
64.79 0.87 
0.9924 
2 65.57 0.9930 
3 64.96 0.9867 
1 
7.5 
56.44 
55.72 1.18 
0.9968 
2 56.36 0.9986 
3 54.35 0.9973 
1 
8.0 
48.91 
48.61 0.32 
0.9980 
2 48.28 0.9976 
3 48.63 0.9921 
1 
8.5 
43.13 
42.79 0.30 
0.9975 
2 42.61 0.9973 
3 42.62 0.9974 
1 
9.0 
40.16 
39.90 0.42 
0.9989 
2 40.13 0.9975 
3 39.42 0.9968 
1 
9.5 
43.19 
43.06 0.18 
0.9954 
2 43.14 0.9951 
3 42.86 0.9953 
hFEN 
1 
6.5 
45.28 
45.33 0.22 
0.9957 
2 45.13 0.9949 
3 45.57 0.9941 
1 
7.0 
46.94 
48.12 1.02 
0.9954 
2 48.63 0.9983 
3 48.78 0.9980 
1 
7.5 
47.23 
47.83 0.61 
0.9971 
2 47.81 0.9966 
3 48.45 0.9963 
1 
8.0 
42.93 
44.51 1.70 
0.9980 
2 44.27 0.9986 
3 46.31 0.9983 
1 
8.5 
35.41 
35.15 0.30 
0.9981 
2 35.21 0.9966 
3 34.82 0.9981 
1 
9.0 
31.22 
31.11 0.13 
0.9992 
2 31.15 0.9981 
3 30.97 0.9985 
1 
9.5 
32.96 
32.69 0.27 
0.9965 
2 32.42 0.9994 
3 32.70 0.9985 
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Buffer Additives 
Table C-3 Melting temperature and R2 values for additive optimisation 
Protein Repeat pH Tm Mean SD R2 
TbFEN 
 
 
 
1 
None 
61.95 
61.55 0.48 
0.9993 
2 61.02 0.9993 
3 61.68 0.9993 
1 
50 mM NaCl 
58.60 
59.12 0.64 
0.9986 
2 58.93 0.9991 
3 59.84 0.9989 
1 
100 mM KCl 
56.37 
56.40 0.03 
0.9984 
2 56.43 0.9984 
3 56.40 0.9912 
1 
10 mM MgCl2 
64.43 
64.29 0.67 
0.9990 
2 63.56 0.9987 
3 64.87 0.9984 
1 
10 mM 
MnCl2 
66.82 
66.25 0.56 
0.9986 
2 65.70 0.9971 
3 66.23 0.9953 
1 
1 mM DTT 
63.07 
63.09 1.12 
0.9971 
2 61.98 0.9977 
3 64.21 0.9950 
hFEN 
1 
None 
51.00 
51.23 0.20 
0.9970 
2 51.35 0.9962 
3 51.34 0.9954 
1 
50 mM NaCl 
49.82 
49.62 0.28 
0.9912 
2 49.42 0.9905 
3   
1 
100 mM KCl 
48.47 
49.83 1.26 
0.9923 
2 50.08 0.9914 
3 50.95 0.9915 
1 
10 mM MgCl2 
55.02 
54.26 0.84 
0.9908 
2 54.41 0.9851 
3 53.36 0.9839 
1 
10 mM 
MnCl2 
54.21 
54.04 0.21 
0.9716 
2 54.10 0.9676 
3 53.81 0.9578 
1 
1 mM DTT 
50.81 
50.95 0.56 
0.9874 
2 50.47 0.9844 
3 51.56 0.9895 
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Table C-4 Melting temperature and R2 values for DMSO and myricetin 
Protein Repeat pH Tm Mean SD R2 
TbFEN 
 
 
 
1 
Buffer 
59.60 
59.39 0.33 
0.9826 
2 59.55 0.9639 
3 59.01 0.8600 
1 
5% DMSO 
58.24 
57.86 0.65 
0.8520 
2 58.23 0.9642 
3 57.11 0.8530 
1 
10 µM Myricetin 
57.61 
57.86 0.73 
0.9427 
2 57.29 0.9013 
3 58.69 0.9769 
1 
50 µM Myricetin 
60.35 
60.34 0.05 
0.9861 
2 60.29 0.9924 
3 60.39 0.9671 
1 
100 µM Myricetin 
62.43 
62.27 0.14 
0.9850 
2 62.19 0.9962 
3 62.18 0.9376 
hFEN 
 
 
 
1 Buffer 
 
54.93 
54.73 0.28 
0.9268 
2 54.53 0.8619 
1 5% DMSO 
 
51.98 
52.13 0.21 
0.9534 
2 52.28 0.9754 
1 10 µM Myricetin 
 
52.73 
52.52 0.30 
0.8626 
2 52.30 0.9868 
1 50 µM Myricetin 
 
55.61 
55.03 0.82 
0.9818 
2 54.45 0.9710 
1 
100 µM Myricetin 
57.60 
56.66 1.33 
0.9621 
2 55.72 0.9879 
 
 
 
